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hiGhly Active AntiretrovirAl  
therApy in children
The disease, the drug and the patient: current issues  
and potential solutions
Chiara Piana, Meindert Danhof and Oscar Della Pasqua
Submitted for publication
summAry
Despite the enormous progresses observed in paediatric Highly Active Antiretroviral Therapy (HAART) 
in the last decades, a high percentage of children continue to experience treatment failure due to de-
velopment of drug resistance, inadequate dosing and poor adherence. This review is aimed at exploring 
the current status of antiretroviral therapy in children with focus on the interaction between disease, 
drug and patient behaviour, all of which are strongly correlated and determinants of treatment out-
come. With respect to the disease, an overview of viral characteristics and of the available antiretrovi-
ral drug classes currently combined to avoid development of resistance is provided. Taking into account 
pharmacokinetic and pharmacodynamic properties, we show the advantages and limitations of exist-
ing methodologies for dosing recommendation. Finally, the role of the patient is scrutinised: a detailed 
definition of adherence to therapy is provided, together with the main strategies used to enhance treat-
ment compliance in children. The importance of adherence is also highlighted in terms of its implication 
for the development of resistance, which has been shown to differ for each class of antiretroviral drugs.
After having identified some of the challenges which need to be overcome to decrease viral failure 
in children, we propose the use of a model-based approach for exploring forgiveness of non-adherence, 
which may allow simplification of current dosing regimens taking into consideration inadequate com-
pliance and its implication for efficacy and drug resistance. In conjunction with clinical trial simula-
tions, we demonstrate that it is possible to evaluate relevant clinical scenarios and predict treatment 
outcome of simplified dosing regimens of antiretroviral drugs in hypothetical populations of HIV-in-
fected children
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1.1. bAckGround
Paediatric HIV infection is a world-wide public health challenge disproportionately affecting 
children in the poorest parts of the world, where access to therapy is still quite limited. Ma-
jor advances occurred during the past 15 years, such as effective prophylaxis and treatment 
in HIV-infected women, and administration of highly active antiretroviral therapy (HAART) to 
those babies who are infected (1). Early antiretroviral treatment has dramatically modified the 
course of HIV infection in children, reducing mortality by fivefold or more and resulting in high 
survival rates in adulthood (2;3). However, one of the greatest challenges for children living with 
HIV is maintaining effective antiretroviral treatment for life. A European study which looked at 
more than a thousand children on antiretroviral treatment found that 12 percent of children 
experienced treatment failure of three classes of drugs after 5 years, over two times the rate of 
adults (4). 
Some of the reasons that lead to earlier treatment failure in children include a lack of choice 
of antiretroviral drugs for children, difficulties with adherence and inadequate dosing, togeth-
er with the risk of running out of drug options sooner in case of drug resistance, and the need 
for psychosocial support - particularly during adolescence. From a therapeutic perspective, a 
comprehensive overview is required of the factors which influence treatment outcome and may 
lead to clinical failure, primarily involving the disease, the drug and the patient’s behaviour to-
wards therapy. An extensive evaluation of such factors will be performed in the next paragraphs. 
Based on such an evaluation, specific goals and effective strategies in clinical practice can be 
identified, which may contribute to overcome existing issues and in turn to reduce the number 
of HIV-infected children experiencing viral failure.  
the disease: why is combination therapy needed?
At present, a combination of at least three antiretroviral drugs from at least two drug classes is 
recommended for initial therapy in adults and in children. The antiretroviral classes currently 
approved in children are NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nu-
cleoside reverse transcriptase inhibitors) and PIs (protease inhibitors).
The mechanism of action of NRTIs and NNRTIs is based on the inhibition of reverse transcrip-
tase, a viral DNA polymerase enzyme that retroviruses need to reproduce, while PIs block the 
HIV protease, an enzyme used by the virus to cleave nascent proteins for final assembly of new 
virions (5). 
There are several causes related to the mechanism of infection and replicative capacity of the 
virus which elucidate the need for drug combination in HIV treatment: (i) the virus is able to rep-
licate at a very fast rate (T1/2 approximately 1 day) once a cell has been infected; therefore one 
drug may be able to only decrease the rate of this process but not to interrupt it; (ii) given that 
viral replication depends on different enzymes which are the targets of the antiretroviral drugs, 
the possibility to reach two targets at the same time increases the chance of stopping HIV and 
protecting new cells from infection; (iii) the virus can infect different types of cells in different 
parts of the body; each drug differs in how well the virus can be attacked in these different cells; 
(iv) combination of anti-HIV drugs may overcome or delay the development of drug resistance 
(6;7). Drug resistance may emerge because of the replication program of HIV, which is rapid and 
error prone (mutation rate ca. 3 × 10−5 mutations/base/replication cycle), resulting in large and 
genetically diverse populations in vivo (8). When HIV is allowed to replicate in the presence 
of antiretroviral drug concentrations, which are insufficient to exert complete suppression, an-
tiretroviral drug-resistance mutations will almost invariably emerge (9;10). Depending on the 
site of viral mutations and their impact on viral fitness, different anti-HIV classes show higher 
or lower barriers to resistance. A combination of different antiretroviral classes is therefore 
needed to assure complete viral suppression and prevent the development of drug resistance.
In the past years direct nucleic acid sequencing has become a common mechanism to obtain 
resistance information; commercial genotyping services, as well as systems for laboratory use 
are available; routine testing with independent panels of resistant viruses is useful to maintain-
ing proficiency in detection of mutations (11;12). Appropriate use of resistance testing provides 
valuable information useful in constructing regimens for treatment-experienced individuals 
with viremia during therapy. 
To date, two therapeutic options are suggested as first-line choice in children: NNRTI- and 
PI- based regimens (13). Regarding NNRTI based regimens, only efavirenz (EFV) and nevirapine 
(NVP) are currently approved for paediatric patients. In children older than 3 years and able to 
swallow capsules, EFV is preferred as first-line therapy because of its once daily administration, 
absence of interaction with food and lower incidence of adverse events compared to nevirapine. 
Regarding PI-based regimens, most recent guidelines agree in recommending lopinavir/ritona-
vir (LPV/r) as a first line therapy in naïve paediatric patients. This drug is available as liquid for-
mulation and appears to be safe and effective in children with regards to virological suppression 
and the increase in CD4 count. 
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nrti Zidovudine Serum 0.9-1.4 hrs
Intracellular 3-4 
hrs(15)
0.003-0.013 mcg/mL (16) 180-240mg/m2-BID (17)
nrti Lamivudine Serum 2-6 hrs
Intracellular 10–15 
hrs(18)
2 nM-15µM(19)      4mg/kg per dose-BID (17)
nrti abacavir Serum 1.5 hrs
Intracellular 12–26 
hrs(20)
0.26-4.0µM (21) 8-10 mg/kg per dose-BID(17)
nrti didanosine  0.97-1.6 hrs(22) 0.49 µM(23) <3 months 50mg/m2 -BID  
>3 months 120 mg/m2-BID(17).
nrti Stavudine 0.9-1.5 hrs(24) 0.009-4µM(25) 1 mg/kg per dose-BID(17)  
nrti Emtricitabine 8-10 hrs(26) 0.0013−0.64µM(26) <3 months 3mg/kg-QD
>3 months 6mg/kg-QD(17)
nrti Tenofovir 17 hrs(27) 0.04 – 8.5 µM(28) 300 mg-QD(> 12 years)(17)
nnrti Efavirenz 40-55 hrs after 
multiple doses(29)     
0.51 ng/mL(30) 15 -18.75mg/kg solid form
 or  19.5 mg/kg syrup-QD (17)





5-6 hrs(32) 0.04- 0.18µg/mL(32) < 15 kg 12/3 mg/kg-BID     
> 15 kg  10/2.5 mg/kg -BID(17)  
 
Pi Nelfinavir 3.5-5 hrs(33) 0.06 µM(34) <10 kg ~75 mg/kg/dose-BID
10 kg to 19.9 kg ~60 mg/kg/dose-
BID(17)
Pi atazanavir  6-7 hrs(35)  2 – 5 nM(36) <20 kg  150mg + 100mg ritonavir
 >20 kg <40 kg 200mg + 100mg 
ritonavir 
> 40 kg  300mg + 100mg  
ritonavir(17)
Two drugs from the NRTI class are needed to form the backbone of HAART, with six NR-
TIs (zidovudine, didanosine, lamivudine, stavudine, abacavir and emtricitabine) approved for 
HIV-infected children younger than 13 years of age. Combinations of lamivudine plus abacavir 
or zidovudine or didanosine are considered the preferred dual NRTIs backbone regimens for 
initial therapy in children. The selection of the initial regimen of antiretroviral drugs is generally 
based on several factors, such as comorbid conditions, potential adverse drug effects, potential 
drug interactions with other medications, results of genotypic drug resistance testing and con-
venience (e.g. pill burden, dosing frequency). In table 1 an overview of the antiretroviral drugs 
currently approved in children and their characteristics is provided, whilst table 2 summarises 
the antiretroviral combinations preferred as initial treatment in HIV-infected children. 
An important point to consider which is still quite debatable is the optimal time to start 
HAART in children. According to the current WHO guidelines, all infants with confirmed HIV 
infection should be started on HAART, irrespective of the clinical or immunological stage, while 
for all children 12 months or older clinical and immunological thresholds should be used to iden-
tify those who need to start HAART (14)
Table 2 Antiretroviral regimens recommended for initial therapy for HIV infection in children (17) 
Preferred	Regimens
Children >14 days and <3 
years
Two NRTIs plus lopinavir/ritonavir
Children  ≥3 years Two NRTIs plus efavirenz 
Two NRTIs plus lopinavir/ritonavir
Children age ≥6 years Two NRTIs plus atazanavir plus low-dose 
ritonavir 
Two NRTIs plus efavirenz 
Two NRTIs plus lopinavir/ritonavir
2-NRTI	Backbone	Options	for	Use	in	Combination	with	Additional	Drugs	
Preferred abacavir plus (lamivudine  or emtricitabine) 
(children ≥3 months) 
tenofovir  plus (lamivudine or emtricitabine) 
(adolescents  ≥12 years) 
zidovudine plus (lamivudine or emtricitabine)
The	drug:	what	is	the	right	dose	in	HIV-infected	children?
Up to now, empirical scaling from adults to children continues to be the mainstream method for 
dose selection in paediatrics, with adjustment for body weight as the most common approach 
(37). Although adjustment of drug pharmacokinetic parameters according to body weight or 
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body surface area (BSA) can occasionally explain the observed exposure differences between 
adult and paediatric patients, the direction and extent of these differences across age groups, 
in general, are not predictable. For example, some drugs are eliminated more rapidly or more 
slowly in younger paediatric patients, compared with adults or older paediatric patients (38). 
Bioavailability may also differ between children and adults due to differences in transit time or 
pH. There are extensive physiological changes with pharmacological impact that occur as a child 
matures from infancy to adulthood, and this process does not occur with precisely predicted 
timing or magnitude on an individual scale (39;40). Weight-based methods for determining pae-
diatric doses may not account accurately for all variables related to the different stages of matu-
ration and are unlikely to predict consistently the correct dose for each paediatric age group.  All 
these aspects are in strong opposition to the concept of “one size fits all” dosing for children (41) 
and to the belief of a linear relationship to scale or correct dose for the effect of body weight. 
Rational considerations on the optimal dose for each child should be taken into consideration. 
Together with body weight, other confounders such as drug-drug interactions and demograph-
ic covariates, i.e. age, gender, body composition, functionality of liver and kidneys and matu-
ration of enzymatic systems throughout the life span from neonates to adults (42)  may affect 
the pharmacokinetics of a drug and consequently its exposure. When selecting the paediatric 
dose, these potential confounders must be taken into account in order to achieve an adequate 
exposure and to avoid the risk of toxicity or poor efficacy. A dosing regimen with more than the 
necessary doses, besides causing toxicity, might also increase the possibility of poor adherence, 
which is seriously related with occurrence of resistance. Suboptimal concentrations of antiret-
roviral drugs might as well be very dangerous because they may exert viral selection pressure 
and thus promote development of drug resistance. 
Limited pharmacokinetic data remains one of the major issues in dosing recommendation for 
HIV-infected children. Although a similar disease progression in children and adults allows for 
dosing in children based on efficacy data in adults, performing pharmacokinetic trials to assess 
optimal dosing in children is critical to avoid inadequate exposure. Clinical studies to determine 
the optimal dosing in children of different ages are also critical to avoid under exposure or tox-
icity in children belonging to a certain age or weight group. Despite the indisputable need to 
perform clinical trials in HIV–infected children, one major limitation of such studies must be 
highlighted. In patients affected by chronic diseases who are obliged to take their medication 
their whole life, adherence to therapy during the clinical trial may not be a realistic surrogate 
of patient adherence in real life, due to the limited duration of the study. Awareness is needed 
with regard to the implications that this may have on treatment outcome. Moreover partici-
pation to clinical trials may enhance adherence to treatment in chronic diseases (43), thus the 
pharmacokinetic profile of the drug might be altered in real life by different patterns of variable 
adherence.
the patient: adherence to hiv antiretroviral therapy
There are several reasons why antiretroviral treatment fails, of which poor adherence is a lead-
ing one (2;44-46). It has been shown that the role covered by the patient in achieving response 
to treatment is comparable to the one of the drug. A review of 17 studies on paediatric HIV 
treatment adherence found adherence in HIV-infected children ranging from 49 percent to 
100 percent (47). Three-quarters of the studies showed adherence rates of 75 percent. Most of 
the studies in lower and middle-income countries revealed adherence rates above 75 percent, 
whereas adherence in higher-income countries was generally below 75 percent.
It is useful to provide an exhaustive definition of the term ‘adherence’ beyond the simple 
‘patient’s tendency to follow medical advice’. Two substituent terms must be defined to have a 
comprehensive understanding of patient adherence: (i) compliance and (ii) persistence (48). The 
former is defined as ‘the degree of correspondence between the patient’s actual dosing history 
and the prescribed dosing regimens’. The latter is defined as ‘the time elapsed between the first 
dose taken and the time of treatment discontinuation’. The term compliance includes also the 
degree of correspondence between the patient’s actual dosing time and the prescribed dosing 
time. We handle this component as “quality” of compliance. The different implications on treat-
ment outcome of variable compliance (the patient sporadically misses some doses or takes the 
drug at different times) and variable persistence (“drug holiday”) are shown in figure 1. It is im-
portant to mention that adherence is a critical issue in every chronic treatment, not only in HIV. 
Numerous studies have investigated the effect of poor adherence in many therapeutic areas 
such as, hypertension (49), glaucoma (50;51) and osteoporosis (52).
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Figure 1 On the upper and central panels  two different patterns of non-adherence and consequent effects on viral 
load are depicted. On the lower panel perfect adherence and consequent decrease in viral load is represented.
Several factors pose specific challenges in children compared to adults (53). First of all young 
children’s adherence depends partly or entirely on a caregiver, who, especially in limited re-
sources countries, may be sick or may need to work when the drug has to be administered 
(54;55). The identification of someone responsible for the child is difficult, especially when both 
parents died or are impaired. The expectation that older children should be able to take the 
medicine independently is often unrealistic (56). Moreover family members often have discrep-
ant perceptions of a child’s level of responsibility for medication, especially in families with old-
er children. Another reason which may affect compliance in antiretroviral therapy is the heavy 
pill burden that sometimes needs to be administered to perinatally infected children in need of 
savage therapy because of drug resistance and treatment experience (57). These complicated 
regimens pose greater issues in terms of adherence and therefore may lead to resistance which 
will create the need for even more complicated regimens. Furthermore, many of the current 
HIV medicines have an unpleasant taste, especially in syrups and powder form. This can make it 
difficult for children to take their antiretroviral drugs daily (58). 
In the past years several strategies have been adopted to improve adherence in HIV-infected 
children, mainly based on the education of the caregivers or on peer support, self-monitoring 
and telephone follow-up (59;60). A brief period of hospitalization may help demonstrating the 
role of non-adherence on antiretroviral therapy and help identifying possible solutions. materi-
al support such as pillboxes, drug identification charts, daily schedules, diaries and educational 
materials are provided to explain the schedules, risks and benefits of ART (61). Age-specific de-
velopmental-level protocols and teaching materials (e.g., cartoons, stories and drawings) have 
been developed to educate children about their treatment, their HIV status, and the importance 
of adherence and medical follow-up.
The possibility to reduce the dosing frequency of antiretroviral drugs is another important 
strategy to enhance adherence to treatment. It has been demonstrated that decreasing the pill 
burden and dosing frequency is associated with increased adherence (62-64). Several studies 
have already been performed to assess the feasibility of reduced dosing frequency of some 
antiretroviral drugs from three times a day to twice daily or from twice to once daily (65-67). 
However deep knowledge of the pharmacokinetic and pharmacodynamic properties of a drug 
is required to understand whether the dosing frequency could be reduced: it has been demon-
strated that missing a dose when following once daily dosing regimens may be more dangerous 
than missing one dose on a twice daily regimen (68). 
Adherence-resistance relationship
Failure to take the prescribed dose of antiretroviral drugs leads to ongoing viral replication in 
the presence of drug and the selection of drug-resistant HIV. It has been shown that poor adher-
ence may increase the risk of drug resistance. 
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However, the relationship between adherence and development of resistance is not that sim-
ple as it may seem and it differs for each class of antiretroviral drugs. Bangsberg et al. have used 
a cohesive model (figure 2) to summarise this complex relationship for each class of antiretrovi-
ral drugs currently used as first line therapy (69). 
Figure 2 Schematic representation of the model developed by Bangsberg to summarise the relationship between 
adherence and resistance for each class of antiretroviral drugs. (Modified with permission from Bangsberg et al. 
(69))
According to this model, low levels of adherence are more likely to promote development of 
resistance to NNRTIs due to their low genetic barriers to drug resistance. On the other hand, 
higher selection pressure is required for single PIs given the high genetic barriers of this class to 
resistance; therefore a level of adherence close to perfect is more dangerous than low levels (70). 
Sporadic missed doses are unlikely to produce high risk combination of actively replicating virus 
and sub-therapeutic levels in NNRTIs, due to their long half-lives; conversely sub-therapeutic 
levels may easily be reached after long periods of treatment interruption and therefore the risk 
of resistance strongly increases. Unboosted PIs have a very short half-life and inferior antiviral 
efficacy compared to NNRTIs. Their rapid disappearance from circulation during non-adherent 
periods leads to lower frequency of new mutations compared to NNRTIs, therefore the majority 
of new PI resistance mutations occur in those with higher adherence rates. Boosted PIs instead 
have a high degree of antiviral efficacy and longer half-lives than unboosted PIs but shorter than 
NNRTIs. Their potency discourages the development of resistance in case of missed doses and 
their intermediate half-lives are impediments to the development of resistance mutations in 
patients who interrupt the treatment for long periods. The relationship between adherence and 
resistance is thus more complex than “non-adherence increases the risk of drug resistance”. A 
good understanding of this relationship is a critical step in drug development and may lead to 
lower risk of viral failure in HAART.
Assessment	of	New	Highly	Active	Antiretroviral	Therapy
Based on the aforementioned data and considerations, optimal dosing regimen and adherence 
to prescribed treatment appear to be the main challenges in paediatric antiretroviral therapy 
and thus constitute the targets for future investigations of researchers and clinicians. The pos-
sibility to develop novel drugs with different mechanisms of action able to prevent the devel-
opment of drug resistance and improve treatment outcome is an alternative solution which is 
beyond the scope of this study. Undoubtedly dosing frequency reduction may be very advan-
tageous for the patients; however the impact of poor adherence on optimised dosing regimens 
must be taken into account. The possibility to evaluate which pharmacokinetic and/or pharma-
codynamic properties of an antiretroviral drug make it less susceptible to suboptimal adher-
ence and predict treatment outcome might be a powerful tool for dosing regimen optimisation. 
These considerations rely on an important concept in antiretroviral therapy, which still lacks an 
established and quantitative measure: forgiveness of non-adherence. Forgiveness of non-ad-
herence is the ability of a drug or regimen to achieve and maintain viral suppression even in 
case of poor adherence (71). A variety of pharmacological, viral and host properties determine 
the level of forgiveness of any specific regimen. It is generally used as comparative descriptor of 
different classes of antiretroviral drugs, based upon the “anchor drug” of the regimen. In 2000 
Paterson et al showed that extraordinarily high rates of adherence were necessary to achieve 
viral suppression in a group of HIV-infected patients receiving unboosted indinavir based reg-
imen (45). These findings lead to the “95% rule”, which means that patients must take at least 
95% of the prescribed antiretroviral doses in order to control viral replication. 
More recent studies have demonstrated that more moderate levels of adherence are need-
ed to achieve and maintain viral suppression in patients treated with NNRTIs and boosted PIs 
based regimens. These findings gave birth to the evidence that some antiretroviral classes are 
more forgiving than others. This would be the starting point for future studies and investiga-
tions which may provide important information usable in clinical practice. Forgiveness is not 
defined in a quantitative manner and still lacks a specific scale and detailed thresholds which 
may influence therapeutic choices and improve the final outcome of the treatment. A quantita-
tive and systematic definition of forgiveness will enable the exploration of new dosing regimens, 
which will provide advantages for the patients without risks of inadequate efficacy and in turn 
of drug resistance.
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1.2. A model-bAsed ApproAch for  
the explorAtion of novel dosinG reGimens
A systematic definition of forgiveness of non-adherence for different drugs and the exploration 
of alternative dosing regimens requires a quantitative methodology which allows evaluating 
contemporaneously the effect of disease, drug and patient behaviour.
 A model-based approach in which pharmacokinetic-pharmacodynamic models for selected 
antiretroviral drugs are integrated with a model for viral dynamics may provide a powerful tool 
to predict efficacy of antiretroviral combination treatments. In addition, the inclusion of a model 
for patient adherence provides the basis for quantifying the relation between adherence, ex-
posure and drug response as well as the impact of adherence on treatment outcome (72). The 
evaluation of adherence, however, may not be feasible in clinical practice due to ethical reasons 
and design issues. Thus an in silico approach is required to assess how different patterns of ad-
herence may affect treatment outcome. Quantitative methods can provide insight into how for-
giving antiretroviral drugs are and provide the scientific basis for alternative dosing regimens. 
Similar model-based methods have been already applied in different therapeutic areas, such as 
statin or antihypertensive therapies (73-75).
The possibility to integrate statistical models that describe disease mechanism, drug 
behaviour and patient adherence to treatment in clinical trial simulation will be crucial in the 
exploration of simplified dosing regimens of antiretroviral drugs in in silico populations of 
HIV-infected children based on hypothetical and real-life scenarios (76).
disease models for viral dynamics
A statistical model that can accurately describe the disease in terms of viral replication and in-
fection is the starting point to predict treatment response of combination antiretroviral therapy 
and to gain insight into possible mechanisms of treatment resistance (77).
HIV dynamics has been widely studied in the past twenty years and several models of differ-
ent levels of complexity have been developed (8;78-80). The main advantage of this approach 
was the possibility to understand, quantify and parameterise viral processes such as replica-
tion, infection and death over time (81). For example modelling of viral dynamics has shown that 
HIV-1 is cleared from chronically infected patients at a rapid rate, with a half-life estimated to 
6 hours. Furthermore quantitative estimates of viral parameters suggest that HIV-1 is a rapidly 
replicating virus and one that could respond to therapy. Finally, modelling has shown that the 
HIV virus can quickly become resistant to any single drug, particularly to those that require only 
one mutation to generate resistance. This phenomenon can be anticipated by the fact that every 
single possible mutation of the viral genome can be expected to occur hundreds or thousands 
times each day.  
Figure 3 Basic model of viral infection by Perelson. (Modified with permission from Perelson et al. (81))
Figure 3 depicts the basic model commonly used for viral dynamics. This model is widely used 
also to study the dynamics of hepatitis C virus, hepatitis B virus and cytomegalovirus infections 
in vivo. 
The model considers a set of cells susceptible to infection, that is, target cells, T, which, through 
interactions with virus, V, become infected. Infected cells, I, are each assumed to produce new 
virus particles at a constant average rate p and to die at rate δ. The average lifespan of a produc-
tively infected cell is 1/ δ and so if an infected cell produces a total of N virions during its life-
time, the average rate of virus replication per cell, p = Nδ. Newly produced virus particles, V, can 
either infect new cells or be cleared from the body at rate c per virion.  This model is defined by 
a system of three differential equations (equation 1- 3).  These equations are applied to obtain 
minimal estimates for the parameters c and δ. From these estimates it is possible to calculate 
upper bounds for the half-life of virions in plasma and the half-life of productively infected cells. 
dT/dt = λ – dT – kVT  (1)
dI/dt = kVT –δI  (2)
dV/dt = pI – cV  (3)
It has been observed that viral load decay in plasma takes place with an initial rapid exponential 
decline of nearly 2 logs of magnitude and continues subsequently with a slower exponential 
decline that leads to virus falling below the detection limit. The slope of this decline depends on 
the efficacy of therapy (82-84). The basic model was implemented to interpret this two-phase 
decay in viral load with the inclusion of more compartments representing a longer-lived popula-
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tion of productively infected cells, activation of latently infected cells and release into the blood 
of virions trapped in tissue reservoirs (85;86).
Equations 1-3 represent the processes of viral infection and replication in absence of an an-
tiretroviral drug. When the effect of an antiretroviral drug or regimen is analysed, the basic 
model is implemented as defined in equation 4-6, where γ represents the antiviral efficacy (87).
dT/dt = λ – dT – (1-γ) kVT  (4)
dI/dt = (1-γ) kVT –δI   (5)
dV/dt = pI – cV  (6)
Given that reverse transcriptase inhibitors block the ability of HIV to infect a cell and protease 
inhibitors cause the production of non-infectious viral particles, the previous equations can be 
implemented taking into account the different mechanism of action of each class as shown in 









are the efficacies of RT and PI respectively (8).
dT/dt =  λ – dT – (1 – εRT)kVIT (7)
dI/dt = (1 – εRT)kVIT – δI (8)
dVI/dt = (1 – εPI)pI – cVI (9)
dVNI/dt = εPI pI – cVNI (10)
Such models have been widely validated and subsequently used to predict the time course of 
clinical endpoints and to design novel strategies in HIV treatment (88;89)  given that they allow 
to link drug efficacy to long-term changes in HIV-1 viral load (87;90;91).
Pharmacokinetic-pharmacodynamic	modelling	in	children	
Characterisation of the pharmacokinetic-pharmacodynamic relationships is required to assess 
the correlation between plasma concentrations of antiretroviral drugs with changes in clinical 
endpoint. In order to define such relationships detailed information on pharmacokinetics and 
potentially also on pharmacodynamics of antiretroviral drugs in children need to be collected. 
Given that only a limited number of observations can be obtained in paediatric subjects due to 
ethical and technical challenges, the population approach using nonlinear mixed effect model-
ling to obtain pharmacokinetics and pharmacodynamics parameters is the preferred approach 
(92;93).
The population approach is based on simultaneous analysis of all data of the entire popula-
tion, while still taking into account that different observations come from different patients. 
Additionally, the population approach allows not only for the analysis of dense data, but also 
for sparse (limited number of observations per individual) and unbalanced data (unequal distri-
bution of observations in various parts of the concentration–time profile in the individuals) or 
a combination of both. Finally, both the inter-individual and intra-individual variability are sep-
arately estimated in the dataset using this approach (94). The term “mixed” in nonlinear mixed 
effects modelling represents a mixture of fixed and random effects. For the fixed effects, a struc-
tural model describing the pharmacokinetics or pharmacodynamics is chosen (e.g. a two-com-
partment model for pharmacokinetics or an Emax model for pharmacodynamics). The random 
effects quantify the variability that is not explained by the fixed effects and include inter-subject 
and intra-subject random variability, which are both simultaneously and separately estimated 
(95). It is often assumed that the variability between subjects follows a normal distribution with 
a mean of zero and variance ω2. Equation 11 is used to describe the relationship between indi-
vidual and population parameter estimates:
θ 1= θ mean*e
ηi                       (11)                   
Where θ
1
 represents the parameter of the ith subject, θ
mean
 the population mean, and η
i
 the vari-
ability between subjects. The residual error is generally described using a proportional error 
(error is dependent on the concentration, which means a higher absolute error at higher con-
centrations (Eq.12)) or an additive error (constant for all observations (Eq. 13)) or a combination 
of both. This means for the jth observed concentration of the ith individual the relation (Y
ij
):
Yij=cpred,ij * (1+ εij)           (12)
Yij=cpred,ij + εij          (13)
Where c
pred
 is predicted concentration and ε
ij
 is a random variable with a mean of zero and a 
variance of σ2. 
The structural model uses fixed effects parameters such as clearance and volume of distri-




 for pharmacodynamics. The population values for 
these parameters are called typical values (TV). After selecting the structural model, the sta-
tistical submodel, which accounts for the inter-individual as well as the residual variability, is 
chosen and tested. Information on the inter- and intra-individual or residual variability is of clin-
ical value, because it describes differences in clinical response between and within patients and 
may therefore provide guidance for rational dose adjustments. In the final step the covariate 
sub-model is determined, which expresses relationships between covariates and parameters of 
the structural model (e.g. influence of body weight on volume of distribution or clearance) (96).
covariate analysis
Differently from adults, developmental changes in children (i.e. metabolising enzyme capacity, 
renal function, liver flow, body composition) profoundly affect the responses to medications. It 
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is important that such changes are considered in the context of all other sources of intra- and 
inter-individual variability resulting from genetic-, environmental- and disease-related  factors 
and drug interactions (97). As shown in figure 4, pharmacokinetic-pharmacodynamic modelling 
permits the exploration of the influence of different demographic covariates to explain the vari-
ability in drug response. As previously mentioned, developmental changes may influence drug 
exposure and/or drug response. Thus the identification of the demographic covariates which 
are related to pharmacokinetic or pharmacodynamic parameters is crucial, specifically in chil-
dren where such covariates may be strongly correlated. 
Figure 4 Schematic representation of the relationship between dose and concentration (pharmacokinetics, PK) 
and between concentration and a pharmacological (side) effect (pharmacodynamics, PD). Important covariates 
that may affect both the PK and/or PD are body weight, age, disease status (e.g. critically ill versus healthy chil-
dren) and genetics. (Modified with permission from De Cock et al. (92))
The influence of developmental changes in childhood can be explored primarily by using size 
and/or age as covariates. Size (body weight) can be incorporated into the model using two dif-
ferent approaches. The first approach, the “allometric size approach”, includes size a priori by 
using a body weight-based exponential equation with a fixed exponent of 0.75 for clearance 
and 1 for volume of distribution (98;99). Once size is incorporated in the model using this fixed 
method, the influence of age is investigated, being the difference between the actual value of 
the pharmacokinetic parameter and the 0.75 allometric equation.
 In the second approach, the “systematic covariate analysis”, body weight is regarded as co-
variate as any other, which means that the descriptive properties on the pharmacokinetic pa-
rameters are evaluated in a systematic covariate analysis as described below (42;100;101). In a 
systematic analysis, when studying the influence of covariates, scatter plots are used to screen 
for appropriate covariates to include in the covariate sub-model. Additionally, these plots are 
used to explore the nature of the influence of the covariate (linear, exponential, allometric, sub-
populations, etc.). Likely candidate covariates are then added to the model (forward inclusion). 
The influence of each covariate on the parameters is examined separately and compared with 
the simple model (no covariates). To assess whether the model with the covariate statistically 
improved the fit to the data, the difference between their objective function values, referred 
to as the log–likelihood ratio, is calculated. This ratio is assumed to be Chi-squared distribut-
ed, which means that a reduction in objective function of 3.84 is considered to be significant 
(P<0.05) (102).
After all covariates that significantly improved the objective function are added to the simple 
model, a backward deletion is performed, which means that each covariate is removed from the 
full model, one at a time. Retaining or removing the covariate is statistically tested by the use of 
the objective function (Chi-squared test) until each covariate has been tested.
The identification of the correct covariates which are correlated to pharmacokinetic and/or 
pharmacodynamic parameters in children is particularly challenging due to the correlation be-
tween the covariates and to the limited number of subjects available for the analysis. In case of 
small populations, incorrect covariates might be selected due to lack of balance of the covariate 
distribution in the population analysed during model building; the selection of the erroneous 
covariates could have serious consequences in the prediction of pharmacokinetic or pharmaco-
dynamic parameters in a different population.
Despite some limitations, pharmacokinetic-pharmacodynamic modelling in paediatrics con-
stitutes a powerful and innovative approach to characterise pharmacokinetic-pharmacody-
namic relationships and to optimise dosing regimens for children of different ages, body weights 
and genetic backgrounds. It has been widely applied to antiretroviral therapy to relate plasma 
concentration to efficacy and to identify the optimal dose of antiretroviral drugs in children 
(103;104).
Modelling	patient	adherence
In order to explore novel regimens of antiretroviral drugs or optimise existing ones, a third sta-
tistical element needs to be implemented, which describes the patients and their behaviour to-
wards the treatment.
As explained in the previous part of this review, dosing patterns may differ between patients 
in terms of the actual dose (compliance), the timing of doses (quality) and the duration of treat-
ment (persistence) (105-107). The consequences of variable adherence on treatment outcomes 
are determined by the magnitude of erratic dosing about the prescribed dosing times, the 
number and frequency of sequentially missed doses or ‘‘drug holidays’’ (when the patient stops 
taking the medication(s) for a period of time) and the pharmacological properties of the drug 
(108). Based on clinical data of adherence to treatment a very large inter-individual variabili-
ty has been identified in dosing timing relative to the prescribed interdose interval. Indices of 
dose-taking compliance (the quantity of the dose) are usually less variable (109).
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Given the need to replace compliance data when not available or to test the impact of var-
ious non-compliance scenarios, several simulation models of treatment execution have been 
proposed in the past years. The simplest one assumes that the prescribed number of pills was 
taken correctly, but at different times than the prescribed ones (110;111). In those models, time 
intervals between two doses are drawn from normal distributions (112). Other models propose 
to simulate number of doses taken at each dose time according to a multinomial distribution 
allowing for 0, 1, 2 or more doses taken at each dosing time (113). Since this number may depend 
on the number of doses previously taken, an earlier attempt suggested using a Markov model 
(114), which has great flexibility and allows description of almost all different compliance pro-
files. The use of covariates in this model allows controlling, for example, the date at which the 
patient will have a “drug holiday”.
In conjunction with variable compliance, patient drop-out constitutes another fundamental 
element in clinical trials. Two types of drop-out exist: non-informative and informative drop-
outs. Non-informative drop-outs simply mean that some patients may randomly stop to be re-
ported in the trial, this independently from the treatment they received, and this independently 
of efficacy or toxic effects. On the contrary, disease progress can be correlated to the marker 
that is being followed. In this case, the drop-out is informative to the disease progress, and mod-
elling the disease progress separately from the drop-out process may be inefficient and may 
produce bias estimates (115;116). For example, in a trial of HIV treatment, disease progress 
may lead a patient to drop-out to seek other treatment options. 
Trial execution models, such as compliance and drop-out models, interact with the drug-dis-
ease models as depicted in figure 5.
Figure 5 Schematic representation of interactions between drug-disease models and two aspects of execution 
model: the compliance model and the dropout model. Drug-disease models interactions are shown with continu-
ous lines, while execution models are presented with dotted line arrows. Notice that compliance influences phar-
macokinetic and pharmacodynamic models, which in turn, by feedback mechanisms, may influence compliance. 
(source: http://www.euroformhealthcare.info/drug-development/protocol-deviations-and-execution-models.html).
clinical trial simulation
Given the characteristics of the HIV-infected population, a model-based approach is a potent 
instrument able to define and characterise the processes driving the disease, the pharmacoki-
netic and pharmacodynamic properties of the drug and the behaviour of the patient towards 
the prescribed treatment. Two elements of a model-based approach need to be distinguished 
and defined: modelling and simulation. The former enables translation of the relevant features 
of a system into mathematical language (i.e. model parameters), whilst the latter allows the as-
sessment of a system’s performance under hypothetical and real-life scenarios (i.e. “what-if” 
scenarios), yielding information about the implication of different experimental designs and 
quantitative predictions about treatment outcome, dosing requirements and covariate effects 
(117;118). In clinical trial simulation (CTS) multiple factors can be evaluated concurrently and 
relevant scenarios can be defined and investigated.  The great advantage of the use of CTS in 
paediatric drug development and clinical practice is the possibility of exploring relevant scenar-
ios before enrolling children into a clinical protocol (119;120). Simulations allow evaluation of 
a range of parameter values, including an assessment of critical scenarios, such as overdosing, 
that cannot be generated in real-life studies (94). 
CTS has been widely used in the past in paediatric drug development and clinical practice 
(121). Läer et al. used CTS to develop an age-specific dosing regimen for sotalol in children (122), 
a CTS evaluation by Yim et al. (123) was used to get US Food and Drug Administration approv-
al to change the dosing regimen for etanercept in juvenile rheumatoid arthritis and CTS was 
applied to select rufinamide doses giving an exposure shown to be safe and efficacious in large 
paediatric populations (124). In CTS three important components are characterised: a disease/
placebo model, a drug model, and the implementation model (trial design and decision criteria) 
(fig 6). Together with a model which describes the biological mechanisms underlying the disease 
(125) and a drug-action model which comprises pharmacokinetic and pharmacodynamic factors 
(126), a trial model that  simulates other important aspects of the trial, such as dropout, compli-
ance and protocol deviations, is required (127). Thus far, despite the widespread use of CTS in 
paediatrics, very few examples exist in which relevant design factors have been evaluated pro-
spectively as part of the planning of a paediatric trial. In particular patient-related components, 
such as adherence and drop-out have not been encompassed in previous paediatric CTS. 
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Figure 6 The diagram depicts the major components of a clinical trial simulation (CTS). In model-based drug 
development, CTS can be used to characterise the interactions between drug and disease, enabling among other 
things the assessment of disease-modifying effects, dose selection and covariate effects (e.g. age, body weight). In 
conjunction with a trial model, CTS allows the evaluation of such interactions, taking into account uncertainty and 
trial design factors, including the implications of different statistical methods for the analysis of the data.
Using the pharmacokinetic-pharmacodynamic relationships and viral dynamics, clinical trial 
simulations with antiviral drugs constitutes a very powerful tool to assess the impact of patient-, 
drug- and protocol-related factors on trial outcome and identify critical factors, such as dose se-
lection, and influence of covariates. CTS may be used to evaluate the consequences of different 
patterns of adherence on treatment outcome for specific drugs or drug combinations, yielding 
a quantitative and systematic definition of forgiveness of non-adherence for each antiretroviral 
drug. Such information could be of indisputable value in the exploration of situations which have 
not been tested in reality, such as new doses, new dosing regimens or new drug combinations.
In the previous paragraphs the advantages of model-based approaches for the characterisa-
tion of pharmacokinetics and pharmacodynamics in children have been extensively elucidated. 
However a previous investigation has shown that limitations exist in such approaches when ex-
trapolations are required from different paediatric populations (128). The use of parametric ap-
proaches must take into account that parameter estimation uncertainty is often accompanied 
by model uncertainty and eventual misspecifications. Therefore the use of adaptive protocols 
in the settings of clinical trial simulation which include monitoring of clinical endpoints at pre-
defined intervals may be considered to overcome uncertainty in parameter distributions and 
obtain better dosing recommendations in children (129).  
1.3. conclusive remArks
The previous paragraphs highlighted three main issues in antiretroviral paediatric therapy: the 
selection of the dose, the optimisation of the dosing regimen and the problem of adherence to 
treatment. The use of an integrated model-based approach in which pharmacokinetic-phar-
macodynamic relationships, viral dynamics, patient behaviour and trial execution factors are 
incorporated provides the basis for comprehensive clinical trial simulation scenarios. CTS rep-
resents a critical step in the evaluation and planning of experimental protocols. It also offers the 
opportunity to explore conditions which may not be feasible or ethically acceptable in children. 
The possibility to evaluate in silico populations of HIV-infected children without exposing the 
patients to experimental settings will strongly simplify the identification of the best dose or dos-
ing regimen for a selected group of HIV-infected children and the investigation of forgiveness of 
non-adherence of current or future treatments.
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c h a P t e r  2
scope And intent  
of the investiGAtion
Undoubtedly, considerable advancements have been made in the last decades in terms of effica-
cy and availability of treatment options for HIV. Cocktails containing three or more antiretrovi-
ral drugs are now available, as well as fixed-dose combinations which may significantly improve 
patient’s quality of life. However, there are other issues that are still unresolved when dealing 
with paediatric HIV. Despite the abovementioned advancements, an estimated 2.5 million chil-
dren worldwide are infected with HIV; 90% of them live in sub-Saharan Africa (SSA), where 
annually 330000 new infections occur (1). HIV remains a disease widely spread in limited-re-
sources areas where the access to the medication is inadequate and monitoring of antiretro-
viral therapy is challenging if not impossible in clinical practice. In addition, the pill burden for 
patients and the potential for drug-drug interactions that can compromise the outcome of the 
treatment continue to be high.   
The chronicity of the treatment implies the administration of several drugs throughout child-
hood. Furthermore, dose adjustment is often necessary to ensure that appropriate exposure 
is achieved and maintained during the course of therapy. Among other factors, physiological 
growth and development in the paediatric patients can significantly affect ADME processes, in 
particular drug absorption and elimination. Immature renal function, altered hepatic enzyme 
activity and differences in drug absorption lead to variations in the systemic exposure of an-
tiretroviral drugs among children (2). 
From a therapeutic perspective, growing evidence also reveals that treatment adherence 
in HIV-infected children is complex and current levels are often suboptimal. Poor adherence 
to therapy may compromise the outcome of the treatment, even when the administered dose 
takes into account demographic characteristics and growth-related changes. It can lead to the 
development of drug resistance towards most medications, which ultimately results in viral fail-
ure. Adherence is influenced by many factors, which may be categorised as characteristics of 
the child, the caregiver(s) and family, the formulation and the regimen (3). Paediatric patients 
usually rely on a caregiver to receive their medication, which may be a challenge when frequent 
dosing is required. In this context, a reduction in dosing frequency has been considered criti-
cal for the optimisation of antiretroviral therapy. Yet, one should bear in mind that simplified 
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dosing regimens should not increase the risk of under or over exposure. Such an evaluation is 
complicated by the fact that efficacy and safety in patients must be assessed for combination 
therapies, in which the contribution of each single drug is often not well defined.
Based on the aforementioned, it is hard to understand why the choice of the dose and dosing 
regimens for the treatment of paediatric HIV continues to be driven by empirical decisions. An 
integrated approach is required in which the evaluation of efficacy and safety is driven not only 
by the evidence arising from paediatric clinical trials, but also by inferences from historical data 
and quantitative pharmacology concepts. 
The aim of this thesis is therefore to explore opportunities to support evidence generation 
and extrapolation across populations, with special focus on the selection of the dose and dosing 
regimens in HIV-infected children. Here we propose the use of a model-based approach to iden-
tify and quantify the potential causes of variation in drug pharmacokinetics in children, taking 
into account the interaction between patient adherence and the pharmacokinetic-pharmaco-
dynamic properties of antiretroviral drugs.  Furthermore, given the known challenges in run-
ning clinical trials in children, we will also show the utility of clinical trial simulations and role 
of simulation scenarios to assess the implications of changes in pharmacokinetics and pharma-
codynamics associated with different doses, dosing regimens and variable adherence patterns, 
which cannot be controlled or evaluated in an ethically acceptable manner in clinical practice.  
Three central questions will form the basis for the work to be presented in the subsequent chap-
ters of this thesis:
1.  How to select the appropriate dose(s) for children given that changes in exposure due to 
developmental growth are often nonlinearly correlated with body size and evidence from 
clinical trials is limited to small, imbalanced cohorts?
2.  Can changes in dosing regimen be assessed by a model-based approach taking into account 
the concepts of pharmacokinetic and pharmacokinetic-pharmacodynamic bridging?
3.  Can pharmacokinetic-pharmacodynamic relationships be used to evaluate the impact of 
variable patterns of adherence to therapy on treatment outcome in a quantitative manner, 
given that this cannot be formally tested in clinical practice due to ethical constraints?
It is our endeavour to show how the use of a model-based approach offers an opportunity to 
assess the impact of pharmacokinetic differences on pharmacodynamics and consequently en-
ables prediction of treatment outcome (i.e., viral failure) in children before exposing them to a 
clinical protocol. Ultimately, we will demonstrate that the assumption of similar exposure-re-
sponse relationships between adult and children enables one not only to account for differenc-
es in physiological processes due to developmental growth when selecting the dose, but also 
provides the basis for evaluating the impact of changes in dosing regimen.
2.1. GenerAl introduction
in Chapter 1, we provide an overview about the current status of antiretroviral (ART) therapy 
in children. In fact, we examine the three main elements which undeniably contribute to the 
outcome of the treatment: the disease, the drug and the patient. First, we explore the concept 
of drug resistance, the need for drug combination therapy in HIV and the progress achieved in 
terms of novel interventions, which prevented the development of treatment resistance in the 
last decades. In addition we introduce the use of mathematical modelling as a tool for character-
ising infection and viral dynamics in humans. In a subsequent section, we focus on the relevance 
of statistical population models to characterise the pharmacokinetics and the pharmacodynam-
ics of antiretroviral drugs in children and to quantify the effect of developmental factors on 
drug exposure and efficacy. Of particular interest is the possibility to apply model-based meth-
odologies to describe and discriminate different sources of variability in pharmacokinetic and 
pharmacodynamic parameters even when only sparse samples are available. Lastly, we look at 
the role of the patient in antiretroviral therapy. Different methods are presented, which enable 
the evaluation of adherence to treatment and how this information can be used to explore vari-
ability in treatment outcome. Lastly, we introduce the concept of clinical trial simulations as a 
tool that allows scrutiny of a variety of factors associated with the drug, the disease, the patient 
population and the clinical study design prior to enrolment of actual patients into a clinical pro-
tocol. Of interest is the possibility to investigate the implications of dose adjustment, titration 
algorithms and changes in dosing regimen under different scenarios taking treatment adher-
ence into account, rather than considering as a random effect. 
Based on the review of the requirements for evidence synthesis in paediatric research, specif-
ic issues have been identified in the accepted strategy for the evaluation of the dose and dosing 
regimens in HIV-infected children which will underpin the scope and intent of the investiga-
tions described here in Chapter 2 and detailed in the subsequent sections of this thesis. From a 
methodological perspective we highlight the need for accurate parameter estimation, the iden-
tification of differences in parameter distributions and formal evaluation of the performance 
of pharmacokinetic-pharmacodynamic models when scaling of the dose and dosing regimens 
across populations. These principles are then used to support the rationale for extrapolating 
efficacy across dosing regimens, an approach which is currently not possible according to exist-
ing regulatory guidelines. Our work is then extended to include uncertainty and patient-related 
factors in pharmacokinetic-pharmacodynamic bridging, providing a framework for inferential 
analysis and evidence synthesis in paediatric drug development.
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2.2. sAmple size, covAriAte distribution And predictive 
performAnce of phArmAcokinetic models 
Pharmacokinetic and pharmacokinetic-pharmacodynamic models must be predictive to be 
used for the purposes of bridging and extrapolation (4). Therefore uncertainty and bias in pa-
rameter estimates need to be assessed accordingly to ensure potential limitations minimised. 
The predictive performance of a model implies its ability to accurately describe the effects of 
developmental growth, physiological function and disease across the populations of interest. 
In this context, the use of small sample sizes has been assumed to be acceptable for data ex-
trapolation, which entails that differences in pharmacokinetics and/or pharmacodynamics are 
primarily driven by the magnitude of parameter estimates, rather than by distinct structural 
components (fixed effects) determining drug disposition across populations. This assumption 
also imposes that a common relationship between parameter and covariates must hold across 
the various age groups and most likely that common biological substrates are involved from 
birth throughout to adolescence. Clearly, these considerations may not always be plausible. In 
fact, available data reveal that pharmacokinetic variability may be caused by different factors at 
different stages of life (4).
To overcome the potential for bias in the inferences from a pharmacokinetic or pharmacoki-
netic-pharmacodynamic model, attention must be given to the identification of the mechanisms 
(and influential factors) underlying differences across populations. Most importantly, one needs 
to consider which model parameterisation will support accurate dose selection when using 
models for extrapolation purposes.
It has been previously shown that small samples may increase the probability to introduce 
bias in the selection of the correct covariate during a stepwise covariate selection (5), which in 
turns leads to erroneous dosing recommendations. Therefore, in Chapter 3, we investigate the 
impact of sample size on parameter uncertainty and model parameterisation, emphasising the 
importance of identifying the causes of variability and quantifying their relative contribution 
(i.e., covariate effect) across populations prior to any inferential analysis. From a methodological 
perspective, we scrutinise the use of small populations when performing covariate analyses, a 
common practice which is often justified by ethical and practical limitations in paediatric re-
search. The impact of imbalanced samples across a wide distribution of occurring values and 
co-linearity between covariates (e.g., age, body weight and height) are investigated.  
We perform a meta-analysis in which pharmacokinetic data from three small clinical trials in 
children aged between 3 months and 12 year old receiving lamivudine are pooled, with a total 
of 77 children available after combining the three studies. A population pharmacokinetic model 
is developed taking into account the imbalanced data distribution of reduced sample size on co-
variate selection. To illustrate the clinical implications of bias in covariate selection, a separate 
analysis is performed using a subset of the population and the results are subsequently com-
pared with the findings of the meta-analysis. Here we also take the opportunity to demonstrate 
the importance of comprehensive validation procedures to assess the predictive performance 
of a model.  Such procedures are often omitted in the reporting of population pharmacokinetic 
and /or pharmacodynamic models (6). We show that a shift in paradigm is needed to allow the 
use of nonlinear mixed effects modelling not only as a statistical data analysis method, but rath-
er as an inferential tool. In addition, we highlight that the availability of parameter estimates 
does not automatically translate into dosing regimen recommendations. This represents one 
of the main shortcomings of model-based analysis of paediatric data. Without comprehensive 
use of simulations in which variables of interest rather than model parameters are taken into 
account, one cannot select the correct dose for children and concomitantly assess whether a 
proposed dosing regimen meets extrapolation or bridging requirements. Given that the main 
application of models should be the prediction of drug exposure and/or efficacy across different 
populations, we apply a range of diagnostic tools to explore model performance, including visual 
predictive check, posterior predictive check, bootstrap, mirror plots and normalised prediction 
distribution error (NPDE).
Despite the availability of population pharmacokinetic models for abacavir in the published 
literature, in Chapter 4 we apply the same meta-analytical approach to this nucleoside reverse 
transcriptase inhibitor (NRTI) commonly used in combination with lamivudine.  In contrast to 
previous studies, which were based on either a small number of patients or included only a limit-
ed, imbalanced sample of the patient population, our analysis shows that accurate characterisa-
tion of covariate factors is critical for further assessment of the individual dosing requirements 
across different age groups. In this context, the use of meta-analysis is proposed as a require-
ment to ensure that insight is gained into the processes determining maturation and metabolic 
capacity. Our analysis also shows the potential implication of co-linearity and confounders dur-
ing covariate model building, which may affect the underlying (true) parameter-covariate cor-
relations.  These points are pre-requisites for subsequent use of the model as an inferential tool 
for predicting drug exposure and/or effect both in individual patients and extrapolation across 
groups or populations.
Whilst covariate model building and validation procedures are important scientific steps in 
the implementation of a model-based approach in paediatric drug research, attention should 
also be paid to the clinical relevance. One should note that the possibility of applying popula-
tion pharmacokinetic models to predict drug exposure across an age range different from the 
population used during model building is very appealing, but challenging (7). In fact, evidence 
from a previous investigation suggests that pharmacokinetic models developed from subsets 
of the overall population may not be predictive beyond the range of covariates available during 
model building  (8).  Given the meta-analytical nature of our approach, in Chapter 5 we investi-
gate the requirements for the use of simulations in the extrapolation of data across populations. 
Here we assess the feasibility of extrapolating the variable(s) of interest in a new population 
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beyond the covariate range explored during model building and the role of covariate-parameter 
correlations in this process. Different pharmacokinetic models for a hypothetical drug will be 
used in which the influential demographic factors are linearly or exponentially correlated with 
clearance. In addition, we explore how the presence of multiple covariate factors affects model 
parameter estimation and consequently causes bias and confounding with regard to the contri-
bution of each individual. Each model will be used to predict drug exposure in a virtual popula-
tion of children. Subsequently, two subgroups of children will be identified and the data from the 
two subgroups will be used to fit a pharmacokinetic model, which in turn will be used to predict 
drug exposure in the other population. The accuracy and precision of model predictions will be 
considered as diagnostics of the predictive performance of the model. It will become clear to 
the readership of this thesis, that the use of simulation tools is crucial to explore the predictive 
performance of models when investigating the possibility of extrapolating beyond the covariate 
range explored during model building.  This requirement needs to be considered for subsequent 
application of the models for bridging and extrapolation purposes.
Another methodological issue to be investigated in this chapter is the so-called “centring” on 
the median or the mean value of the covariate in the population when expressing the covari-
ate-parameter relationship in a model. Thus far, it has been unclear whether the median of the 
covariate must be kept when the model is used for simulation purposes in a new population or 
must be adjusted to reflect the covariate distribution in the new population. Again, simulation 
tools will help us quantifying the accuracy and precision of model predictions when extrapolat-
ing across populations.
From a statistical perspective, the modelling issues described here also illustrate the limitations 
of maximum likelihood methods. Model parameter (fixed and random effects) and covariate se-
lection are determined by diagnostic tools (e.g., goodness-of-fit) which assess model performance 
relative to the available data, making models primarily descriptive, rather than predictive.
2.3. simplified dosinG reGimens in children
In the previous section of this thesis special attention is given to the use of model-based meth-
odologies as a tool for the selection of the appropriate dose(s) for children given that evidence 
from clinical trials is limited and often derived from small, imbalanced cohorts. Clearly, one 
needs to account for the effect of developmental growth on pharmacokinetics if the right dose 
is to be recommended using bridging and extrapolation methods. This also implies accurate 
identification of the sources of variability and assumptions about the relevance of pharmacoki-
netic-pharmacodynamic relationships as a proxy for efficacy and safety. 
In this context, a second important application of modelling and simulation is the evaluation 
of changes in dosing regimen. Together with the selection of the optimal dose, dosing frequency 
is another challenging aspect in antiretroviral therapy. Reduced dosing frequency, such as once 
daily administration, may be very appealing for patients and may increase adherence to ther-
apy, as shown previously in various studies (9). Many antiretroviral drugs have been approved 
in adults for their use as oncedaily dosing. However, fewer options are available in children. In 
a paediatric population, where adherence can be compromised because of the patients’ young 
age, poor palatability of the medications, and dependence on caregivers, a oncedaily regimen 
is preferred (10). In this section, we will evaluate the feasibility of oncedaily dosing for lamivu-
dine and abacavir, which are currently approved in adults, but are still recommended according 
to a twicedaily dosing regimen in children. Despite the favourable pharmacokinetic properties 
of these drugs and the availability of clinical trials which show comparable pharmacokinetics 
between once and twice daily dosing, an extensive evaluation in a large paediatric population is 
required. In Chapters 6 and 7 the pharmacokinetic models previously developed and validated 
for lamivudine and abacavir will be used to assess whether the exposure levels achieved after 
once daily dosing in a hypothetical population of 180 HIV-infected children is comparable to his-
torical values in children and adults. Here it is also assumed that similar efficacy can be inferred 
based on evidence of comparable exposures between dosing regimens. 
In contrast to the typical bridging studies in which pharmacokinetic data is used to simply 
generate evidence of comparable drug exposure (figure 1), changes in dosing regimen require 
an additional assumption, i.e., that the underlying pharmacokinetic-pharmacodynamic relation-
ships are dose and concentration-independent. Unfortunately, little has been done in this area 
to demonstrate that such a requirement is biologically plausible in most diseases where phar-
macokinetic processes do not represent the rate limiting step for the onset and maintenance of 
response.  According to the ICH guidelines, in these circumstances studies aimed at the eval-
uation of the pharmacological effects would usually be expected and the dose recommenda-
tions in children may be defined based on the biomarker response if established biomarkers are 
available, which can then be correlated with efficacy. This means that the use of pharmacoki-
netic-pharmacodynamic bridging in paediatric trials implies that even when pharmacodynamics 
cannot be used as a direct proxy for efficacy, it should suffice to demonstrate that the changes in 
viral load are correlated with systemic exposure.
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Figure 1 Paediatric study decision tree (adapted from FDA’s Guidance to industry: exposure-response relationships 
- study design, data analysis, and regulatory applications; 1993). First, the disease and its time course or progres-
sion must be similar in adults and children. Second, the pharmacokinetic-pharmacodynamic relationships need 
to be comparable across the two populations. The third requirement refers to the use of efficacy endpoints in trial 
protocols which can be compared across population or for which a correlation has been demonstrated. If these 
three prerequisites are met, PK and safety studies are sufficient to infer efficacy. By contrast, evidence of efficacy 
and safety must be generated in the paediatric population when one or more requirements cannot be satisfied. PK: 
pharmacokinetic; PD: pharmacodynamic. 
From a clinical perspective, our approach offers the opportunity for applying pharmacokinet-
ic-pharmacodynamic relationships as the basis for the dose rationale. The availability of such 
data also offers the opportunity to explore hypothetical scenarios in large populations without 
the need to expose the patients to the actual protocol, thereby characterising in a quantitative 
manner the impact of drug-, disease- and patient-specific factors. 
2.4. forGiveness to poor Adherence
In the previous sections of this thesis we have dealt with general issues regarding the predic-
tive value of population models for bridging and extrapolation purposes and consequently for 
paediatric dose selection. We make clear that whilst the changes in pharmacokinetics due to 
developmental growth may be easily characterised as long as covariate factors are included in a 
balanced manner, the use of pharmacokinetic-pharmacodynamic bridging based on inferences 
about comparable efficacy and safety imposes an additional assumption, i.e., that fluctuation in 
exposure levels are truly random in the population and that pharmacokinetic-pharmacodynam-
ic relationships are time and concentration-independent. This assumption may be confound-
ed by variable adherence patterns.  Yet, one needs to keep in mind that perfect adherence to 
antiretroviral therapy is very difficult to achieve, especially in children (11). In fact, numerous 
studies have shown that non-adherence to antiretroviral therapy is one of the main causes of 
viral failure (12). In addition, it has been demonstrated that imperfect adherence can lead to 
sub-therapeutic drug levels, which may boost the development of drug resistance to one or sev-
eral drugs in the treatment.
Here we propose a model-based approach to evaluate forgiveness of drug to treatment inter-
ruptions and deviations from the prescribed regimen, which cannot be assessed in a randomised 
controlled experimental protocol due to obvious ethical and clinical reasons. From a method-
ological standpoint, we show for the first time how clinical trial simulations can be used as a 
framework to evaluate complex adherence patterns and explore in a strictly quantitative man-
ner its implications for efficacy and safety. Different mathematical and statistical models are 
combined together to describe the interaction between drug properties, disease characteristics 
and patient behaviour. Most importantly, we envisage the use of such a framework for virtual, 
rather than real populations.
The main objective of this section is therefore to assess adherence as a covariate effect on 
drug exposure using a range of scenarios. The forgiveness of a drug is the ability to achieve 
and maintain viral suppression despite sub-optimal adherence to the prescribed dosing regi-
men. This may depend on many factors, such as drug, viral and host properties. In Chapter 8, 
we investigate which properties of an antiretroviral drug might be related with its degree of 
forgiveness using a putative population of HIV-infected children (n=100). Three paradigm drugs 
belonging to different antiretroviral classes currently approved in children will be investigat-
ed, including a variety of patterns of non-adherence, which corresponds to the most common 
deviation(s) observed in protocol execution. Despite the somewhat complex framework, which 
involves pharmacokinetic, pharmacodynamic and disease models, the impact of poor adherence 
will be limited to the evaluation of the effects on viral load after monotherapy. In Chapter 9, the 
concept will be subsequently expanded to allow characterisation of the effects of poor adher-
ence to a NNRTI-based regimen (efavirenz, lamivudine, abacavir). The probability to experience 
viral failure will be assessed in each scenario of non-adherence and a correlation between ad-
herence and probability for the virus to mutate and become drug resistant will be included in 
the clinical trial simulation framework. In this chapter, we will also explore the feasibility to use 
pharmacokinetic-pharmacodynamic relationships as “proxy” for efficacy in the investigation 
of forgiveness of non-adherence. It is envisaged that evidence of comparable pharmacokinet-
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ic-pharmacodynamic relationships could be treated in a similar manner to pharmacokinetics in 
bioequivalence studies, i.e., a “proxy” for efficacy and safety. 
The predictive value of pharmacokinetic-pharmacodynamic relationships as a proxy for effi-
cacy will be evaluated for a range of  adherence patterns. A clinical trial simulation will be per-
formed to simulate treatment outcome in a virtual population (n=30) of children.  Of interest is 
the relevance of  changes in dosing regimen to  pharmacokinetics and viral load. Based on this 
concept, in Chapter 10 the forgiveness of non-adherence to a simplified dosing regimen (efa-
virenz, lamivudine and abacavir, all administered once daily) is compared with the forgiveness 
of non-adherence of the currently approved dosing regimen. 
2.5. conclusions And perspectives
A summary of the results and conclusions drawn from the various chapters is provided in Chap-
ter 11. Here we show that three main topics regarding the development of antiretroviral pae-
diatric therapy are intertwined, namely the dose, the dosing regimen and patient adherence to 
treatment. As such, they all contribute to success or failure of treatment. Despite the challenges 
in characterising such a complex interaction, throughout the various chapters, we highlight the 
relevance of evidence synthesis in paediatric drug development, as opposed to evidence gen-
eration as the basis for treatment optimisation in children. Pharmacokinetic-pharmacodynam-
ic relationships can be used in conjunction with modelling and simulation to make inferences 
about efficacy and safety, overcoming many if not most of the ethical and technical constraints 
associated with clinical studies in children.
We also attempt to provide practical recommendations regarding the evaluation of models 
for the purposes of bridging and extrapolation of pharmacokinetic and pharmacodynamic data 
across populations. As highlighted in the first section of the thesis the challenge is to identify the 
factors that accurately describe the changes associated with developmental growth. Once the 
predictive performance of a model has been evaluated, its application in subsequent simulation 
scenarios must be considered carefully. The availability of a framework for clinical trial simula-
tions offers not only the possibility to investigate the benefits and risks of a simplified dosing 
regimen, it also provides the basis for evaluating the role of patient behaviour. In this context we 
highlight that the importance of our investigation mainly relies on the use of an in silico approach 
to evaluate critical scenarios which could not be investigated in real-life due to obvious ethi-
cal issues. The possibility to derive quantitative measures of forgiveness may become critical 
for the development of novel antiretroviral compounds.  Special attention is also given to the 
novelty of an in silico methodology for the exploration of non-adherence to therapy and to its 
potential applications to other chronic diseases. 
references
1. Kenny, J., Mulenga, V., Hoskins, S., Scholten, F. & Gibb, D.M. The needs for HIV treatment and care of 
children, adolescents, pregnant women and older people in low-income and middle-income countries. 
AIDS (London, England) 26 Suppl 2, S105-16 (2012).
2. King, J.R., Kimberlin, D.W., Aldrovandi, G.M. & Acosta, E.P. Antiretroviral pharmacokinetics in the pae-
diatric population: a review. Clinical pharmacokinetics 41, 1115-33 (2002).
3. Haberer, J. & Mellins, C. Pediatric adherence to HIV antiretroviral therapy. Current HIV/AIDS reports 6, 
194-200 (2009).
4. Mahmood, I. Prediction of drug clearance in children: impact of allometric exponents, body weight, 
and age. Therapeutic drug monitoring 29, 271-8 (2007).
5. Ribbing, J. & Jonsson, E.N. Power, selection bias and predictive performance of the Population Phar-
macokinetic Covariate Model. Journal of pharmacokinetics and pharmacodynamics 31, 109-34 (2004).
6. Brendel, K. et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evalu-
ated? A survey of the literature from 2002 to 2004. Clinical pharmacokinetics 46, 221-34 (2007).
7. Laventhal, N., Tarini, B.A. & Lantos, J. Ethical issues in neonatal and pediatric clinical trials. Pediatric 
clinics of North America 59, 1205-20 (2012).
8. Cella, M., Zhao, W., Jacqz-Aigrain, E., Burger, D., Danhof, M. & Della Pasqua, O. Paediatric drug devel-
opment: are population models predictive of pharmacokinetics across paediatric populations? British 
journal of clinical pharmacology 72, 454-64 (2011).
9. Moyle, G. Once-daily therapy: less is more. International journal of STD & AIDS 14 Suppl 1, 1-5 (2003).
10. Scherpbier, H.J., Bekker, V., Pajkrt, D., Jurriaans, S., Lange, J.M.A. & Kuijpers, T.W. Once-daily highly 
active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing 
regimen. Pediatrics 119, e705-15 (2007).
5 7
C h a p t e r  2
5 6
11. Simoni, J.M., Montgomery, A., Martin, E., New, M., Demas, P.A. & Rana, S. Adherence to antiretroviral 
therapy for pediatric HIV infection: a qualitative systematic review with recommendations for re-
search and clinical management. Pediatrics 119, e1371-83 (2007).
12. Gross, R., Bilker, W.B., Friedman, H.M. & Strom, B.L. Effect of adherence to newly initiated antiretrovi-
ral therapy on plasma viral load. AIDS (London, England) 15, 2109-17 (2001). 
section ii
sample size, covariate distribution 
and predictive performance  
of pharmacokinetic models
5 9
c h a P t e r  3
covAriAte effects And  
populAtion phArmAcokinetics 
of lAmivudine in hiv-infected 
children
Chiara Piana, Wei. Zhao, Kim Adkison, David Burger, Evelyne Jacqz-Aigrain, Mein-
dert Danhof and  Oscar Della Pasqua
In press - Br J Clin Pharmacol
summAry
Aim: Lamivudine is widely used as first-line therapy in HIV-infected children. Yet, the influence of devel-
opmental growth on drug exposure has not been fully characterised. Here we show how a comprehen-
sive population pharmacokinetic model can be developed to account for the influence of demographic 
covariates on lamivudine exposure (i.e., AUC, Cmax).
Methods: Data from 3 trials including children between 3 months and 13 years old were used in con-
junction with a stepwise covariate selection to describe the pharmacokinetics across the overall popu-
lation. Modelling was performed using nonlinear mixed-effects as implemented in NONMEM v.6.2. A 
stepwise forward inclusion and backward elimination procedure was used for covariate model building.
Results: A one-compartment model with first-order elimination was found to best describe the phar-
macokinetics of lamivudine in children. The effect of body weight on clearance and volume of distribution 
was characterised by an exponential function. The exponent for the effect of weight on CL and V was 
0.705 and 0.635, respectively. The estimate of CL for a patient of 17.6 kg (median body weight) was 
16.5 L/h (CI 15.2-17.7), while the estimate of  volume of distribution for a patient of 17.6 kg was 46.0 
L (CI 42.4-49.5). There were no pharmacokinetic differences between the two formulations (tablet and 
solution). The predicted steady-state AUC0-12 for twice daily dosing after a dose of 4 mg/kg ranged from 
4.44 mg•h/L for children lighter than 14 kg to 7.25 mg•h/L for children heavier than 30 kg. 
Conclusions: The use of a meta-analysis is critical to identify the correct covariate-parameter rela-
tionships, which must be assessed before a model can be applied for predictive purposes (e.g., defining 
dosing recommendations for children).  In contrast to prior modelling efforts, we show that the covari-
ate distribution in the target paediatric population must be considered.
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3.1. introduction
Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) widely administered as 
the nucleoside backbone in combination of highly active antiretroviral therapy to HIV-infected 
children. Lamivudine’s mechanism of action is based on the competitive inhibition of the HIV 
reverse transcriptase.  It is phosphorylated to an active metabolite that competes for incorpo-
ration into viral DNA. According to the latest WHO guidelines (1), lamivudine is administered as 
paediatric first-line therapy in combination with abacavir (ABC), with either a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). In fact, given its excellent 
record of efficacy, safety and tolerability in HIV-infected children, lamivudine is contained in 
practically all recommended combinations in paediatric antiretroviral therapy. in addition, it is a 
frequent component of fixed-dose, including low-cost, drug combinations. 
 Lamivudine is rapidly absorbed after oral administration and it is excreted primarily in the 
urine as unchanged drug (2–6). The intracellular triphosphate has a long half-life of 16 to 19 
hours, as compared to the plasma lamivudine half-life of 5 to 7 hours (7). Lamivudine is currently 
administered to HIV-infected children based on body weight according to the dose of 8 mg/kg/
day for children lighter than 14 kg, 150 mg/day from 14 to 21 kg, 225 mg/day from 21 to 30 kg, 
and 300 mg/day thereafter, all given twice a day.
Over the last years, various attempts have been made to describe the effect of developmental 
growth on the pharmacokinetics of lamivudine in children. Tremoulet et al. performed an exten-
sive population pharmacokinetic analysis in infants between 3 days and 3 years (8); Burger et al. 
also investigated the influence of age on lamivudine pharmacokinetics in HIV-infected children, 
showing that in children of 6 years of age and younger,  the recommended dose of 4 mg/kg twice 
daily leads to exposure levels lower than those observed in children ≥ 7 years of age and adults 
(9). These findings have prompted additional evaluation of the effects of developmental growth 
on the pharmacokinetics of lamivudine. In this context, focus has been given to the use of allo-
metric models to characterise the effect of body weight on clearance. Bouazza et al. described 
the covariate effects in large group of children (n=580) aged between 2 days and 18 years (10), 
whilst  Zhang et al. developed a population pharmacokinetic model in young children between 
0.5 and 4.5 years (11).  In all these studies, either small populations (i.e., group size) or narrow 
age ranges (i.e., population inclusion criteria) were used or the relationship between parameter 
and covariate was fixed a priori. 
Bearing in mind the known issues associated with covariate selection when dealing with 
small datasets, we propose the use of a model-based meta-analysis for the analysis of the phar-
macokinetics of lamivudine. Here we analyse data from three groups of HIV-infected children, 
focusing on the requirements for 1) accurately assessing the correlation between demographic 
covariates and pharmacokinetic parameters and 2) balance in the covariate distribution across 
the groups, without relying on a priori assumptions about the parameter-demographic covariate 
correlation. 
Given the need for a scientifically driven dose rationale in paediatric diseases (12), it can be 
anticipated that the correct identification of influential covariates on drug disposition is essen-
tial when a population pharmacokinetic model is used for simulations and dosing recommenda-
tion purposes (13–15). 
Dosing recommendations should be therefore obtained without introducing bias due to fac-
tors such as unbalanced distribution of the covariates, or due to the small sample size available 
for data analysis. Such a bias may result into suboptimal dosing across different groups in the 
population and consequently lead to increased risk of toxicity or reduced efficacy. A deep un-
derstanding of the correlation between the demographic covariates and pharmacokinetic pa-
rameters is still required to assess the implications of developmental growth on drug exposure 
and, as a consequence, on the efficacy of lamivudine. 
3.2. methods
patients and samples
This investigation was a retrospective pooled analysis of data obtained from three studies: 
PENTA (Paediatric European Network for the Treatment of AIDS) 13; PENTA 15 and ARROW 
(AntiRetroviral Research fOr Watoto). The primary objectives of these studies were to compare 
the pharmacokinetics of once daily versus twice daily lamivudine regimens in HIV type-1-in-
fected children. PENTA 13 and PENTA 15 were conducted in European children aged from 2-13 
years and from 3 months-3 years, respectively. The ARROW study was conducted in Uganda 
with children aged 3-12 years. The studies have been conducted in full conformance with the 
principles of the Declaration of Helsinki and with the local laws and regulations concerning clin-
ical trials. The protocol and the informed consent documents for each study have been formally 
approved by the relevant research ethics committee of each clinical site and by a national ethics 
body. In total data from 77 paediatric patients were available (19 from PENTA 13 study (16), 18 
from PENTA 15 study (17) and 40 from the ARROW trial (18)). The analysis population consist-
ed of male and female patients across the age range between 3 months and 13 years (median 
age 5.79 years), and weight between 7.43 and 61.3 kg (median weight 17.6 kg).  Demographic 
details are summarised in Table 1. In total 1184 blood samples were available for pharmacoki-
netic modelling, with 9 samples below the quantification limit.
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Table 1 Summary of demographic characteristics
 
penta13 penta 15 ArroW Integrated	analysis
SUBJECTS 19 18 40 77
steady state yes yes yes
MEDIAN AGE (years) 5.79 1.91 7.56 5.79
MIN (years) 2.14 0.42 3.5 0.42
MAX (years) 12.84 2.81 12.57 12.84
MEDIAN WEIGHT (kg) 21.75 11.71 20.125 17.6
MIN (kg) 12.5 7.43 14 7.43
MAX (kg) 61.3 16.1 30 61.3
CREATININE CLEARANCE (mL/
min) 81.72 59.9 63.89 95.59
MIN (mL/min) 41.25 31.99 50.43 31.99
MAX (mL/min) 199.59 87.58 168.32 199.59
ethnicity 17 black,     
2 others
14 black,    4 
others
40 black 71 black, 6 others
Assay of lamivudine
For the PENTA13 and PENTA15 studies, plasma concentrations of lamivudine were determined 
by high performance liquid chromatography assay with UV detection (HPLC-UV) with a lower 
limit of quantification (LLOQ) of 0.015 mg/L (19). For the ARROW study, the high performance 
liquid chromatography assay with tandem mass spectrometry detection (HPLC-MS/MS) meth-
od was used, which had a LLOQ of 0.0025 mg/L.
population pharmacokinetic analysis
The pharmacokinetic analysis was done in two steps:
1.  Development of the population pharmacokinetic model using a subset of two studies (PENTA 
13 and PENTA 15 studies) to allow for an initial assessment of model stability and predictive 
performance. 
2.  Integrated pharmacokinetic analysis of the patient data from all three studies, followed by 
model validation, as implemented by standard graphical and statistical methods.
 
Model	Building
Nonlinear mixed effects modelling was performed in NONMEM version 6.2 (Icon Development 
Solutions, USA)(20). Model building criteria included: (i) successful minimisation, (ii) standard 
error of estimates, (iii) number of significant digits, (iv) termination of the covariance step, (v) 
correlation between model parameters and (vi) acceptable gradients at the last iteration (21). 
Fixed and random effects were introduced into the model in a stepwise manner. A parameter 
value of an individual i (post hoc value) is therefore given by the following equation:




 is the typical value of the parameter in the population and η
i
 is the variability be-
tween subjects which is assumed to follow a normal distribution with mean zero and variance 
ω2. Residual variability, which comprises measurement and model error, was described with a 




Yij = Fij + εij * W
Where f
ij
 is the predicted concentration and ε
ij
 the random variable with mean zero and vari-
ance σ2. W is a proportional weighing factor for ε.
Goodness of fit was assessed by graphical methods, including population and individual pre-
dicted vs. observed concentrations, conditional weighted residual vs. observed concentrations 
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and time, correlation matrix for fixed vs. random effects, correlation matrix between parame-
ters and covariates and normalised predictive distribution error (NPDE) (22).  Comparison of 
hierarchical models was based on the likelihood ratio test. A superior model was also expected 
to reduce inter-subject variability terms and/or residual error terms. 
covariate analysis
Continuous and categorical covariates were tested during the analysis. The relationship be-
tween individual pharmacokinetic parameters (post-hoc or conditional estimates) and covari-
ates was explored by graphical methods (plot of each covariate vs. each individual parameter). 
Relevant demographic covariates (body weight, age, height, creatinine clearance) were entered 
one by one into the population model (univariate analysis). Given that different lamivudine for-
mulations were administered in the trials, formulation was also treated as a covariate. After 
all significant covariates had been entered into the model (forward selection), each covariate 
was removed (backward elimination), one at a time. The model was run again and the objective 
function recorded. The likelihood ratio test was used to assess whether the difference in the 
objective function between the base model and the full (more complex) model was significant. 
The difference in –2Log  likelihood (DOBJF) between the base and the full model is approxi-
mately χ2 distributed, with degrees of freedom equal to the difference in number of parameters 
between the two hierarchical models. Because of the exploratory nature of this investigation, 
for univariate analyses, additional parameters leading to a decrease in the objective function of 
3.84 was considered significant (p<0.05). During the final steps of the model building, only the 
covariates which resulted in a difference of objective function of at least 7.88 (p<0.005) were 
kept in the final model.
model validation
The validation of the final model was based on graphical and statistical methods. Given the im-
portance of the validation procedures for the subsequent use of a model for simulation purpos-
es, in this study we used different tools to validate the model. First, a bootstrap procedure was 
performed in PsN v2.30 (University of Uppsala, Sweden) (23). Bootstrap was used to identify 
bias, stability and accuracy of the parameter estimates (standard errors and confidence inter-
vals). PsN does so by generating a set of new datasets by sampling individuals with replacement 
from the original dataset, and fitting the model to each new dataset. 
Subsequently, parameter estimates were used to simulate plasma concentrations in paedi-
atric HIV patients with similar demographic characteristics, dosing regimens and sampling 
scheme as in the original clinical studies. Mirror plots were then applied to evaluate the degree 
of similarity between the original fit and the pattern obtained from the fitting of the simulated 
data sets using the final pharmacokinetic model.
In addition to the graphical analysis, posterior predictive check was performed using AUC 
(area under the plasma concentration vs. time curve) and Cmax (peak plasma concentration) as 
a measure of model performance. AUC and Cmax values were calculated non-compartmentally 
by trapezoidal method from simulations of 1000 data sets with the same demographic charac-
teristics, dosing regimens and sampling scheme as in the original clinical studies. The distribu-
tion of model-predicted AUC and Cmax values were presented for geometric mean, lower and 
upper boundaries of the 95% confidence intervals and compared to the findings from non-com-
partmental analysis in the two clinical studies. Model performance was demonstrated by the 
location of the original estimates across the predicted distribution (histograms).
3.3. results
Population	pharmacokinetic	modelling
The results shown in this paper are derived from the analysis of the combined datasets from 
three studies. A one-compartment pharmacokinetic disposition model with first order absorp-
tion was fitted to the plasma concentration vs. time data derived from the three populations. 
Inter-individual variability was identified for CL, V and Ka. In all three studies used in our in-
vestigation the patients received lamivudine according to once and twice daily dosing regimen. 
Therefore inter-occasion variability on CL and Ka was included in the model to quantify poten-
tial differences in parameter estimates between the two dosing regimens. The residual error 
was described using a combined model including a weighing factor for the variance estimate, 
which showed a better fit  of the data compared with a simple combined error model. CL and V 
were found to increase with body weight. An exponential function best described the correla-
tion between these pharmacokinetic parameters and body weight. The exponent for the effect 
of weight on CL was 0.705 and the exponent for the effect of weight on V was 0.635.
It should be pointed out that both body weight and age showed an influence on lamivudine 
clearance and volume of distribution. However, based on the magnitude of the changes in ob-
jective function (i.e., statistical criteria used for model building), body weight was found to be 
more influential than age on lamivudine pharmacokinetics. In addition to the statistical criteria, 
graphical diagnostics were used to assess the goodness-of-fit. As shown in figures 1, population 
and individual predictions are unbiased. 
Although concentrations below the quantification limit were present at time 0 and 24h, the 
predicted mean concentrations did not significantly differ from the observed mean concentra-
tions (0.081 mg/L vs. 0.098 mg/L at time 0 h and 0.059 mg/L vs. 0.061 mg/L at 24 hours after 
dose).
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model validation
The validation procedure has been performed for twice daily and once daily data separately 
to ensure accurate characterisation of the data irrespective of the dosing regimen. The visual 
predictive check (VPC) (figure 1) indicated model stability and absence of significant bias in the 
estimates for fixed and random effects. Bootstrapping was also performed as part of the valida-
tion procedures. All runs carried out (n= 500) were successful. As shown in Table 2, the final pa-
rameter estimates and their confidence intervals were very similar to original fitting. Given that 
few patients between 3 to 24 months of age were included in the analysis (n=11), scatter plots 
of observed vs. model predicted AUC and Cmax for these subjects are shown to illustrate model 
performance in young children (figure 2). The predictive performance of the model in subse-
quent simulations was deemed critical to achieve the objective of our analysis. To this purpose, 
mirror plots were used to o assess whether the variance and covariance structures have been 
well characterised.  Mirror plots explore whether model parameters can accurately replicate 
the findings in the original study, enabling therefore further assessment of the covariate effects 
on dosing regimen and dose recommendations.  
To complete the validation, a graphical summary of model performance across different 
weight ranges was used to assess the predicted distribution for the variable of interest [AUC
0-t
]. 
As shown in figure 3, the predicted AUC distribution encompasses the exposure observed in the 
original dataset. 
Table 2 Summary of pharmacokinetic parameter estimates from the final model. Parameters are presented only for 
the final model and not for the initial model built using data from PENTA 13 and PENTA 15 studies.
parameter1 population 
estimate



























absorption rate constant 
(Ka) 1/h            
3.68 15.9 3.86 (1.92-5.43)
ALAG1 h 0.755 4.5 0.755 (0.658-0.851) 
Weighing factor in $ERR -2.69 14.7 -2.73 (-4.13,-1.24)
interindividual variability
ηCL/F variance 26%




2 37.8 66.3 (31.3 -88.1)
inter-occasion variability
Occcl 27%3 27.2 26.8 (15.5 -34.8)
Occka 72%3 42.5 72.1 (41.6-94.1)
OCCV 20%3 32.73 19.7 (10.5 -26.3)
residual error
Additive error mg/l 7% 21.48 7.07 (4.5-8.4)
1. Population parameter point-estimates for the full one-compartment model and 95%CI and %CV from a non-parametric 
bootstrap are presented. 
2. Value in parentheses represents the interindividual variability of the pharmacokinetic parame ters calculated as the 
square root of Ω x 100%.
3. Value in parentheses represents the inter-occasion variability of the phar macokinetic parameters calculated as the 
square root of the Ω x 100% 
Figure 1 (a) Goodness-of-fit (Left). Left upper panel shows the population prediction (PRED) vs. observed con-
centration values (DV). Right upper panel shows individual predictions (IPRE) vs. observed concentration values 
(DV). Left lower panel shows conditional weighted residuals (CWRES) vs. population predictions (PRED). Right 
lower panel shows conditional weighted residuals (CWRES) vs. time (TIME). Solid line represents the identity line. 
(b) Visual predictive check (VPC) of the population PK model for lamivudine (Right). The dots represent observed 
concentrations, the dotted lined represent the 5th and 95th percentiles of the simulated values. The solid blue 
line represents the median of the simulated profiles. The VPC is presented for the data following twice daily (upper 
panel) and once daily (lower panel) dosing.  
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 Figure 2 Scatter plots of observed vs. model predicted AUC0-24 (top panels) and Cmax (bottom panels) for children 
younger than 24 months. Left panels show children from 0 to 12 months, whereas children from 12 to 24 months 
are shown on the right panels.
Figure 3 Distribution of the model-predicted area under the plasma concentration vs. time curve [AUC0-∞] (1000 
replicate trials) compared to the original dataset. The left panels show AUC0-∞ predictions for children weighing 
less than 14 kg, middle panels show AUC0-∞ predictions for children from 14 to 21 kg and right panels show AUC0-∞ 
predictions for children weighting more than 21 kg. These weight boundaries were defined according to dosing 
recommendations available in the approved label . Predictions for twice and once daily doses are shown in the 
upper and lower panels, respectively. The solid line represents the geometric mean of the observed AUC0-∞ in the 
three sub-groups for each dosing regimen. AUC0-∞ =AUC0-12 for twice daily dosing and AUC0-24 for once daily. 
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3.4. discussions And conclusions
pharmacokinetic model for the paediatric population
A model-based approach has been applied in our study to describe the pharmacokinetics of 
lamivudine in HIV-infected children across a wide age range. A one-compartment model with 
first order absorption was found to best describe lamivudine pharmacokinetics, which is consis-
tent with previous studies in adults and children (5, 8). In our analysis body weight was the only 
covariate found to influence lamivudine apparent clearance and volume of distribution, which 
is also in agreement with earlier investigations (5, 8, 10). However, differently from the study in 
adults, creatinine clearance was not found to have an effect on lamivudine apparent clearance, 
probably because its effect was confounded by body weight. Apparent clearance estimates in 
our study were very similar to literature findings in children (16.5 vs. 16.9 L/h). In addition, it was 
not possible to find a significant effect of the formulation on relevant pharmacokinetic parame-
ters or to estimate a relative bioavailability of the two formulations. Similar results were report-
ed previously by Bouazza  (24), whereas Kasirye et al. (25) showed in a study with  19 children ( 
aged 1.8 to 4 years) that lamivudine exposure was 55% higher after administration of the solid 
dosage form (i.e., tablet) as compared to the liquid formulation. Such differences may be partly 
due to dose approximation in scored tablet as compared to the precise dose administration of 
the solution. 
Identification	of	covariates	in	lamivudine	pharmacokinetics	in	children
Our meta-analysis using three groups of HIV-infected children (see Table 1) included model 
building and validation steps to ensure predictive performance in subsequent application of the 
model, as e.g., in clinical trial simulations.
In contrast to common practice, an integrated analysis of the full population was performed 
after preliminary model-building based on a subset of the full population. Such a method was 
chosen to assess model stability and confirm the selection and magnitude of the effect of influ-
ential covariates. This approach can be particularly useful in paediatric studies, given the dif-
ficulties in identifying  the correct demographic covariates, which are often highly correlated 
with each other (13, 14, 26). Given that a wrong decision in covariate selection may affect fu-
ture dosing recommendation, special attention should be paid to  covariate model building. As 
shown in a previous study, the stepwise approach commonly used for covariate selection may 
introduce selection and omission bias in the model when the dataset used during the analysis is 
small (27). In fact, in small datasets the distribution of the covariates may not allow identifica-
tion of a correlation between the covariate and the pharmacokinetic parameters. 
In our analyses, the initial lamivudine model accurately predicted the pharmacokinetic pro-
files of the group which was not used for initial model building (results not shown). The same 
parameter-covariate correlations were identified when the model was re-evaluated using the 
full paediatric population. It is important to point out that the correlation between clearance 
and body weight is exponential. For example, the apparent clearance has a median value of 9.33 
L/h for a child weighing 10 kg. It increases to 16.55 L/h in children whose weight is 20 kg, but 
only increases by an additional 1.27 L/h in children of 30 kg (17.82 L/h).   
A separate analysis of the data from the ARROW trial (age range 3 to 12 years) was also per-
formed and a one-compartment model with first order absorption and elimination was identi-
fied to best describe this subset of data. Very interestingly, none of the demographic covariates 
available was found to be significantly correlated to the pharmacokinetic parameters. Further-
more, diagnostic measures, such as the visual predictive check of the model, were not able to 
show any inaccuracy or bias in model-based predictions of the data (figure 5). These results sug-
gest that the model could be used subsequently for dosing recommendation purposes. How-
ever, its use would yield incorrect model-based predictions in a different population since the 
correct parameter-covariate relationship was not identified during covariate model building. 
This finding strongly underlines the importance of an integrated data analysis and the risk of 
inaccurate covariate selection when only a part of the full population is available for analysis.
Limitations	of	current	approaches	in	paediatric	dosing
Many examples are available in literature of population pharmacokinetic analyses based on less 
than 40 patients (28–31). In such small populations an unbalanced covariate distribution may 
lead to the identification and selection of wrong covariate-parameter relationships and, in turn, 
to wrong model-based predictions when applying the model to  a different population (i.e., ex-
trapolation). Many experts in  paediatric pharmacology claim to be able to define the type and 
magnitude of the effect of a covariate on pharmacokinetic parameters; however they do not 
take into account that the parameter-covariate correlation may be biased by the covariate dis-
tribution in that particular group of children and as such should not be used in a different pop-
ulation. In these circumstances, one should talk about a data-driven approach, in the sense that 
the model is able to correctly describe the data (as shown in our analysis by the visual predictive 
check in figure 4), but is not able to predict correctly the variable of interest in a different popu-
lation. It is also worth mentioning that such a hidden bias is not addressed by simply increasing 
the sample size as often is the case in pooled analysis of patients undergoing therapeutic drug 
monitoring. Meta-analyses should therefore be the preferred method in paediatric pharmaco-
kinetics to avoid model misspecification and consequently expose children to suboptimal drug 
levels or to a higher risk of toxicity. When sufficient paediatric data are not available, one should 
consider overcoming the limitations of small populations by  incorporating prior information 
from pharmacokinetic parameters in adults and include them in the model, as suggested by 
Cella et al (12).  There are also other research groups, who choose not to use pharmacokinetic 
modelling for the analysis for drug exposure and dose selection in children. Instead, they prefer 
to solely rely on non-compartmental analysis, ignoring the issues highlighted above. The use 
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of a model-based approach presents significant advantages compared to non-compartmental 
analysis, which cannot be overlooked from a scientific and ethical point of view.
Figure 4 Visual predictive check (VPC) of the population model for lamivudine using only the data from the 
ARROW trial. The dots represent observed concentrations, the dotted lines represent the 5th and 95th percentiles 
of the simulated values. The solid line represents the median of the simulated profiles. The VPC is presented for the 
data following twice daily (left) and once daily (right) dosing. 
Clinical	implications	of	an	integrated	population	analysis	for	accurate	dosing	
recommendation
Given that drug exposure drives efficacy, it should be clear that model misspecification may lead 
to incorrect dosing recommendations. The identification of the correct covariate-parameter re-
lationships is therefore crucial to accurately predict drug exposure across different groups in the 
paediatric population. Yet, this issue is further compounded by current prescription practices.
The role of covariate-parameter correlations is apparently even more important when ex-
ploring changes in dosing regimen.  For instance, we could not investigate the effect of obesity 
in this population. However, given the low lipophilicity of lamivudine (which is water soluble), 
we anticipate no major impact of obesity on its pharmacokinetics. It is conceivable that doses 
based on lean body mass might be required for very obese patients, as drug distribution and 
metabolism would not increase proportionally to total body weight.
How to dose a drug in children remains a very debatable subject. Whereas normalisation 
of the dose by body weight makes prescription easy and reduces the risk for prescription er-
rors, deriving dose recommendations without a thorough understanding of drug disposition in 
children has been proven to be unsafe and harmful (32). Clearly, the effect of developmental 
growth on pharmacokinetics is a nonlinear phenomenon and as such can be best described by 
a model-based approach.  However, modelling and simulation techniques should be used with 
caution. Too little attention has been paid so far to the implications of unbalanced covariate dis-
tributions on pharmacokinetic analyses outcome, as shown by the elevated number of examples 
available in literature. We are fully aware of the challenges in performing paediatric trials and in 
collecting clinical data in children. These difficulties must not prompt us to neglect the problems 
caused by small datasets, which may lead to the wrong dose selection. The use of meta-analyses, 
i.e., combined datasets from available clinical trials in children is strongly encouraged to avoid 
erroneous predictions of the paediatric dose.  
limitations in our approach                                                                                  
It is important to mention that lamivudine plasma concentrations represent a limited marker 
of drug exposure, as it is the intracellular lamivudine triphosphate metabolite that becomes 
pharmacologically active. Unfortunately adequate sampling for determination of intracellular 
concentrations of nucleoside transcriptase inhibitor triphosphate is logistically and technical-
ly difficult (33). Furthermore the volume of blood needed to measure intracellular lamivudine 
triphosphate concentrations with current technology makes serial evaluations impractical for 
paediatric patients.
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conclusions
The clinical relevance of a pharmacokinetic model depends on the generalisability of the co-
variate model across the overall population. Here we have shown that covariate effects may 
be under or overestimated if the available data do not support accurate identification of the 
correlation between pharmacokinetic parameter and covariate. Unbalanced distribution of co-
variates may result in hidden bias and yield inaccurate dosing recommendations in children. In 
addition, our work shows that the concept of pharmacokinetic bridging has been met for lami-
vudine, in that the dosing corrected by body weight does account for developmental growth, 
yielding comparable systemic exposure throughout the population older than 3 months of age.
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summAry
Aims: To characterise the pharmacokinetics of abacavir in infants, toddlers and children, and assess the 
influence of covariates on drug disposition across these populations.
Methods: Abacavir concentration data from three clinical studies in HIV-infected children (n=69) 
were used for model building. The children received either a weight-normalised dose of 16 mg/kg/day 
or the WHO recommended dose based on weight-bands. A population pharmacokinetic analysis was 
performed using NONMEM v6. The influence of age, gender, body weight and formulation was evalu-
ated. The final model was selected according to graphical and statistical criteria.
Results: A two-compartmental model with first-order absorption and first-order elimination best 
described the pharmacokinetics of abacavir. Body weight was identified as significant covariate in-
fluencing the apparent oral clearance and volume of distribution. Predicted steady-state Cmax and 
AUC0-12 of standard twice daily regimen were 2.5 mg/L and 6.1 mg•h/L for toddlers and infants, and 
3.6 mg/L and 8.7 mg•h/L for children, respectively. Model-based predictions showed that equivalent 
systemic exposure was achieved after once and twice daily dosing regimens. There were no pharmaco-
kinetic differences between the two formulations (tablet and solution). The model demonstrated good 
predictive performance for dosing prediction in individual patients and as such can be used to support 
therapeutic drug monitoring in conjunction with sparse sampling.
Conclusions: The disposition of abacavir in children appears to be affected only by differences in size, 
irrespective of the age of the patient. Maturation processes of abacavir metabolism in younger infants 
should be evaluated in further studies to demonstrate the potential impact of ontogeny. 
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4.1. introduction 
Abacavir is a potent nucleoside reverse transcriptase inhibitor (NRTI), prescribed in combi-
nation with other antiretroviral agents (nucleoside reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs)) for the 
treatment of human immunodeficiency virus (HIV) infection in both paediatric and adult pa-
tients (1,2). It is marketed for paediatric patients from 3 months to 16 years at the dose of 8 mg/
kg twice daily, up to a maximum of 300 mg twice daily.
Abacavir is well absorbed following oral administration and distributed into body tissues, in-
cluding the central nervous system. It is extensively metabolized by the liver and less than 2% is 
excreted as unchanged drug in the urine. The two major catabolic pathways include oxidation by 
alcohol dehydrogenase (ADH) and conjugation by uridine diphosphate glucuronyltransferase 
(UGT), resulting in inactive carboxylate and glucuronide metabolites (3,4). The antiviral activity 
of abacavir results from its intracellular activation to carbovir triphosphate (CBV-TP). CBV-TP 
competes with the endogenous nucleotide 2’-deoxyguanosine triphosphate (dGTP) for incor-
poration into the nucleic acid chain and terminates the DNA chain by preventing addition of 
new bases (5). The endpoint for efficacy, as indicated by the change from baseline in viral load 
(plasma HIV-1 RNA) and T cells count rise was significantly correlated with area under the con-
centration–time curve (AUC) (6). The AUC
0-12 
value of 6.02 mg•h/L was set as target exposure 
both in adults and children (7).
The pharmacokinetics of abacavir has been previously investigated in children (8-15). How-
ever these studies were based on either a small number of patients, sparse sampling or narrow 
age range of the children, which renders difficult the assessment of the role of developmen-
tal factors on drug disposition. Accurate characterisation of these factors may allow not only 
further assessment of the individual dosing requirements across different age groups, but also 
insight into processes determining maturation and metabolic capacity, which may be deemed 
drug-independent. In this investigation, we make use of a model-based approach to analyse 
three different studies in children across a wide age range, with the objective of obtaining more 
reliable prediction of pharmacokinetic profiles in individual patients. In addition, given the avail-
ability of tablet and solution dosage forms, this analysis offered us the opportunity to explore 
the potential influence of formulation on paediatric pharmacokinetic parameters.
4.2. methods 
clinical trials
The data were obtained from three studies: PENTA (Pediatric European Network for the Treat-
ment of AIDS) 13, PENTA 15 and a pharmacokinetic sub-study within the main ARROW (An-
tiRetroviral Research fOr Watoto) trial (8-10). Briefly, the primary objectives of these studies 
were to compare the pharmacokinetics of once daily versus twice daily of abacavir and lamivu-
dine in HIV type-1-infected children. The European studies PENTA 13 and PENTA 15 were con-
ducted in children aged from 2-13 years and from 3 months-3 years, respectively. The ARROW 
pharmacokinetic sub-study was conducted in Uganda with children aged 3-12 years. In total, 
sixty-nine children were included in this population pharmacokinetic meta-analysis. The mean 
(SD) age was 5.74 (3.40) (range 0.42 – 12.84) years and the mean (SD) weight was 18.7 (8.0) 
(range 7.6 – 60.9) kg. Pharmacokinetic samples were obtained at steady-state at time T0 (imme-
diately before administration) and T1, T2, T3, T4, T6, T8 and T12 h after administration for the 
twice daily regimen and an additional sample at T24 h for the once daily regimen. A summary 
of trial design, dosage regimens, and patient characteristics are presented in Table 1. The stud-
ies have been conducted in full conformance with the principles of the Declaration of Helsinki 
and with the local laws and regulations concerning clinical trials. The protocol and the informed 
consent documents for each study have been formally approved by the relevant research ethics 
committee of each clinical site and by a national ethics body.
bioanalysis 
For the PENTA13 and PENTA15 studies, plasma concentrations of abacavir were determined 
by high performance liquid chromatography assay with UV detection (HPLC-UV). The details 
of the analytical method have been reported (8,9). The lower limit of quantification (LLOQ) was 
0.015 mg/L. Within-day and between-day variability were 1.1–1.9% and 0.16–2.3%, respec-
tively. For ARROW study, plasma concentrations of abacavir were determined using validated 
HPLC/MS/MS method by GlaxoSmithKline (Research Triangle Park, NC, USA). The LLOQ was 
0.0025 mg/L (10).
Pharmacokinetic	modelling
Pharmacokinetic analysis was carried out using the nonlinear mixed effects modelling program 
NONMEM v6 (V2.0; Icon Development Solutions, USA) (16). First order conditional estimation 
(FOCE) method with interaction option was used to estimate pharmacokinetic parameters and 
their variability. 
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Inter-individual variability of the pharmacokinetic parameters was estimated using an expo-





 represents the parameter value of the ith subject, θ
TV
 the typical value of the parame-
ter in the population and ηi the variability between subjects which is assumed to follow a normal 
distribution with a mean of zero and variance ω2. 
Covariate analysis followed a forward and backward selection process. The stepwise covari-
ate modelling (17,18) and likelihood ratio test was used to test the effect of each variable. Model 
validation was based on graphical and statistical criteria, including goodness-of-fit plots (19), 
mirror plots, bootstrap, visual predictive check (VPC) and normalized prediction distribution 
errors (NPDE) (20,21).
Clinical	application	in	therapeutic	drug	monitoring	
Given our interest in clinical application of model-based approaches, the performance of the 
final model to support therapeutic drug monitoring and dosing adjustment was tested via simu-
lation scenarios. To assess its predictive value, we have extensively evaluated whether the final 
model could be used to accurately predict observed drug exposure with current dosing regi-
mens. For this purpose, the time course of abacavir concentrations was simulated 100 times in 
each sub-population (infants, toddlers and children) and for each dosing regimen (once vs. twice 
daily). The area under the concentration vs. time curve (AUC
0-24
) was selected as endpoint for 




 for twice daily) was calculated using 
trapezoidal rule. The simulated AUC
0-24




The feasibility of a model-based approach  in therapeutic drug monitoring was evaluated by 
considering two main scenarios in which pooled population data and sparse pharmacokinetic 
sampling are used as basis for predicting drug exposure in new patients:
1.  To assess model performance in new patients, 10 children were randomly removed from the 
original dataset. The parameters for the remaining 59 children were re-estimated. The model 
parameters were then used to predict individually the pharmacokinetics of the 10 children 
excluded from the analysis, taking into account the effect of covariates in each patient. Pre-
dictions were compared to the observed data graphically by means of visual predictive check 
plots (1000 simulations/patient).
2.  To assess the impact of empirical sparse sampling on model predictions, data from new pa-
tients using only three samples (T0, T1 and T3) were added in a stepwise manner to the data-
set (i.e., initial population, n=59). Model parameters were then re-estimated for all 60 chil-
dren (of which 59 had frequent sampling scheme). The new model was used to predict the 
full pharmacokinetic profile of single patients with sparse samples. Results were compared 
graphically with the original data using visual predictive check plots (1000 simulations/pa-
tient). This approach was selected as an initial step to the use of a full Bayesian analysis, in 
which model parameter values from a historical population (instead of the data) are used as 
priors to anchor the estimation of the parameters of interest for a new subject or population.
4.3. results
Population	pharmacokinetic	modelling
A total of 1065 plasma abacavir concentrations were available for population modelling. Data 
fitted a two-compartment model with first order absorption and elimination. Inter-individual 





/F and CL/F. Inter-occasion variability on CL/F was coupled to inter-individual variability by 
an additive model, respectively. Residual variability was best described by a proportional model. 
Table 1: Summary of three pharmacokinetics studies and characteristics of patients
 
penta13 penta 15  ArroW Integrated	analysis
SUBJECTS 14 18 37 69
steady state yes yes yes yes
MEDIAN AGE (years) 5.10 1.93 7.61 5.74
MIN (years) 2.14 0.42 3.62 0.42
MAX (years) 12.84 2.81 12.54 12.84
MEDIAN WEIGHT (kg) 19.2 11.6 20.5 17.6
MIN (kg) 14.0 7.6 14 7.6
MAX (kg) 60.9 15.8 29.8 60.9
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During covariate model building, the inclusion of age, weight and formulation on CL/F, and 
weight on V
1
/F all separately produced a significant decrease in objective function (OFV). How-
ever, following the backward exclusion process, only the effect of weight on CL/F and V
1
/F was 
found to be significant ((∆OFV >7.88 (p<0.005, c2 distribution)). Therefore, the influence of 
weight on CL/F and V
1
/F was retained in the model as follows: 
CL/Fi=CL/Fref × (WTi / WTref)
 θ1








 are, respectively the CL/F and V
1
/F of the ith individual, WT
i
 the weight 
of the ith individual, WT
ref
 the reference weight. The subscript “ref” indicates the individual with 
a reference weight. In our study, the reference weight was the median value of our population 
17.6 kg. The allometric exponents were estimated to be 0.802 for CL/F and 0.810 for V
1
/F.
Model diagnostics indicated acceptable goodness-of-fit for the final model. As shown in figure 
1a, population and individual predictions are unbiased. In addition, the mean parameter esti-
mates resulting from the bootstrap procedure very closely agreed with the respective values 
from the final population model, indicating that the estimates for the population pharmacoki-
netic parameters in the final model were accurate and that the model was stable. The results of 
1000 bootstrap replicates are summarised in table 2.
Mirror plots reveal that the variance-covariance structure was well characterised, as the sim-
ulated datasets reproduce the similar dispersion pattern observed in the original data (results 
not shown). The NPDE distribution and histogram indicates that the assumption of normal dis-
tribution of the differences between individual predictions and observed data is acceptable (fig-
ure 1b). No trends were observed on the diagnostic plots of NPDE versus time. The VPC (figure 
2) of the final model with all patients shows that observed concentrations were well predicted 
by the model (Exact Binomial Test, 7.4% out of limits observed, 95% confidence interval [5.9% – 
9.2%]). VPCs for each sub-population (infants, toddlers and children) and each dosing regimen 
(once and twice daily) are also shown in figure 2. 
Figure 1 (a) Goodness-of-fit. Left upper panel shows the population prediction (PRED) vs. observed concentration 
values (DV). Right upper panel shows conditional weighted residuals (CWRES) vs. time (TIME). Left lower panel 
shows individual predictions (IPRE) vs. observed concentration values (DV). Right lower panel shows conditional 
weighted residuals (CWRES) vs. population predictions (PRED). Solid line represents the identity line. 
(b) Normalized Prediction Distribution Errors (NPDE) analysis. Upper panel shows the histogram of the distribu-
tion of the NPDE, with the density of the standard Gaussian distribution overlaid. Lower panel shows NPDE versus 
time (TIME)
Figure 2 VPC in infants and toddlers (a), children (b), following once daily (c) and twice daily dosing regimen (d): 
observed data are plotted using a circle (○). The dashed lines represent the 5th, and 95th percentiles of simulated 
data (n=1000). The solid lines represent the 50th of simulated data (n=1000).
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Absorption rate constant (K
a





2 41.7 41.0 (27.5-62.1)
ηV1/F variance 47.7%
2 33.6 46.2 (29.7-66.4)
ηV2/F variance 57.5%
2 40.5 55.8 (38.3-76.4)
Inter-occasion variability
Occcl 20.4%3 25.3 20.2 (15.7-24.8)
Residual Error
Proportional error 38.2% 8.2 38.1 (35.7-40.9)
1. Population parameter point-estimates for the full two-compartment model and 95% CI and %CV from a non-paramet-
ric bootstrap are presented.
2. Value in parentheses represents the interindividual variability of the pharmacokinetic param eters calculated as the 
square root of Ω x 100%
3. Value in parentheses represents the inter-occasion variability of the pharmacokinetic parameters calculated as the 
square root of the Ω x 100%
predictive performance in clinical applications
To assess the performance of the final model for therapeutic drug monitoring and dose adjust-
ment, pharmacokinetic parameter estimates were also used to simulate drug exposure, ex-
pressed as area under the concentration vs. time curve AUC
0-24
, in different sub-populations 
(infants and toddlers [n=21, age range: 0.42-2.81]; children [n=48, age range: 3.58-12.84]) and 
for currently used dosing regimens (once and twice daily dosing). As shown in figure 3, consider-
able overlap was observed in the simulated and observed AUC
0-24 
values in infants and toddlers, 




(geometric mean) of standard dose regimen 
(8mg/kg twice daily) were 2.5 mg/L and 6.1 mg•h/L in toddlers and infants, and 3.6 mg/L and 8.7 
mg•h/L in children, respectively. These values were in agreement with the observed values in 




(geometric mean) were respectively 
2.3 mg/L and 5.8 mg•h/L in toddlers and infants, and 3.6 mg/L and 8.2 mg•h/L in children. Simi-
larly, drug exposure was not different after once or twice daily doses of abacavir.
Figure 3 Simulated AUC distribution and median (continuous line) and 5th and 95th percentiles (dashed lines) of the 
observed AUC in infants and toddlers (a), in children (b), following once daily dosing (c) and twice daily dosing (d)
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Moreover, the assessment of the predictive performance of the model included scenarios in 
which drug exposure was predicted in new patients taking sparse sampling schemes into ac-
count. In both cases, estimates of parameter accuracy and precision were acceptable. As shown 
in figure 4, accurate predictions can be made of individual patient profiles using this model, de-
spite some evidence of over-estimation of residual variability.
Figure 4 Individual VPC for new patients. Scenario (a): VPC for 10 new patients. Scenario (b): VPC for 1 patient 
with sparse sampling. Open circles (○) represent the observed data, whilst dashed lines depict the 5th and 95th 
percentiles of the simulated data (n=1000). The solid lines indicate the median obtained from the simulated data 
(n=1000).
4.4. discussions And conclusions
In the present study, we have shown the use of population pharmacokinetic meta-analysis of 
abacavir based on data obtained by a rich sampling strategy in 69 children from three pharma-
cokinetic studies. We believe that pooling of data offers the opportunity to evaluate drug dispo-
sition across a wide age and body weight range. Such an evaluation may be essential to assess 
the suitability of dosing recommendations for children. Even though our analysis is limited to 
abacavir data, we anticipate that such considerations are necessary and applicable to most if 
not all compounds for paediatric indications.
From a methodological perspective, meta-analytical concepts are required to ensure thor-
ough understanding of the implications of developmental growth on pharmacokinetics in pae-
diatric patients. Despite attempts to describe changes in drug disposition by allometric models, 
it should be clear that the paediatric population encompasses a very heterogeneous group of 
patients. Inferences about pharmacokinetics in individual patients may be challenging with data 
arising from a very limited number of patients, especially when the objective is to predict indi-
vidual exposure in prospective patients or to adjust dosing regimens in chronic treatment, as in 
the case of therapeutic drug monitoring. The scope of population pharmacokinetic modelling 
is to enable the description and prediction of ADME processes in a parametric manner, so that 
hierarchical parameters can be derived that can discriminate population from individual patient 
characteristics. In paediatric pharmacokinetics, however, discrimination between population 
and individual differences is further confounded by the role of maturation and other factors as-
sociated with developmental growth, including changes in metabolic capacity (22). In a previous 
work (7), Cella et al have shown that a model-based approach offers a suitable basis for estima-
tion of pharmacokinetic parameters even when only sparse samples may be available. However, 
such models do not necessarily permit accurate prediction of the differences in pharmacokinet-
ics for individuals whose characteristics are not represented in the population used during mod-
el building and validation. As shown in a previous analysis (23), a model developed using data in 
older children cannot reliably predict exposure in infants and toddlers, and vice versa. This lack 
of predictive performance is partly explained by the fact that covariate-parameter correlations 
may not remain constant beyond the range of observations. Estimation of covariate effects is 
therefore not sufficient to allow accurate extrapolation of pharmacokinetics from a reference 
population to another population. 
Our results indicate that it is not the overall number of patients that determines the predictive 
performance of a model, but rather the availability of data from the overall population, so that 
parameter distributions can be accurately estimated and imputations can be made about individ-
uals belonging to any part of the population with adequate precision. Our results show that good 
predictive performance of a model can be achieved with a considerably limited number of indi-
viduals as long as the covariate distribution in the subjects used for model building represents 
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the covariate distribution in the population described by the model. This is critical to ensure that 
differences driven by covariates are not captured as random effects, nor random effects are 
wrongly associated with covariates. This is illustrated by the difference in the magnitude of pa-
rameter estimates in our analysis and in estimated parameters from single trials (table 3).
Table 3 Covariate-parameter relationships identified for abacavir in previous population pharmacokinetic analyses.





covariates in the 
model
covariate-parameter relationship
Penta 13 [7] 14 2.14-12.84 Weight on cl 
and V
CL/F (L/h) = 37.2 •{BW/23.8}0.553
V/F (L) = 64.8 • {BW/23.8}0.537






69 0.42-12.84 Weight on cl 
and V1
CL/F (L/h) = 20.1 • {BW/17.6}0.802




[11] 105 0.0685-16 Weight on cl 
and V
CL/F (L/h) = 24.3 • {BW/25}1.0
V/F (L) = 42.9 • {BW/25}0.95.
Whereas the focus of previous publications was on the use of modelling as the basis for drug de-
velopment (i.e., early paediatric trials), little attention has been paid to the implications of simi-
lar modelling requirements for accurate dosing adjustment and therapeutic drug monitoring in 
clinical practice (24, 25). In the present study, we have assessed the predictive performances of 
the final model using several simulation scenarios in which potential differences in individual 
exposure are evaluated. Our results indicated that the final model can accurately predict drug 
exposure with currently used dosing regimens in new patients, even in case of sparse sampling. 
Population pharmacokinetic and/or pharmacodynamic model validation is another key- issue 
to consider when models are to be used for simulation purposes (i.e. dosage optimisation or 
clinical trial simulation). Validation procedures are lacking in many publications reporting the 
development of population pharmacokinetic and /or pharmacodynamic models (26). In fact, ad-
vanced internal evaluations were performed on merely 16% of the models in children (27). In 
the present study, five evaluation / validation criteria were included: 1) Standard goodness-of-
fit plots, which inform on model misspecification and allow assessment of trends or bias in the 
model predictions. 2) Mirror plots, which allow comparison of the variance structure between 
simulated and observed data. 3) Bootstrap, which provides information on the stability of the fi-
nal model. A robust model is not affected by the contribution or influence of specific individuals 
in the data set. 4) Visual Predictive check, which yields information on the presence of systemic 
bias or deviations (trends) in model predictions. 5) NPDE, which provides details on the distribu-
tion of the differences between predictions and observations. It is an important criterion for the 
validation of a model for subsequent simulation purposes. Even though each of the aforemen-
tioned diagnostic tools reveals different aspects of model performance, it is critical to point out 
that there is no guarantee that model predictions will be accurate unless the relevant covariates 
are included in the initial model.
limitations
During this investigation only body weight, age, gender and formulation were tested as poten-
tially influential covariates on pharmacokinetic parameters. Information on ethnicity and other 
potential demographic factors were not available. Given that abacavir is metabolised primarily 
through alcohol dehydrogenase or glucuronyl transferase, metabolic information would have 
been useful to describe abacavir pharmacokinetics. Further studies are required to evaluate the 
ontogeny of abacavir metabolism.
In summary, we have shown that abacavir pharmacokinetics in children can be characterised 
by a two-compartment model with first order absorption. Body weight was identified as the 
primary covariate influencing the apparent oral clearance and volume of distribution. The avail-
ability of data across a wide range of ages and consequently across body weights enabled the 
identification of the accurate relationships between pharmacokinetic parameters and covari-
ates in the paediatric population. These relationships may not be evident or even missed when 
analysing small datasets or when the relevant range of values for the influential covariates is 
not included in the overall population. The use of an integrated, meta-analytical approach is 
therefore essential to ensure accurate prediction of drug exposure in new patients or in clinical 
conditions different from the original trial setting.
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summAry 
The accuracy of model-based predictions often reported in paediatric research has not been thoroughly 
characterised. The aim of this exercise is therefore to evaluate the role of covariate distributions when 
a pharmacokinetic model is used for simulation purposes. Of interest is the evidence that model pre-
dictions are unbiased when the covariate range is beyond the data distribution available during mod-
el-building. Such an analysis is critical for the use of nonlinear hierarchical modelling in extrapolation 
and bridging of findings across different populations in paediatric drug development.
Plasma concentrations of a hypothetical drug and demographic characteristics of a paediatric popu-
lation were simulated using a pharmacokinetic model in which body weight was correlated to clearance 
and volume of distribution. Two subgroups of children were then selected from the overall population 
according to a typical study design, in which pre-specified body weight ranges (10-15 kg and 30-40 
kg) are used as inclusion criteria. The simulated data sets were then analysed using non-linear mixed 
effects modelling. Model performance was assessed by comparing the accuracy of AUC predictions ob-
tained for each subgroup, based on the model derived from the overall population and by extrapolation 
of the model parameters across subgroups.
Our findings show that systemic exposure as well as pharmacokinetic parameters (CL and V) cannot 
be accurately predicted from the pharmacokinetic model obtained from a population with a different 
covariate range than the one explored during model building. Predictions were accurate only when a 
model is used for prediction in a subgroup of the initial population. In contrast to current practice, the 
use of pharmacokinetic modelling in children should be limited to interpolations within the range of 
values observed during model building. Furthermore, the covariate point estimate must be kept in the 
model even when predictions refer to a subset different from the original population. These findings 
highlight the importance of meta-analytical procedures in paediatric bridging. It also suggests the need 
for more mechanistic parameterisations, which discriminate drug from system-specific parameters.
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5.1. introduction
Modelling and simulation (M&S) of clinical data represents a powerful approach for evidence 
synthesis and consequently for a more comprehensive interpretation of the data available at 
any point in time during the process of drug development. Ideally, it should also provide the ba-
sis for inferences and extrapolation of findings from a subgroup to the entire target population 
(1, 2). At present, regulatory bodies in Europe encourage the application of the M&S approach 
during drug development (3), as it may circumvent some practical and ethical difficulties in the 
evaluation of paediatric medicines. In fact,  industry and academia have been developing and 
applying models under the assumption that  nonlinear mixed effects modelling methods are ro-
bust enough to enable the characterisation of pharmacokinetics and pharmacodynamics even 
when sparse sampling and unbalanced data sets are used (4–8). 
More recently, M&S has been applied as a design tool for pharmacokinetic and pharmacoki-
netic-pharmacodynamic bridging. In this case, the main objectives of such models include the 
selection of dose and prediction of drug exposure and/or effects in a new population, for which 
no data has been generated. In this context, the identification of influential covariates such as 
demographic characteristics can play a major role in the accuracy of parameter estimates and 
subsequent predictions. The assessment of the correct correlations between covariates and 
parameters is crucial, given that it will have direct implication for the dose selection in a new 
population with different demographic characteristics. In the paediatric research, however, the 
identification of the correct covariates is often complex due to the presence of correlations and 
co-linearity between covariates. As shown by a previous investigation from Ribbing et al, com-
petition between multiple covariates may further increase selection bias, especially when there 
is a moderate to high correlation between the covariates (9).
Different methods are available to select significant covariates during model building. The 
most used one is the stepwise covariate selection in which two processes, forward inclusion 
and backward elimination, are applied (10,11). Alternative methods,  such as genetic algorithms 
for covariate selection (12) and automated covariate model building (13, 14) are also becoming 
more common, but have not been scrutinised to the same extent in pharmacokinetic research. 
In contrast to traditional data analysis, models developed by the stepwise covariate selection 
are also being used to predict drug exposure and consequently define the dose rationale in new 
patients, whose characteristics differ from the original patients in the trial.
Model-based predictions can be considered for a population with similar characteristics 
as the one under investigation during model building (interpolation) or for a new population 
beyond the covariate range explored during model building (extrapolation). Many examples 
are available in literature of studies in which modelling has been applied to interpolate data 
(15–17). Fewer examples exist however in which extrapolations are made to a population which 
does not share exactly the same characteristics or includes individuals beyond the range of 
values explored during model building.  In fact, two  recent publications by Cella et al. (18, 19) 
showed the lack of predictive performance of  pharmacokinetic models when they are used for 
extrapolation purposes. 
The current analysis has two main objectives. First of all, we want to define the feasibility and 
pre-requisites to use pharmacokinetic models as an extrapolation tool, i.e., to make predictions 
about a population in which the values of the covariates are beyond the covariate ranges ex-
plored during model building. Secondly, we want to investigate how the parameter-covariate 
correlation needs to be expressed when a model is used for simulation purposes. From a meth-
odological perspective, there are different ways to express the correlation parameter-covariate 
during covariate selection. Among other options, as shown in equations 1 and 2, we evaluate 
the impact of “centring” on the median or the mean value of the covariate in the population. This 
approach is supposed to stabilise parameter estimation and facilitate the interpretation of the 
coefficients in the correlation.
P = θ1+ θ2*COV                    (1)
P = θ1+ θ2*(COV/COVmedian)   (2) 
In these equations P is the parameter, COV is the covariate, COVmedian the median value 
of the covariate in the dataset and θ1 and θ2 are the slope and the intercept which describes 
the correlation between the parameter and the covariate, respectively. In both equations the 
intercept and the slope are estimated during model building. In the first case (equation (1)), the 
variation in the values of the covariate can cause instability in the estimation of slope and inter-
cept. This contrasts with the second case (equation (2)) as the intercept is roughly centred; this 
means, for instance, that for adult populations 70 is commonly used as a median value of body 
weight.
In this study, in addition to investigating the predictive performance of a pharmacokinetic 
model for extrapolation purposes, we evaluate whether the covariate point estimate must be 
retained in the model when extrapolations refer to a population in which the median or mean 
value differ from the one in the population previously analysed or whether it should be adapted 
to reflect the covariate distribution of the new population.
C h a p t e r  5
9 8 9 9
I n f l u e n c e  o f  c ova r I at e  d I s t r I b u t I o n  o n  m o d e l  p r e d I c t I v e  p e r f o r m a n c e
5.2. methods
Population	demographics	and	hypothetical	protocol
A group of 43 virtual paediatric patients with a weight range between 7.43 and 61.3 kg (medi-
an weight 14.2 kg) were sampled from a pooled dataset including demographic characteristics 
from three pharmacokinetic studies (20–22). The sampling procedure was performed in such a 
way that the age and body weight distribution in the virtual population was balanced across the 
weight range of interest.
These patients were then treated with a hypothetical drug, given orally every 12 hours. A to-
tal of 8 plasma samples per subject were then simulated throughout the dosing interval. Using 
data from the overall population (group C), two subgroups were selected based on different body 
weight range. As shown in table 1, the first subgroup (subgroup A) comprised 20 children with 
weight between 10.3 and 15.4 kg (median body weight 12.5 kg), whilst the second group (sub-
group B) included 8 children with weight between 30 and 43.8 kg (median body weight 35 kg).
Table 1 Summary of demographic characteristics of the hypothetical population.
subGroup A subGroup b Group c (full pop-
ulation)
Subjects 20 8 43
Median weight (kg) 12.5 35.05 14.2
Min weight (kg) 10.3 30.05 7.43
Max weight (kg) 15.4 43.8 61.3
Median age (years) 2.18 8.85 2.81
Min age (years) 0.99 8.1 0.42
Max age (years) 3.89 12.67 12.92
Predefined	covariate	effects
The pharmacokinetics of the compound was assumed to be described by a one compartment phar-
macokinetic model with first-order absorption and elimination. A base model previously developed 
by our group for lamivudine (Covariate effects and population pharmacokinetics of lamivudine in 
HIV-infected children-In press, British Journal of Clinical Pharmacology) was used for simulations.
Various scenarios were simulated, in which body weight was linearly and/or exponentially 
correlated to clearance and volume of distribution. Allometric scaling concepts were also taken 
into account, but the exponents were explored with values higher and lower than 0.75. Four 
different scenarios in which one covariate was significant were simulated, based on realistic pa-
rameter-covariate correlations: 
• Body weight linearly correlated with clearance (with a slope of 0.65)
• Body weight linearly correlated with clearance (with a slope of 1.5)
• Body weight exponentially correlated with clearance (with an exponent of 0.65)
• Body weight exponentially correlated with clearance (with an exponent of 1.5)
Given that usually more than one covariate is found to influence pharmacokinetic parameters, two 
additional scenarios were simulated in which a second covariate was incorporated into the model.
•  Body weight linearly correlated with volume of distribution (with a slope of 1.8) (15) and expo-
nentially correlated with clearance (with an exponent of 0.65)
•  Body weight exponentially correlated with volume of distribution (with an exponent of 0.635) 
and exponentially correlated with clearance (with an exponent of 0.705) (Covariate effects and 
population pharmacokinetics of lamivudine in HIV-infected children -In press British Journal of 
Clinical Pharmacology)
The relationship between parameter and covariate was described as follows:
P=θ1 + (WT/WTMedian)*θ2 (3) 
P=θ1*(WT/WTMedian) **θ2 (4)        
In these equations P is the pharmacokinetic parameter (in this case clearance or volume of 
distribution), WT is body weight and WT
median
 is the median of the body weight distribution in 
the population analysed during model building. Equation (3) represents a linear relationship 






as the intercept and the slope of the 
correlation, respectively. Equation (4) represents an exponential relationship between the pa-






as the coefficient and the exponent of the correlation, 
respectively. 
Analysis of simulated patient data: pharmacokinetic model and covariate criteria
The simulated plasma concentration datasets (full population and subgroup A) were subse-
quently fitted to a pharmacokinetic model according to the standard model building criteria. 
Body weight and age were tested according to a stepwise covariate inclusion approach (23), 
i.e., the covariates were entered one by one into the population model. After all significant co-
variates have been entered into the model (forward selection), each covariate was removed 
(backward elimination), one at a time. The likelihood ratio test was used to assess whether the 
difference in the objective function between the base model and the full (more complex) model 
was significant.  
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Additional parameters leading to a decrease in the objective function  ≥ 3.84 were considered 
significant (p<0.05). During the final steps of the model building, only the covariates which result-
ed in a difference of objective function ≥ 7.88 (p<0.005) were kept in the final model. Each model 
was internally validated using a visual predictive check. 
model predictive performance: posterior predictive check (ppc)
In order to evaluate model performance, a posterior predictive check (PPC) was carried out. 
PPC operates under the basic assumption that, if the model provides an adequate description 
of the data, then the simulated data from the same model should mimic the essential features 
of the observed data. In this investigation, model performance was assessed by comparing the 
accuracy of area under the curve (AUC) estimates obtained for each subgroup, based 1) on a 
model derived from the overall population and 2) by extrapolations to subgroup B  (n=8), based 
on a model derived from subgroup A (n=20). This was done for each scenario, as described pre-
viously. AUC estimation was performed by keeping the median body weight of the population 
analysed during model building or by adapting the parameter correlation using the body weight 
median of the new population. Integration of the concentration time data was performed ac-
cording to the trapezoidal rule.
5.3. results
In this paper, we summarise the results from two out of the six simulation scenarios that were 
evaluated. These scenarios are representative of the whole investigation, in that they capture 
the key issues regarding covariate model building and the use of model-based approaches for 
dose selection or extrapolation of pharmacokinetics across populations. In particular, we focus 
on the scenario in which body weight is exponentially correlated with clearance according to an 
exponent higher or lower than 0.75. As shown in figure 1, each pharmacokinetic model was val-
idated using a visual predictive check. Both the models obtained from the full population (group 
C) and from the subgroup of children weighting between 10 and 15 kg (subgroup A) seem to 
accurately predict the observations.
In figure 2 predictions of the AUC in the children from subgroup B are derived from the mod-
el built with the data from subgroup A. Clearly, the model does not accurately predict the pa-
rameter of interest when the covariate range in the new population differs from the one of the 
original model. Moreover, as shown on the right panel of figure 2, adjusting the median of body 
weight to the distribution of the new population did not result in any improvement in model 
performance.
In contrast to the aforementioned results, accurate predictions of the pharmacokinetic param-
eter of interest are obtained in each of the subgroups when using the model obtained by fitting 
the full population data set (figure 2 and figure 3). In addition, the model seems to perform well 
if the covariate point estimate is kept in the model (left panels). These results also show that 
predictions are accurate only when a model is used for interpolation purposes, i.e., when pre-
dictions encompass the range of covariate values included in the model building. Interestingly, 
the model does not perform accurately anymore when the relation between clearance and body 
weight is adapted to reflect the covariate distribution in the new population. This happens irre-
spectively of the magnitude of the exponent which correlates body weight to clearance. 
Figure 1 Visual predictive check of the models obtained from the fit of the simulated plasma concentrations of the 
children in  subgroup A (right) and C (left) when body weight was exponentially correlated to clearance with an 
exponent of 0.65.
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AUC (mg•h/L)
Figure 2 Predicted AUC distribution in subgroup B based  on model parameter estimates obtained from data fitting 
of subgroup A. Upper panels show prediction distributions for an exponential correlation between clearance and 
body weight with an exponent of 0.65, whilst lower panels show prediction distributions for an exponent of 1.5. 
The line represents the true point estimate of AUC in the population. In the left panels the difference in the covari-
ate distribution between subgroups A and B is not taken into account, with the median of the weight distribution 
in subgroup A being used in the simulations. In the right panels a shift is observed in the predictions when the 
covariate range of subgroup B is used in the simulations.  
AUC (mg•h/L)
Figure 3 Predicted AUC distribution in subgroup A based on model parameter estimates obtained from data fitting 
of the full population (group C). Upper panels show prediction distributions for an exponential correlation between 
clearance and body weight with an exponent of 0.65, whilst the lower panels show prediction distribtutions for an 
exponent of 1.5. The line represents the true value of AUC in the population. In the left panels the difference in the 
covariate distribution between group C and subgroup A is not taken into account, with the median of the weight 
distribution of subgroup C being used in the simulations. In the right panels a shift is observed in the predictions 
when the covariate range of subgroup A is used in the simulations.  
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Figure 4 Predicted AUC distribution in subgroup B based on model parameter estimates obtained from data fitting 
of the full population (group C). Upper panels show prediction distributions for an exponential correlation between 
clearance and body weight with an exponent of 0.65, whilst the lower panels show prediction distributions for an 
exponent of 1.5. The line represents the true value of AUC in the population. In the left panels the difference in the 
covariate distribution between group C and subgroup B is not taken into account, with the median of the weight 
distribution of subgroup C being used in the simulations. In the right panels a shift is observed in the predictions 
when the covariate range of subgroup B is used in the simulations.  
 AUC (mg•h/L) 
Figure 5 Predicted AUC distribution in subgroup B based on the model parameter estimates obtained from 
data fitting of subgroup A. The histograms show AUC predictions for a linear relation between clearance and 
body weight with a slope of 1.5. The line represents the true value of AUC in the population. In the left panel the 
difference in the covariate distribution between subgroups A and B is not taken into account, with the median of 
the weight distribution of subgroup A being used in the simulations. In the right panels a shift is observed in the 
predictions when the covariate range of subgroup B is used in the simulations.  
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5.4. discussions
The main focus of our study was to investigate the role of demographic covariates during bridg-
ing and extrapolation of pharmacokinetic data across paediatric populations. Clearly, the iden-
tification of influential covariate effects on pharmacokinetic parameters is crucial to ensure 
accurate dose selection or dose adjustment in a new population. This is particularly important 
during the planning phase of a bridging exercise, when pharmacokinetic models are used for 
simulation purposes. Ideally, the predictive performance of population models should be war-
ranted before its application in paediatric therapeutic research and drug development. Here 
we have shown the potential for bias in model predictions when extrapolating data beyond the 
covariate range explored during model building, a common practice in industry and academic 
research, which relies in small sample sizes for the characterisation of pharmacokinetic proper-
ties of a compound. These findings emphasise the importance of meta-analysis and other tech-
niques for evidence synthesis as the basis for any quantitative evaluation of pharmacokinetics 
and pharmacodynamics in children. From a methodological point of view we have also shown 
the relevance of “centring” on the point estimate of the covariate distribution, which must be 
retained in the model when extrapolations are performed, irrespectively of the differences in 
the covariate distribution in the population or subgroup of interest.
model-based extrapolation and interpolation
The current findings show that extrapolation to a new population beyond the covariate range 
explored during model building is not possible for exponential parameter-covariate correla-
tions. These results appear to be in agreement with a previous publication which showed that, 
irrespective of whether extrapolation methods are to be applied during paediatric drug devel-
opment, model predictions beyond the range of the data used for parameter estimation may be 
biased (18, 19). Adaptations or adjustments of parameter-covariate correlations to account for 
the covariate range of the new population does not improve model predictive performance. In 
fact, it appears that the farther the median of the covariate of the new population deviates from 
the original one, the less accurate is the predicted AUC distribution (right panels, figure 2). The 
only scenario which appears to yield accurate extrapolation from one group to another with 
different covariate values is when a linear correlation is used to describe the covariate effects 
(as shown in figure 5).
The (often physiologically-driven) exponential correlation between pharmacokinetic param-
eter and covariate is linked to nonlinearities that cannot be predicted without a semi- or fully 
mechanistic approach to bridging or extrapolations beyond the evidence derived from the avail-
able data. From a statistical perspective, this issue could be handled by defining uncertainty in 
parameter estimation. 
However this would lead to wide parameter distributions, with little value for dosing recom-
mendation purposes. It should also be noted that this bias cannot be eliminated by the iden-
tification of additional covariates. Extrapolation to a different population requires accurate 
estimation of the underlying parameter-covariate correlations, which in turn imposes the 
availability of data (likelihood) or alternatively, the use of priors that support inferences about 
the parameter distribution in a different population, including the magnitude and nature of the 
covariate effects in those conditions. At present, our findings suggest that only interpolation 
is feasible when making use of nonlinear hierarchical models to describe pharmacokinetics in 
children. Interpolations will be accurate independently of the nature of the parameter-covari-
ate correlations. 
Influence	of	sample	size	on	predictive	performance	
In addition to the hurdles for the use of bridging and extrapolation across populations, another 
issue in the covariate analysis presented here was the limited sample size of the data available 
for model building, which may clearly lead to wrong covariates selection and inclusion bias. In 
our study, the correct covariate (body weight) was identified when the full dataset was anal-
ysed, whilst a confounding factor (age) or no covariate effects (results not shown) were iden-
tified when evaluating the small, imbalanced subgroup of children (n=20). This problem, previ-
ously highlighted by Ribbing in his simulation study (9), emphasises the importance to perform 
a stepwise covariate selection only when large paediatric datasets are available. If this is not 
the case, meta-analysis or different methods, such as the use of a genetic algorithm in covariate 
selection (12) or automated covariate model building (13), should be considered.
recommendations on the use of models for simulation purposes
M&S represents a powerful tool to avoid unnecessary studies in the target population as well as 
facilitate the interpretation of the limited evidence available (24). However, our findings under-
score the importance of a careful and cautious use of models. Awareness about model assump-
tions and formal evaluation of the predictive performance of a model is required to avoid biased 
predictions, which in turn, could lead to wrong dosing adjustments in clinical practice. 
The main recommendations from this investigation are listed below:
•  Unless a mechanism-based model can be warranted, the use of a stepwise approach for co-
variate analysis is not recommended when small datasets are available. Instead, alternative 
approaches should be considered for paediatric bridging and extrapolation   
•  Extrapolation of the covariate effects beyond the parameter distributions explored during 
model building cannot be performed without bias, and consequently erroneous dosing rec-
ommendations.
•  Pharmacokinetic models can be used for simulation purposes only when the population of 
interest can be considered a subgroup of the initial population.
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•  The covariate point estimate must be retained in the model when predictions refer to a popu-
lation in which median or mean values differ from the population used during model building.
limitations
Two main limitations need to be acknowledged in our study. First, we have restricted the anal-
ysis to a fixed number of virtual patients. This choice was based on the need to assess whether 
the dataset size may influence the final results. Therefore the same bioavailability was assumed 
in the whole population of children. We also acknowledge that from a methodological perspec-
tive, other algorithms could have been tested to confirm that these findings are not an artefact 
of the maximum likelihood, as implemented in NONMEM. The use of a different method, such 
as the stochastic approximation of the standard expectation maximization (SAEM) might have 
yielded different results in terms of the magnitude of the bias seen with the first-order condi-
tional estimation method with interaction (FOCEI) (25)
conclusions
In summary, model performance appears to be independent of the nature of the parameter-co-
variate correlations if predictions are restricted to interpolations. Biased results may be ob-
served when predictions are aimed at extrapolations, i.e. covariate distribution lies outside the 
range observed during model building. The use of meta-analysis, mechanistic models and other 
alternative methods in which prior or historical data are used for inferential purposes is there-
fore recommended for bridging and extrapolation of pharmacokinetic data across paediatric 
populations. In addition, parameterisation of covariate effects based on the point estimate of 
the covariate distribution imposes the use of the same point estimate even when the population 
to be simulated differs from the original population. 
These findings emphasise the need to discriminate between models for estimation and mod-
els for simulation, which are required when performing bridging and extrapolations. The dis-
crepancies observed in the predicted distributions are not detectable with standard diagnostic 
tools currently used during model validation procedures.
references
1. Breimer, D.D. PK/PD modelling and beyond: impact on drug development. Pharmaceutical research 25, 
2720-2 (2008).
2. Bellanti, F. & Della Pasqua, O. Modelling and simulation as research tools in paediatric drug develop-
ment. European journal of clinical pharmacology 67 Suppl 1, 75-86 (2011).
3. Jönsson, S., Henningsson, A., Edholm, M. & Salmonson, T. Role of modelling and simulation: a European 
regulatory perspective. Clinical pharmacokinetics 51, 69-76 (2012).
4. Manolis, E. & Pons, G. Proposals for model-based paediatric medicinal development within the current 
European Union regulatory framework. British journal of clinical pharmacology 68, 493-501 (2009).
5. De Cock, R.F.W., Piana, C., Krekels, E.H.J., Danhof, M., Allegaert, K. & Knibbe, C.A.J. The role of popula-
tion PK-PD modelling in paediatric clinical research. European journal of clinical pharmacology 67 Suppl 
1, 5-16 (2011).
6. Della Pasqua, O. & Rose, K. Study and protocol design for paediatric patients of different ages. Guide to 
Paediatric Clinical Research (2007).
7. Howie, S.R.C. Blood sample volumes in child health research: review of safe limits. Bulletin of the World 
Health Organization 89, 46-53 (2011).
8. Meibohm, B., Läer, S., Panetta, J.C. & Barrett, J.S. Population pharmacokinetic studies in pediatrics: 
issues in design and analysis. The AAPS journal 7, E475-87 (2005).
9. Ribbing, J. & Jonsson, E.N. Power, selection bias and predictive performance of the Population Phar-
macokinetic Covariate Model. Journal of pharmacokinetics and pharmacodynamics 31, 109-34 (2004).
10. dartois, c. et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 lit-
erature survey. British journal of clinical pharmacology 64, 603-12 (2007).
11. Wählby, U., Jonsson, E.N. & Karlsson, M.O. Comparison of stepwise covariate model building strate-
gies in population pharmacokinetic-pharmacodynamic analysis. AAPS pharmSci 4, E27 (2002).
C h a p t e r  5
1 1 0 1 1 1
I n f l u e n c e  o f  c ova r I at e  d I s t r I b u t I o n  o n  m o d e l  p r e d I c t I v e  p e r f o r m a n c e
12. Bies, R.R., Muldoon, M.F., Pollock, B.G., Manuck, S., Smith, G. & Sale, M.E. A genetic algorithm-based, 
hybrid machine learning approach to model selection. Journal of pharmacokinetics and pharmacody-
namics 33, 195-221 (2006).
13. Lunn, D.J. Automated covariate selection and Bayesian model averaging in population PK/PD models. 
Journal of pharmacokinetics and pharmacodynamics 35, 85-100 (2008).
14. Khandelwal, A., Harling, K., Jonsson, E.N., Hooker, A.C. & Karlsson, M.O. A fast method for testing co-
variates in population PK/PD Models. The AAPS journal 13, 464-72 (2011).
15. Knibbe, C.A.J. et al. Morphine glucuronidation in preterm neonates, infants and children younger than 
3 years. Clinical pharmacokinetics 48, 371-85 (2009).
16. Cella, M., Gorter de Vries, F., Burger, D., Danhof, M. & Della Pasqua, O. A model-based approach to 
dose selection in early pediatric development. Clinical pharmacology and therapeutics 87, 294-302 
(2010).
17. Anderson, B.J., van Lingen, R.A., Hansen, T.G., Lin, Y.-C. & Holford, N.H.G. Acetaminophen developmen-
tal pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 
96, 1336-45 (2002).
18. Cella, M., Zhao, W., Jacqz-Aigrain, E., Burger, D., Danhof, M. & Della Pasqua, O. Paediatric drug devel-
opment: are population models predictive of pharmacokinetics across paediatric populations? British 
journal of clinical pharmacology 72, 454-64 (2011).
19. Cella, M., Knibbe, C., de Wildt, S.N., Van Gerven, J., Danhof, M. & Della Pasqua, O. Scaling of pharma-
cokinetics across paediatric populations: the lack of interpolative power of allometric models. British 
journal of clinical pharmacology 74, 525-35 (2012).
20. Bergshoeff, A. et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: 
simplification of combination treatment in HIV-1-infected children (PENTA-13). Antiviral therapy 10, 
239-46 (2005).
21. Musiime, V. et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and ab-
acavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antiviral therapy 15, 1115-24 
(2010).
22. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily 
versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Anti-
viral therapy 15, 297-305 (2010).
23. Mandema, J.W., Verotta, D. & Sheiner, L.B. Building population pharmacokinetic--pharmacodynamic 
models. I. Models for covariate effects. Journal of pharmacokinetics and biopharmaceutics 20, 511-28 
(1992).
24. Harnisch, L. , Shepard, G.P. and Della Pasqua, O. Modeling and Simulation as a Tool to Bridge Efficacy 
and Safety Data in Special Populations. CPT: Pharmacometrics & Systems Pharmacology (2013). 
25. Chan, P.L.S., Jacqmin, P., Lavielle, M., McFadyen, L. & Weatherley, B. The use of the SAEM algorithm in 
MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics 
parameters of maraviroc in asymptomatic HIV subjects. Journal of pharmacokinetics and pharmacody-
namics 38, 41-61 (2011). 
1 1 3
section iii
Simplified dosing regimens  
in children 
1 1 5
c h a P t e r  6
A model-bAsed ApproAch for 
the evAluAtion of once dAily 
dosinG of lAmivudine in  
hiv-infected children
Chiara Piana, Wei Zhao, Kim Adkison, David Burger , Evelyne Jacqz-Aigrain,  
Meindert Danhof , Oscar Della Pasqua
In press - Br J Clin Pharmacol
summAry
Aim: Little attention has been paid to the effects of compliance and prescription practice on treatment 
outcome in HIV-infected children. In this context, an evaluation of the role of covariates on pharmaco-
kinetics is required to establish the impact of differences in dosing regimen. Here we investigate wheth-
er a once daily dosing regimen of lamivudine provides comparable exposure to the currently approved 
paediatric regimen.
Methods: A hypothetical group of 180 patients between 3 months and 12 years old was used to 
evaluate the impact of body weight on systemic exposure to lamivudine. Simulation scenarios were 
evaluated using AUC and Cmax as parameters of interest. The analysis was performed using a popula-
tion pharmacokinetic model previously implemented in NONMEM v.6.2.
Results: The simulations show that once daily dosing of lamivudine yields comparable exposure to 
historical values observed in children and adults, both for liquid and solid dosage forms. Simulated 
steady-state AUC0-24 and Cmax values after once daily doses ranged respectively from 9.95 mg•h/L 
and 1.9 mg/L for children lighter than 14 kg to 13.75 mg•h/L and 3.0 mg/L for children heavier than 
30 kg. These values are comparable or higher than historical values observed after once daily dosing 
in children and adults.
Conclusions: Our findings illustrate how dosing regimens can be evaluated taking into account the 
effects of developmental growth on drug disposition. Most importantly, they suggest that the reduction 
in dosing frequency to once daily warrants safe, efficacious exposure, while representing an improve-
ment in treatment acceptability and adherence. 
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6.1. introduction
Historically prescription practice and patient compliance have not been considered as factors 
determining the successful use of antiretroviral drugs in HIV-infected children. Increasing ev-
idence now shows that not only the availability of suitable paediatric dosage forms, but also 
dosing frequency can be an important determinant of compliance and consequently of treat-
ment outcome (1). In fact, a significant correlation between lower pill burden and better viro-
logical outcome has been observed for antiretroviral drugs (2). In addition, numerous surveys of 
HIV patients in both the United States and Europe indicate that there is a strong preference for 
once daily dosing and compact therapy (3) and according to several studies once daily regimens 
are significantly better adhered to than other dosing regimens (4). It is well known that current 
combination antiretroviral therapy (cART) regimens require large numbers of pills or capsules 
to be taken several times per day and the overall pill burden may thus be too large to permit ad-
herence for periods of many years. Differences in dosing regimen and/or dosing frequency may 
clearly constitute a burden for patients and in particular for younger children. 
The availability of  fixed-dose combinations and the possibility to administer all the drugs as 
once daily regimen may be very advantageous, with direct implications for  adherence to ther-
apy and for the overall treatment outcome (5,6,7). The use of a simple once daily cART regimen 
may therefore be a powerful solution to optimise treatment adherence and patient’s quality of 
life (8). Particularly in the paediatric field, there may be considerable benefits for both children 
and caregivers if dosing frequency can be reduced to once daily for all drugs in the regimen, 
allowing minimal interference with everyday school and home activities. Furthermore, one spe-
cific concern with older children is the stigma of taking medications during the day or having 
friends discover that they have an illness, so limiting the number of times a child has to take a 
medication can significantly improve not just compliance, but well-being. 
Once daily dosing may provide the flexibility to maximise adherence according to individual 
circumstances – particularly in resource limited settings where most HIV-infected children live 
(9). For example, caregivers who are sellers in the market may find it hard to give drugs in the 
morning if they leave before the child is awake. Caregivers who work evenings may have to rely 
on others to administer evening doses. In addition, reducing administration frequency may sig-
nificantly reduce medication error.
Lamivudine (3TC), a nucleoside reverse transcriptase inhibitor commonly administered in 
combination antiretroviral therapy to HIV-infected children (10), was initially administered 
twice daily in both adults and children. Lamivudine enters infected lymphocytes and is pro-
gressively phosphorylated by intracellular enzymes to the active moiety, lamivudine-5’ triphos-
phate, which acts as a chain terminator. The active intracellular lamivudine-triphosphate has a 
long half-life (16-19 hours) relative to the half-life of parent lamivudine in plasma (5-7 hours) 
(11).  The long half-life of lamivudine-triphosphate coupled with intracellular pooling of precur-
sor lamivudine-diphosphate supported the investigation of once daily dosing in adults. In fact, a 
once daily dose regimen was subsequently approved for adults based on clinical studies which 
showed equivalent antiviral activity (12) and equivalent area-under-the-curve [AUC0-24] of plas-
ma lamivudine and intracellular lamivudine-triphosphate (13) following once versus twice daily 
dosing of the same total daily dose. Even though a formal concentration-antiviral effect rela-
tionship is lacking due to the difficulties in routinely measuring the intracellular lamivudine-tri-
phosphate concentrations, the plasma AUC
0-24
 of lamivudine can be considered the best plasma 
predictor of antiviral activity based on the mechanism of action and long half-life of the active 
moiety.
Currently lamivudine is labelled for twice daily administration in children based on clinical 
trials which demonstrated antiviral activity at doses yielding similar exposure to those observed 
in adults. Given the mechanism of action of lamivudine (14) the exposure-antiviral response to 
HIV infection is likely to be similar between children and adults. Therefore, a once daily dose 
regimen in children that can match the AUC
0-24
 of the approved twice daily regimen in children 
or the once or twice daily regimen in adults should demonstrate equivalent antiviral activity in 
children. To that purpose, several studies have been conducted to explore the pharmacokinet-
ics and feasibility of once daily dosing in children (15, 16). Nevertheless, an integrated, mod-
el-based evaluation of the impact of developmental growth factors has not been performed for 
once daily dosing in children. It can be envisaged that the use of once daily dosing in children 
will allow alignment with the approval of once daily fixed-dose combination antiretroviral pills 
for the adult indication. The aim of this study is therefore to assess whether lamivudine phar-
macokinetics after once daily dosing is comparable to lamivudine pharmacokinetics after twice 
daily administration to HIV-infected children between 3 months and 12 years old. The use of 
simulation scenarios is proposed as the basis for evidence synthesis on the suitability of this 
new regimen in children. Simulated pharmacokinetic profiles are characterised in a large hypo-
thetic paediatric cohort to determine the dose rationale without the requirement for further 
enrolment of children into a clinical trial (17, 18).
The relevance of this type of model-based extrapolation exercise has been recently highlight-
ed in the concept paper of the EMA (19). The document emphasises how extrapolations enable 
one “to extend information and conclusions available from studies in one or more subgroups of the 
patient population (source population), or in related conditions or with related medicinal products, 
to make inferences for another subgroup of the population (target population), or condition or prod-
uct, thus reducing the need to generate additional information (types of studies, design modifications, 
number of patients required) to reach conclusions for the target population, or condition or medicinal 
product”.
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6.2. methods
Simulations were performed to compare the systemic exposure of lamivudine after once daily 
dosing to historical values in children and adults and to explore how differences in demographic 
covariates affect steady-state exposure. The hypothetical population was represented by chil-
dren between 3 months and 12 years old. For the purposes of our analysis, children were split 
into various age groups, each with 5 patients with different body weight (n=180). The correla-
tion between age and body weight was based on the WHO weight-for-age tables (20). Lami-
vudine total daily doses were determined according to the currently recommended dose and 
method of administration, as indicated in the latest Summary of Product Characteristics (21).  
A one-compartment model with first order absorption and elimination processes previously 
developed and validated by our group was used to simulate the pharmacokinetic profiles (Chap-
ter 3). The model was built using pharmacokinetic data in 77 HIV-infected children receiving 
lamivudine both as twice and once daily dosing regimens. Body weight was found to be expo-
nentially correlated to clearance and volume of distribution. Given that formulation was not 
found to influence the pharmacokinetic parameters, the same model was used to predict lami-
vudine pharmacokinetics in children receiving tablets or solution.
 The frequency and times for pharmacokinetic sampling were based on a serial sampling 
scheme to mimic current practice with regard to estimating AUC over the dosing interval. 
Concentration vs. time data was then integrated using the trapezoidal rule to ensure realistic 
estimates of variability, as observed in a typical non-compartmental analysis. The hypothetical 
experimental protocol is depicted in figure 1. Given that a significant concentration-effect rela-
tionship for lamivudine could not be found in the past, the adequacy of the simulated dosing reg-
imens was assessed graphically by determining the fraction of the paediatric population reach-
ing systemic exposure comparable to AUC
0-24
 values previously observed in studies of adults 
on approved once and twice daily regimens and children on approved twice daily regimens. 
Cmax values of the paediatric population were also compared to historical values of Cmax from 
previous clinical trials. Simulations were performed using NONMEM version 6.2. Results were 
graphically summarised using R 2.8.2.
Figure 1 Diagram depicting the hypothetical experimental protocol
6.3. results
Simulations were performed using a population pharmacokinetic model previously developed 
and validated by our group. The goodness of fit and visual predictive checks are shown in figure 2. 
Figure 2 (a) Goodness-of-fit. Left upper panel shows population prediction (PRED) vs. observed concentration 
values (DV). Right upper panel shows individual predictions (IPRE) vs. observed concentration values (DV). Left 
lower panel shows conditional weighted residuals (CWRES) vs. population predictions (PRED). Right lower panel 
shows conditional weighted residuals (CWRES) vs. time (TIME).  (b) Visual predictive check (VPC) of the population 
pharmacokinetic model for lamivudine.
Based on the original parameter estimates, the distribution of the area under the curve (AUC
0-
24
) and peak concentration (Cmax) values associated with a once daily dosing regimen for lamivu-
dine were evaluated in a hypothetical group of paediatric patients. In total, the simulated popula-
tion consisted of 180 patients between 3 months and 12 years old, which represent a population 
with comparable demographic characteristics of HIV-infected children in a typical clinical set-
ting. The demographic characteristics of the simulated population is summarised in Table 1. In 
table 2 the doses of lamivudine administered to the simulated population are depicted.
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SUBJECTS 180 85 34 31 30
MEDIAN AGE (years) 3.5 0.91 4.5 8 10.5
MIN (years) 0.25 0.25 2 5 7.5
MAX (years) 12 3.5 7.5 11 12
MEDIAN WEIGHT (kg) 14.9 9.73 17.2 24.9 35.9
MIN (kg) 5.41 5.41 14.1 21.1 30.2
MAX (kg) 53.9 13.6 20.7 29.1 53.9
The simulation results are presented graphically in figures 3 and 4, which show the compari-
son between the simulated distributions of the secondary pharmacokinetic parameters [AUC
0-
24
 and Cmax] and historical data from previous clinical trials with lamivudine in children and 
adults (22, 23). For completeness, the pharmacokinetic parameters of lamivudine are present-
ed in table 3. Box plots show that the predicted lamivudine exposure reached after once daily 
dosing was comparable or higher in every weight range than the exposure reached in historical 
trials where lamivudine was administered at approved once or twice daily doses to adults and 
twice daily doses to children. The predicted Cmax values on the once daily regimen exceeded 
those of the twice daily regimen in children; however, there was considerably overlap of the 
predicted Cmax values with those observed in adult subjects on the once daily regimen.
Table 2 Currently recommended doses of lamivudine in children
Weight	Band Lamivudine	Dose	Regimen lamivudine total 
daily dose
<14kg Oral solution (4mg/kg) twice daily 8mg/kg/day
14 to 21kg One-half tablet (75mg) twice daily 150mg
>21 to <30kg One-half tablet (75mg) in the morning;
 One whole tablet (150mg) in the evening
225mg
30kg One whole tablet (150mg) twice daily 300mg
Figure 3 Box plots showing the comparison between simulated distributions of lamivudine AUC0-24 after once daily 
dosing and historical data from clinical trials. Box represents median, 25th and 75th percentiles, bars represent 10th 
and 90th percentiles. Simulated distributions (N= 500 replicate trials) are comparable or higher than historical 
data in each weight range.
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Figure 4 Box plots showing the comparison between simulated distributions of lamivudine Cmax after once daily 
dosing and historical data from clinical trials. Box represents median, 25th and 75th percentiles, bars represent 10th 
and 90th percentiles. Simulated distributions (N= 500 replicate trials) are comparable or higher than historical 
data in each weight range
6.4. discussions And conclusions
Evidence	synthesis	by	modelling	and	simulation
Undoubtedly, the use of once daily dosing of antiretroviral drugs in HIV-infected children may 
offer significant clinical advantages, especially in resource limited countries. There can be sev-
eral benefits for both children and caregivers and adherence may be strongly maximised, with 
consequent improvements in treatment outcome.
Given that previous studies have shown similar pharmacokinetics between once and twice dai-
ly dosing and evidence on the preference of caregivers for once daily regimen, evidence synthe-
sis rather than new evidence generation needs to be considered to support once daily dosing of 
lamivudine in HIV-infected children. We have used a model-based approach to evaluate whether 
differences exist in the pharmacokinetics of lamivudine after once daily dosing, as comparable to 
the achieved exposure after twice daily administration. Our results clearly show that simulation 
scenarios offer the possibility to evaluate the potential implications of changes in dosing regimen 
based on existing evidence in the adult population and limited experience in children.
It is unfortunate that historically population pharmacokinetic models have been used pri-
marily as an alternative estimation method, with simulations being performed primarily as a 
diagnostic procedure during model validation, rather than as an evidence synthesis tool for sub-
sequent decision making. Yet, evidence synthesis and in particular extrapolations are often used 
implicitly in many situations involving clinical or regulatory decisions, e.g. when extending con-
clusions from trial populations to the general populations. By applying a model-based approach, 
one can ensure explicit and systematic assessment of the assumptions, clinical implications and 
risks associated with the use of extrapolations.
Once	daily	dosing	regimen:	systemic	exposure
Simulation scenarios show that lamivudine AUC
0-24
 reached after once daily dosing are compa-
rable to historical values in children on a twice daily regimen of lamivudine and adults receiving 
the approved once or twice daily lamivudine regimens. Figure 3 shows that the youngest group 
of children (between 0 and 14 kg) had quite a lower exposure compared to the older, heavier
children. This fact, previously shown by Burger et al (24), could be partly explained by a slight-
ly lower dose that the small children receive (as shown in table 3). Effectively, higher mg/kg 
doses are administered with the score tablet dosage regimens due to the pre-defined tablets 
strengths (either 75mg half tablet or 150mg whole tablet) and because of the weight band cut-
offs selected to minimise under-dosing in heavier children. Therefore, lighter children in the 
same weight band receive doses that are substantially higher than the 8mg/kg/day when the 
solution is administered. There may also be some effect of the formulation, since these children 
receive solution and the heavy ones receive tablets, as shown in a recent study from Kasirye et 
al. (25)
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Table 3. Summary of the pharmacokinetic parameters of the simulated population. Values are presented as geomet-
ric mean (95% CI) except for dose which is presented as median (range)
 






























































However, such effect is probably not large enough, as it could not be identified as a significant 
covariate during model building. Lastly, it is worth mentioning that distributional mechanisms 
may also be implicated in low exposure in younger children (26, 27). Although simulated expo-
sures varied across the paediatric weight range, children in all weight bands showed predicted 
lamivudine AUC
0-24
 values after once daily administration comparable to or higher than the ref-
erence values previously observed in children on twice daily regimen or adults on once daily 
or twice daily dosing regimen. Given a similar exposure-antiviral response relationship for HIV 
infection in adults and children, a once daily regimen that matches the AUC
0-24
 of the approved 
twice daily regimen in children and the once daily regimen in adults should demonstrate equiv-
alent antiviral activity in children.  
Once	daily	dosing	regimen:	peak	concentrations
As anticipated from drugs showing linear pharmacokinetics, the reduction in dosing frequen-
cy resulted in an increase in median Cmax by approximately two-fold. Figure 4 shows that the 
maximum peak concentration reached after once daily dosing is much higher compared to twice 
daily administration. Once daily administration of lamivudine to HIV-infected children also re-
sults in higher Cmax than the historical values observed in adults and children during previous 
clinical trials in which twice daily dosing has been used. Given that once daily lamivudine was ap-
proved for use in adults based on good safety and efficacy and the positive tolerability and safe-
ty profile of once daily lamivudine was observed in small studies of children (28), the predicted 
increase in Cmax after once daily administration is unlikely to result in a higher risk of adverse 
events. Again Cmax values appear to be slightly lower for children lighter than 14 kg. However 
the simulated maximum peak concentration in this group of children is comparable with refer-
ence Cmax values in adults receiving once daily dosing  and higher than reference Cmax values 
in children receiving lamivudine twice daily and in adults receiving lamivudine twice daily.
Clearly one of the major concerns about once daily administration of antiretroviral drugs is the 
higher risk of viral failure. In adults it has been shown that once daily lamivudine in combination 
with zidovudine and efavirenz would provide comparable treatment outcome as twice daily lami-
vudine (12). It has also been shown that didanosine, another NRTI with similar pharmacokinetic 
properties as lamivudine, allows for once daily administration without increased risk of viral fail-
ure (29–31). Regarding the increased risk of drug resistance, previous studies demonstrated that 
once daily dosing of antiretrovirals is strongly correlated to increased patient adherence to thera-
py. Given that high levels of adherence may avoid development of resistance, the use of once daily 
dosing regimen is not expected to increase the probability of virus mutations and drug resistance. 
limitations 
One of the main limitations in our study was that lamivudine plasma pharmacokinetics can only 
be considered as a limited marker of drug exposure as it is the intracellular lamivudine triphos-
phate metabolite that becomes pharmacologically active. However, no alternative is available 
due to the requirements for adequate sampling of intracellular concentrations of nucleoside 
transcriptase inhibitor triphosphate, which is logistically and technically difficult. This is further 
complicated by the volume of blood required for the bioanalysis of intracellular lamivudine tri-
phosphate concentrations, which makes serial evaluations impractical for paediatric patients. 
Instead, we have made explicit assumptions about the use of plasma concentrations, namely 
that equilibrium between plasma and intracellular concentrations is rapidly reached and drug 
distribution into cells is driven by a first order process, without the risk of saturation occurring 
within the range of concentrations observed after once or twice daily dosing.
conclusions
In conclusion, the possibility of evaluating the implication of different dosing regimens using a 
model-based approach shows one of the various applications of virtual clinical trials in paediat-
ric clinical pharmacology research. Our findings strongly suggest that when the same total daily 
lamivudine dose is administered, the reduction in dosing frequency to once daily does not rep-
resent a potential risk of under- or over-dosing in the paediatric population. Taking into account 
the evidence regarding acceptability and adherence in previous paediatric and adult HIV trials, 
the current results provides evidence for an alternative, once daily dosing regimen, with the 
advantages of improved adherence and consequently efficacy and clinical outcome for children, 
particularly in resource limited settings.
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summAry 
This investigation is aimed at evaluating whether abacavir exposure reached after once daily dosing 
regimen is comparable to abacavir exposure following the currently recommended twice daily regimen 
in HIV-infected children between 3 months and 12 years old. Simulation scenarios were carried out 
using a pharmacokinetic model previously developed in HIV-infected children. Abacavir exposure was 
simulated in a hypothetical paediatric population (n=180) between 3 months and 12 years old. Sim-
ulations were performed in NONMEM v6 and R 2.8.1 was used to graphically summarise the results. 
According to the evaluated simulation scenarios, abacavir exposure [AUC0-24] reached after once daily 
dosing in children is comparable to previous values observed in children on twice daily dosing regimens 
and in adults on once or twice daily dosing. Based on our findings, the reduction in abacavir dosing fre-
quency from twice daily to once daily in HIV-infected children provides appropriate values of exposure 
and may represent an opportunity for the improvement of adherence and clinical outcome.
7.1. introduction
Poor adherence is among the main causes of reduced activity of antiretroviral drugs in children 
(1). Failure to take the prescribed doses of antiretroviral drugs may lead to ongoing viral replica-
tion in the presence of drug and the selection of drug-resistant HIV strains (2, 3). Adherence has 
been shown to be a strong predictor of therapeutic impact in HIV medication in several studies 
(4, 5). Wiener et al. reported that among children with an HIV-1 RNA viral load <10000, 75% had 
taken 100% of their medication doses in the previous week, while among those with a viral load 
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7.2.methods
clinical data
 Historical clinical data of abacavir were used for comparison with the data from the simulated 
population of children following once daily dosing regimen. Several historical studies in which 
abacavir was administered to children (ACTG330 (twice daily) (22), CNAA1001 (twice daily) 
(23), PENTA 13 (twice daily and once daily) (20), PENTA 15 (twice daily and once daily) (19), 
ARROW-part 1 (twice daily and once daily) (21)) and to adults (CNAA2001 (twice daily) (24), 
CAL10001 (once daily) (25), CAL102120 (once daily) (26)) were used during the investigation. 
In table 1 an overview of each trial is provided in terms of study design, objective and number 
of subjects.  The studies have been conducted in full conformance with the principles of the 
Declaration of Helsinki and with the local laws and regulations concerning clinical trials. The 
protocols and the informed consent documents for each study have been formally approved by 
the relevant research ethics committee of each clinical site and by a national ethics body.
pharmacokinetic model
A pharmacokinetic two-compartment model previously developed by our group (27) to de-
scribe abacavir disposition in HIV-children between 3 months and 12 years old has been used 
to simulate abacavir exposure in a hypothetical paediatric population. The model used for simu-
lation purposes was a two-compartment model with first order absorption and elimination and 
body weight as a significant covariate for apparent clearance and volume of distribution of the 
central compartment.
simulation scenarios- in silico trial protocol 
Abacavir exposure following once daily administration was simulated in a hypothetical popu-
lation of 180 children between 3 months and 12 years old (table 2). Each age group was repre-
sented by 5 children with different body weight. WHO weight-for-age tables (28) were used to 
correlate age and body weight in the simulated patients in order to guarantee a realistic age-
body weight correlation. Abacavir was administered according to the currently recommend-
ed dose and method of administration (table 3), as indicated in the latest Summary of Product 
Characteristics (29).
The variable of interest were the area under the curve (AUC) and the peak concentration 
(Cmax) associated with once daily abacavir administration based on the currently recommend-
ed doses in children. Abacavir formulation was not identified as a significant covariate; there-
fore the same model was used to simulate the administration of solution (for children with body 
weight lower than 14 kg) and tablets.  The frequency and times for pharmacokinetic sampling 
were based on a serial sampling scheme for the purposes of estimating AUC over the dosing in-
terval. Figure 1 depicts the hypothetical experimental setting. Integration of the concentration 
of >100000, only 36% reported taking all of their medication (6). Pediatric adherence main-
ly depends on a caregiver to administer the medication. In limited resource countries, where 
mostly HIV-infected children live, it is sometimes problematic to identify someone who can be 
responsible for drug administration, especially because this person may be impaired by com-
plications of HIV infection or may need to work for most of the day. Once daily antiretroviral 
therapy is one possible approach to improve treatment outcome, as it simplifies the caregiver’s 
role and presumably increases paediatric adherence. An ideal once daily drug should have a fa-
vorable pharmacokinetic profile such that standard dosing would provide a high probability of 
efficacy and a low probability of toxicity (7). Maintaining  drug  plasma  concentrations above a 
certain threshold is generally believed to be related to the efficacy of antiretroviral agents (8). 
Therefore reliable bioavailability and a long half-life for the active moiety are the most import-
ant characteristics for once daily antiretroviral agents.
 Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor (NRTI) extensively prescribed 
in HIV paediatric combination therapy (9–13). Abacavir tablets are 83% bioavalable after oral 
administration and rapidly reach peak plasma concentrations between 0.63 and 2.5 hours (14). 
Abacavir is phosphorylated to its intracellular anabolite, carbovir triphosphate (CVB-TP), which 
inhibits transcription of HIV viral RNA to DNA by competing with an endogenous nucleotide 
transcriptase enzyme (15). Since the pharmacologically active moiety of abacavir is the intracel-
lular CBV-TP, its pharmacokinetic profile is essential for determining the appropriate dosing in-
terval for abacavir. Although CBV-TP pharmacokinetic parameters are difficult to estimate due 
to large within-subject variability, several studies demonstrated a half-life for CBV-TP greater 
than 12 hours, supporting once daily abacavir administration (16–18).
Abacavir is currently administered as once daily regimen to adults and twice daily to children. 
The possibility to administer abacavir according to a once daily dosing regimen in children has 
been demonstrated in several studies. PENTA 15 study showed comparable plasma abacavir 
exposure in terms of AUC0-24 for twice and once daily dosing in children between 3 months and 
3 years old administered the oral solution formulation (19); PENTA 13 study and the sub-study 
of the ARROW trial showed similar twice daily and once daily pharmacokinetics in children 
between 2 and 13 years old receiving the oral solution or tablet formulations (20, 21). These 
studies also showed that once daily dosing was preferred to twice daily dosing by children and 
their caregivers. Further investigation is however needed to assess the feasibility of once daily 
abacavir in a large group of children.
 The aim of this study is to evaluate, using modelling and simulation tools, whether abacavir 
exposure after once daily is comparable to abacavir exposure following twice daily regimens in 
HIV infected children between 3 months and 12 years old. The use of a previously developed 
pharmacokinetic model combined with simulation scenarios allows performing the investiga-
tion in a large hypothetical population of HIV-infected children. 
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time data was applied according to the trapezoidal rule to ensure realistic estimates of variabil-
ity. 500 replicates were performed. 
Simulations were performed using NONMEM version 6.2. R version 2.8.2 was used to graph-
ically summarise the results. 
comparison with historical data 
The simulated values of AUC and Cmax were compared with historical values from previous 
clinical trials in which abacavir was administered to children and to adults in order to assess 
whether abacavir once daily administration provides appropriate values of plasma exposure. 
Weighted mean and standard deviation of the historical trials were used for comparison. AUC 
mean and standard deviation  in each body weight group were each compared with the histor-
ical values using a two-tailed Z-test and a p-value of 0.05. Non-normality in the data was ad-
dressed by using a log10-transformation. Given that higher values of Cmax were expected, no 
formal statistical comparison was deemed necessary for Cmax.
Table 1 Historical studies of abacavir in adults and children used for comparison
study Design objective subjects
cal 102120 Non-randomised, 
open-label, two-period, 
pharmacokinetic study.
To assess the pharmacokinetics of intra-
cellular CBV-TP at steady state following 
administration of 600 mg once daily 





ACTG 330 Open-label, dose-esca-
lating study
To evaluate the pharmacokinetic fea-
tures, safety, and tolerance of abacavir, 
given alone and in combination with 




cnaa 2001 Open-label, parallel 
dosing cohorts
To determine the multiple-dose pharma-
cokinetics and pharmacodynamics of aba-
cavir in HIV-1-infected subjects following 
oral administration of daily doses that 




Penta 13 One arm, open label 
cross-over study
To compare plasma pharmacokinetics of 
twice daily versus once daily lamivudine 
and abacavir in children aged 2-13 years
14 HIV-infect-
ed children
PENTA 15 Cross-over, open-label 
pharmacokinetic
multi-centre study
To compare plasma pharmacokinetic 
parameters of once versus twice daily  
dosing of abacavir in HIV-1 infected 




arrOW part1 Randomized controlled 
study
To compare the pharmacokinetics of once 
versus twice-daily lamivudine and ab 
cavir treatment using the World Health 
Organization recommended weight band 
dosing of scored adult tablets.
36 HIV-infect-
ed children
cnaa 1001 Single-dose, open label 
study 
To assess the safety of single oral doses 
of abacavir in HIV-infected children ≤13 
years of age, to deterimine the pharma-
cokinetics of abacavir in HIV-infected 
infants and children, and to determine the 
effect of development age on the pharma-
cokinetics and metabolism of abacavir.
19 HIV-infect-
ed children




To demonstrate the bioequivalence be-
tween a single tablet composed of 600mg 
abacavir and 300mg lamivudine versus 
the treatment of abacavir 2 x 300mg 








between 3 month 
and 12 years old
Doses 
administered
Based on the 
latest SPC for 
abacavir
Sampling times
0, 1, 2, 3, 4, 6, 8, 





AUC (0-24) based 
on the trapezoidal 
rule
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Demographic characteristics of the simulated paediatric population
 
overall <	14	kg 	14-21	kg 21-30	kg >	30	kg
Subjects 180 85 34 31 30
Median Age (years) 3.5 0.91 4.5 8 10.5
Min (years) 0.25 0.25 2 5 7.5
Max (years) 12 3.5 7.5 11 12
Median weight(kg) 14.9 9.73 17.2 24.9 35.9
Min (kg) 5.41 5.41 14.1 21.1 30.2
Max (kg) 53.9 13.6 20.7 29.1 53.9
Table 3 Demographic characteristics of the simulated paediatric population
Weight	Band Abacavir	Dose	Regimen Abacavir total daily dose
<14kg Oral solution (8mg/kg) twice 
daily
16mg/kg/day
14 to 21kg One-half tablet (150mg) twice 
daily
300mg
>21 to <30kg One-half tablet (150mg) in the 
morning; One whole tablet 
(300mg) in the evening
450mg




A hypothetical population of 180 children between 3 months and 12 years old was used during 
this investigation. The characteristics of the simulated paediatric population are summarised in 
table 2. Abacavir was administered once daily to the hypothetical population at the same total 
daily dose used in the currently approved twice daily regimens. 
Abacavir area under the curve (AUC
0-24
) and peak concentration (Cmax) distributions following 
once daily administration were simulated in the abovementioned paediatric population based on 
a pharmacokinetic model previously developed by our group (27). The model has been select-
ed based on graphical and statistical criteria and has been validated using several tools, namely 
bootstrap, mirror plots, NPDE and visual predictive check to guarantee its predictive power. 
The simulation results are summarised graphically in figures 2 and 3, which show the com-
parison between the simulated distributions of the secondary pharmacokinetic parameters 
[AUC
0-24
 and Cmax] and historical data from previous clinical trials with abacavir administered 
to children and to adults.  Box plots show that the predicted abacavir exposure reached after 
once daily dosing of abacavir was comparable in every weight range to the exposure reached 
in historical trials where abacavir was administered at approved once or twice daily doses to 
adults and twice daily doses to children.  A statistical test was performed to compare simulated 
AUC values with historical data. Based on a two-tailed Z-test the difference between the AUC 
values in each of the four groups and the historical data was not significant (p-value of 0.779, 
0.1096, 0.09 and 0.1336, respectively). 
Abacavir pharmacokinetic parameters of the simulated population are summarised in table 4. 
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Table 4 Summary of the pharmacokinetic parameters of the simulated population. Values presented as geometric 
mean (95% CI) except for dose which is presented as median (range)
 






























































7.4. discussions And conclusions
Clinical	implication	of	a	once	daily	dosing	regimen	for	abacavir
This investigation is aimed at assessing whether once daily administration of abacavir to HIV-in-
fected children between 3 months and 12 years old provides appropriate values of exposure 
compared to historical trials in adults and children. Given that paediatric adherence is a major 
problem in antiretroviral combination therapy, abacavir once daily dosing to children may con-
stitute a great advantage in improving patient compliance. It is well known that young children 
must rely on caregivers for drug administration. In limited resource countries, where caregivers 
may be unable to administer the medication for various reasons, compliance is a serious issue. 
The relation between poor adherence and drug failure has been clearly demonstrated in several 
studies. Therefore the possibility to reduce dosing frequency may be an effective solution to 
increase patient adherence and to improve treatment outcome. 
Figure 2 Box plots showing the comparison between simulated distributions of abacavir AUC0-24 after once daily 
dosing and historical data from clinical trials. Box represents median, 25th and 75th percentiles, bars represent 10th 
and 90th percentiles. Simulated distributions (N= 500 replicate trials) are comparable or higher than historical 
data in each weight range.
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Figure 3 Box plots showing the comparison between simulated distributions of abacavir Cmax after once daily 
dosing and historical data from clinical trials. Box represents median, 25th, and 75th percentiles, bars represent 10th 
and 90th percentiles. Simulated distributions (N= 500 replicate trials) are comparable or higher than historical 
data in each weight range.
A	model-based	approach	for	the	evaluation	of	alternative	dosing	regimens
In this investigation we use a model-based approach to simulate abacavir exposure in a large 
group of hypothetical HIV-infected children. The great advantage of a modelling and simula-
tion approach in paediatrics is the possibility of exploring relevant scenarios without putting 
children into a clinical protocol (30). Simulations allow evaluation of a dosing regimen in a large 
population with a wide range of demographic characteristics which cannot be tested in reality 
for obvious ethical and technical issues. In this case we used a hypothetical population of 180 
HIV-infected children uniformly distributed between 3 months and 12 years old and a previ-
ously validated pharmacokinetic model for simulation purposes. As shown in figures 2 and 3, 
simulated abacavir AUC
0-24
 appears to be comparable to all the historical values deriving from 
clinical trials in children and adults based on twice daily or once daily dosing regimen except 
the historical AUC
0-24
 value deriving from the ACTG330 trial, performed in children receiving 
abacavir as twice a day dosing regimen (figure 3). However, as shown in figure 2, the mean value 
of AUC
0-24
 from the ACTG330 study is considerably higher compared to every other previous 
study.  Moreover, a statistical comparison in which simulated AUC
0-24
 values are compared with 
weighted mean and standard deviation of the historical values showed that the difference be-
tween the AUC
0-24
 values in each weight group and the historical data is not statistically signif-
icant.
As shown in a similar analysis performed on lamivudine by our group (Chapter 6), the older 
children (>14 kg) have a higher exposure compared to younger children (<14 kg). This difference 
may be partly explained by a slightly higher mg/kg dose that the older children (>14 kg) are ad-
ministered when given the tablet formulation (as shown in table 3), as for lamivudine. There may 
also be an effect of the formulation, since younger children (< 14 kg) were assigned to receive 
solution and the older children (> 14 kg) were assigned to receive tablets, but this effect was not 
found to be significant in the previously developed model. Despite the slightly higher dose, the 
box plots illustrate the considerable overlap in AUC
0-24
 values between those predicted for chil-
dren on once daily regimens and those observed in prior studies of adults and children; there-
fore, a once daily abacavir regimen is expected to have similar antiviral activity to the twice daily 
regimen in children. As shown in figures 2 and 3, abacavir simulated peak concentrations appear 
to be comparable to or higher than historical values, especially those of twice daily regimens. 
Given that once daily abacavir was approved for use in adults based on good safety and efficacy 
and the positive benefit-risk balance and acceptable safety profile of once daily abacavir was 
observed in small studies of children (19-21), the predicted increase in Cmax after once daily 
administration is unlikely to result in a higher risk of adverse events. 
The higher plasma Cmax with the once daily regimen may raise questions about the potential 
for increased toxicity and adverse events in children. Abacavir has been studied at doses as high 
as 12mg/kg twice daily in children (31) and at doses up to 600mg three times daily in clinical 
trials in adults (32). Possible trends in adverse event incidence were observed for nausea, mal-
aise, and gastrointestinal discomfort in these high dose studies. However, Cmax values from 
pediatric subjects on once daily dose regimens in PENTA 13, PENTA 15 or ARROW were similar 
to those in the high dose adult studies and no new safety concerns were raised in PENTA 13, 
PENTA 15 or ARROW suggesting that abacavir is relatively safe and well-tolerated at higher 
doses and Cmax values in children
C h a p t e r  7
1 4 0 1 4 1
S u i ta b i l i t y  o f  o n c e  da i ly  d o S i n g  a b ac av i r  i n  c h i l d r e n
limitations
One of the main limitations of our investigation was the use of abacavir plasma pharmacoki-
netics, which can only be considered as a limited marker of drug exposure as it is the intracel-
lular abacavir triphosphate metabolite that becomes pharmacologically active. However, given 
that adequate sampling for determination of intracellular concentrations of nucleoside tran-
scriptase inhibitor triphosphates is logistically and technically difficult and the volume of blood 
needed to measure intracellular abacavir concentrations with current technology makes serial 
evaluations impractical for paediatric patients, abacavir plasma pharmacokinetics can be con-
sidered as an appropriate marker in children. 
conclusions
We have demonstrated that abacavir pharmacokinetics after once daily dosing is comparable 
to abacavir pharmacokinetics following twice a day administration. Abacavir AUC
0-24
 was simu-
lated in a hypothetical paediatric population and appeared to be comparable to historical values 
of abacavir AUC
0-24
 from previous clinical studies in adults and children for every weight range. 
Therefore, comparable antiviral activity would be expected on a once daily abacavir regimen. 
Simulated Cmax was found to be comparable or higher than historical values.  The increase in 
Cmax does not constitute a risk of toxicity given the safe and tolerable abacavir profile (30, 31). 
This work is supportive of previous clinical studies which showed the feasibility of once daily 
dosing of abacavir in children. A model-based approach enabled the evaluation of an alternative 
dosing regimen in a large population of children. Based on these findings we can conclude that 
once daily dosing abacavir to HIV-infected children provides appropriate drug exposure and 
does not lead to risk of under dosing. Abacavir once daily regimen may therefore be used to im-
prove adherence and provide optimal efficacy in paediatric antiretroviral combination therapy.
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summAry 
The aim of this investigation was to evaluate the forgiveness of antiretroviral therapy to variable adher-
ence, taking into account the differences in pharmacokinetic and pharmacodynamic properties of the 
drugs currently administered to HIV-infected children as first-line therapy. 
Simulation scenarios were evaluated using a hypothetical population of HIV-infected children 
(n=100) between 3 and 12 years. Three drugs, belonging to the three antiretroviral classes approved 
as first-line therapy in children, were selected: efavirenz (NNRTI), lamivudine (NRTI) and lopinavir/ri-
tonavir (boosted PI). Published pharmacokinetic and pharmacodynamic models were integrated with 
an established model for viral replication to predict treatment outcome based on different degrees of 
adherence to therapy for each drug. Simulations were performed in NONMEM7 and R 2.13.0 was used 
for data manipulation, statistical and graphical summaries.
 Despite its long half-life, efavirenz may be susceptible to viral failure for treatment interruptions 
longer than one week. Due to its short half-life, lamivudine appears to be forgiving only to very short 
periods and few missed doses. Similarly, forgiveness of non-adherence to treatment with lopinavir/ri-
tonavir is limited to short treatment interruptions and few missing doses. Based on the current dosing 
regimens, no relevant clinical effect is observed for delays in drug intake of up to six hours for the three 
drugs. 
Our results show that simulations can be applied as a tool to explore non-adherence to treatment. 
The use of a model-based approach provides a framework for the optimisation of the dosing regimens 
for antiretroviral drugs, unravelling the set of pharmacokinetic and pharmacodynamic properties that 
determine forgiveness.
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properties such as half-life and potency. For the sake of clarity, the forgiveness of a drug is de-
fined as the ability to achieve and maintain viral suppression despite sub-optimal adherence to 
the prescribed dosing regimen. This may depend on many factors, such as drug, viral and host 
properties. Forgiveness of non-adherence may be a powerful factor in the selection of the most 
suitable treatment in resource limited countries. 
In contrast to empirical protocols, here we propose a model-based approach to evaluate for-
giveness of drug to treatment interruptions and deviations from the prescribed regimen, which 
cannot be assessed in a real-life randomised controlled trial due to obvious ethical and clinical 
reasons.  We assess adherence as a covariate effect on drug exposure using a range of scenarios. 
Similar approaches dealing with adherence have been proposed before (9). However, an inte-
grated analysis of the impact of adherence on pharmacodynamics has not been performed so 
far. Instead, Markov models have been developed to estimate the effect of patient adherence on 
the rate at which patient progress through the HIV infection (10–12). More recently, Genberg et 
al (13) have shown the implication of treatment interruptions on the outcome of antiretroviral 
therapy, but their work has not explored how pharmacokinetic-pharmacodynamic properties 
contribute to or prevent treatment failure.  
8.2. methods
Hypothetical	population	and	paradigm	drugs	
A hypothetical population consisting of 100 HIV-infected between 3 and 12 years old was se-
lected with individuals evenly spread across two groups based on body weight (15-40kg and 
>40kg). Three paradigm drugs were evaluated as monotherapy: efavirenz (NNRTI), lamivudine 
(NRTI) and boosted lopinavir/ritonavir (boosted PI). The drugs were selected to represent the 
antiretroviral classes presently approved as first-line therapy in children (6). Each drug was ad-
ministered according to the currently recommended dose (table 1), as indicated in the latest 
Summary of Product Characteristics. The duration of the treatment in this hypothetical trial 
was 90 days. Viral load was considered the measure of interest in the study. Further details of 
the proposed experimental protocol are summarised in table 2.
Models	for	drug	pharmacokinetics,	drug	resistance	and	drug	efficacy
In order to explore the effect of a range of sub-optimal adherence scenarios on treatment out-
come, including that of drug holidays, three mathematical models were used for simulation pur-
poses during the analysis. First a pharmacokinetic model was used to predict the time course of 
plasma concentrations for each drug. Subsequently a pharmacodynamic model was applied to 
predict the time varying inhibitory effect of the drugs and ultimately a disease model for viral 
replication and infection was employed to predict the time varying clinical endpoints (viral load).
8.1. introduction  
      
The goal of antiretroviral therapy is to delay disease progression by minimizing viral replica-
tion and preserving immune function, with minimal drug-toxicity effects. Several antiretroviral 
drugs are currently approved in children. They are classified by their target in the HIV life-cycle 
as nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) (1). Yet, children with HIV rep-
resent a highly complex population. In fact, despite the available drugs, viral failure remains a 
serious issue in paediatric HIV. A previous study has shown that 24% of children followed up 
over 4 years were triple-class exposed, and 10% had triple-class viral failure (2).
These failure rates may be explained by the chronic nature of the disease, which requires the 
use of drug combinations throughout adolescence and adulthood. During growth, time vary-
ing developmental factors that affect the pharmacokinetics of antiretroviral drugs are often 
ignored, which leads to inappropriate exposure levels. Secondly, young children must rely on 
a caregiver to receive their medications. Given the social and economic constraints, caregivers 
may be busy during the day, causing dosing frequency to be variable and making adherence to 
treatment rather challenging. Although simplified treatments are highly advantageous, current-
ly only few antiretroviral medications are available as a once daily dosing regimen in children. 
Indeed, fewer than 50% of the children/caregivers report an adherence of 100% to their treat-
ment (3).
Reasons of non-adherence include: forgetting doses, changes in routine, being too busy, and 
child refusal. In some cases, however, the cause of poor adherence is unrelated to the patient; 
it is due to the environment: patients in limited resource countries do not always have access 
to antiviral drugs as drug supplies may be limited or they cannot afford the cost of treatment. 
Therefore, even when a child receives the optimal dose and has access to simplified dosing regi-
mens, the impact of poor adherence to treatment still needs to be considered carefully: compli-
ance to the prescribed regimen is very difficult to achieve in practice.  It has been demonstrated 
that the risk of viral failure increases as the amount of missed doses increases (4–6). Imperfect 
adherence can lead to sub-therapeutic drug levels, which may boost the development of drug 
resistance to one or several drugs in the treatment. In fact, it is estimated that a degree of ad-
herence equal or higher than 95% is required for a successful viral treatment (95 rule) (7). More 
recent studies with new classes of antiretroviral drugs show that a degree of adherence lower 
than 95% may be sufficient to maintain viral suppression, but these findings result from empiri-
cal experimental protocols and as such may not be generalisable (8).
Given that HIV therapy is usually a lifelong treatment it is critical to understand whether a 
drug allows for such patterns of poor adherence. The objective of our analysis is therefore to 
investigate the forgiveness of non-adherence of each class of antiretroviral drugs currently 
used as first-line therapy in children based on their pharmacokinetic and pharmacodynamic 
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Table 1 Doses of antiretroviral drugs administered to the hypothetical population of HIV-infected children based 
on current guidelines  
Antiretroviral	drug Dosing	regimen
Efavirenz 250 mg once daily (14-20 kg)   
300 mg once daily (20-25 kg)  
350 mg once daily (25-32 kg)   
400 mg once daily (32-39 kg)   
600 mg once daily (>39 kg)    
Lamivudine 150 mg twice daily (14-21 kg)
225 mg twice daily (21-30 kg)
300 mg twice daily (>30 kg)
Boosted lopinavir/ritonavir 15/40 mg/Kg twice daily (15-40 kg)
400/100 mg twice daily (>40 kg)
Table 2 Details of the hypothetical clinical protocol
efv 3tc lpv/r
Number of virtual patients 100 100 100
Treatment duration (days) 90 90 90
Dosing frequency Once daily Twice daily Twice daily
Sampling frequency Daily Daily Daily
Assumed failure time (days) 40 40 40
The pharmacokinetic profiles over time for each drug were simulated based on validated 
models available in literature (14, 15).
The median inhibitory concentration (IC
50
) was used to quantify agent-specific drug suscepti-
bility. To model within-host changes over time in IC
50
 attributable to the emergence of new-drug 





 are respective values of IC
50 
(t) at baseline and at time point t
r,
 at which the re-




, no new drug resistant mutation is developed during treat-
ment. More complicated models for IC
50
 are available in literature (17, 18); however in clinical 
practice it is common to collect IC
50
 values only at baseline and failure time (19). 
In our investigation the failure time was fixed at 40 days after the start of the treatment given 
that when antiretroviral drugs are administered in monotherapy resistance usually develops 
within few weeks after the start of treatment. The values of IC
50 
for the drugs explored in this 
analysis were obtained from literature (20–22), such as the values of I
r
 based on phenotypic 
resistance tests for each drug. 
Efficacy was considered to be constant over time in several viral dynamic studies (23–25). 
However, treatment response may vary because of differences in drug concentration and other 
factors or conditions (i.e. development of resistance), which may change during treatment. A 
pharmacodynamic additive sigmoid I
max




 is the maximal inhibitory effect that can be achieved and equals to 1, C is the drug 
concentration, and ic
50
 is the drug concentration that induces an effect equivalent to 50% of 
the maximal inhibitory effect. 
Given that during our analysis the three drugs were administered as monotherapy, the 
time-varying efficacy or response to treatment equals the effect of the drug at each time point, 
as calculated in equation 2. Time-varying efficacy γ (t) ranges from 0 to 1 and is referred to as the 
drug efficacy index (the inhibition rate of viral replication) in the viral dynamic model (Equation 
3-5). If γ (t) = 1, the drug is 100% effective, whereas if γ (t) = 0, the drug has no effect.
mathematical models for hiv dynamics
A widely used model for viral infection and replication was used to simulate the time course of the 
clinical endpoints (viral load and CD4 count) (19). As depicted in figure 1, the model consists of 3 
compartments: uninfected target cells (T), free virions (V) and infected target cells (T*). Although 
more complex models for viral replication were available in literature, this simple model showed 
characteristics of stability and robustness  deemed suitable for the purpose of our analysis. 
(1)
(2)
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The model for viral replication is defined by three differential equations (equation 3-5). Sev-
eral parameters are required to describe the viral and immunological processes: λ (day-1 mm-3) 
is the birth rate of new T cells appearing in the body, d
t
  (day-1) is the death rate of the T cells, N 
is the amount of virions produced by each of the infected target cells, c (day-1) is the clearance 
of the free virions, k (day-1 mm3) is the infection rate, δ (day-1) is the death rate of infected target 
cells; γ (t)  is the time varying efficacy of the drug, predicted by the pharmacodynamic model 
depicted in equation (2).
Figure 1 Three-compartment model for viral replication and infection used to simulate time-varying viral load and 
CD4 count.
dT / dt = λ – dT – [1-γ (t)] kTV          (3)
dT* / dt = [1-γ (t)] kTV –δT*            (4)
dV / dt = NδT* – cV                          (5)
simulation scenarios of variable adherence to treatment
The diagram in figure 2 depicts all the scenarios which were simulated for different patterns of 
non-adherence to treatment (treatment interruption, delay in drug intake or single doses ran-
domly missed throughout the clinical trial).
Based on average adherence in clinical trials derived from objective measures (4, 26, 27), a pre-
defined fraction of patients (40%) was randomly selected to be non-adherent to the prescribed 
dosing regimen. For each scenario the period of non-adherence was randomly assigned to each 
subject across the duration of the trial as shown in figure 3. 100 replicates were simulated for 
each scenario. Simulations were performed with NONMEM v7 and R (v 2.13.0) was used to pro-
duce the datasets for each simulation scenario and to numerically and graphically summarise the 
results.  A comparison between treatment outcome for the full population in case of perfect and 
imperfect adherence was made to evaluate the forgiveness of non-adherence for each drug and 
explore which drug-specific properties have to be considered to achieve viral success.
Figure 2 Diagram depicting the simulation scenarios of non-adherence to treatment investigated 
during the analysis.
Figure 3 Example of randomly assigned periods of non-adherence for one subject (treatment interruption of 14 
days (7x2)).
Pharmacodynamic	vs.	clinical	forgiveness
Given the lack of quantitative measures to characterise forgiveness of non-adherence, two 
thresholds were defined in our study. The first threshold corresponds to an increase of 20% in 
the median value of viral load compared to perfect adherence. Such a threshold, which indicates 
a variation in drug response, was selected to account for the inter-individual variability defined 
in the models. If the viral load is below this threshold, we consider that the drug allows for phar-
macodynamic forgiveness. 
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The second threshold corresponds to an increase in median viral load equal to 0.5 log10 cop-
ies/mL. Such an increase, which was selected to account for essay variability (28), can be con-
sidered clinically relevant and indicate viral failure. If the viral load is below this threshold we 
consider that the drug  allows for clinical forgiveness. 
Two main assumptions were required to implement the simulations presented here. First 
of all, we have assumed the same failure time for the three drugs (day 40). This was done to 
avoid additional variability in the study and evaluate adherence as the only variable in our anal-
ysis. Secondly, the selection of discrete scenarios of non-adherence was deemed necessary to 
evaluate the forgiveness of each drug. Nevertheless, these scenarios reflect the most common 
patterns of non-adherence and were defined according to a more detailed taxonomy for compli-
ance, based upon which treatment interruptions, random missingness of doses or delays in drug 
intake can be characterised. 
8.3. results 
Viral load and CD4 counts were derived by simulations for all three drugs. Given that both end-
points appeared to be equally affected by varying patterns of compliance, only viral load data 
will be presented and summarised in the next paragraphs.
The boxplots in figure 4-6 show the median viral load for the children non-adherent to therapy 
(n=40) for each simulated scenario of non-adherence at the last time point before resistance 
dominates. After this time point the treatment is no longer effective due to resistance. As indi-
cated previously, the evaluation of the effects of poor adherence according to a model-based 
approach requires a more detailed taxonomy. Therefore, our results will be presented in terms 
of treatment interruptions, random missingness and delays in drug intake.
Figure 4   Boxplots show the implications of poor adherence on viral load prior to drug failure (i.e. resistance) 
for variable persistence of compliance. On the x-axis the duration of the treatment interruption is displayed. In 
parenthesis the number of interruptions is illustrated. The lines represent two thresholds for variation in response 
assuming perfect adherence to treatment: the dashed line indicates the threshold for pharmacodynamic forgive-
ness; the solid line indicates the threshold for clinical forgiveness. 
a. efavirenz, b. lamivudine, c. lopinavir/ritonavir
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Figure 6 Boxplots show the implications of poor adherence on viral load prior to drug failure (i.e. resistance) for 
variable quality of compliance. On the x-axis the number of hours of delay in drug intake is depicted. In parenthe-
sis the percentage of days of treatment in which the delay happens is displayed. The lines represent two thresholds 
for variation in response assuming perfect adherence to treatment: the dashed line indicates the threshold for 
pharmacodynamic forgiveness; the solid line indicates the threshold for clinical forgiveness. The lower dashed line 
in panel c represents the quantification limit for viral load.
a. efavirenz, b. lamivudine, c. lopinavir/ritonavir
Figure 5   Boxplots show the implications of poor adherence on viral load prior to drug failure (i.e. resistance) for 
randomly missed doses. On the x-axis the percentage of doses missed is displayed. For lamivudine and lopinavir/
ritonavir, administered twice daily, the scenarios in which only the morning dose is missed are illustrated as well. 
The lines represent two thresholds for variation in response assuming perfect adherence to treatment: the dashed 
line indicates the threshold for pharmacodynamic forgiveness; the solid line indicates the threshold for clinical 
forgiveness.
a. efavirenz, b. lamivudine, c. lopinavir/ritonavir
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treatment interruptions
Median viral load values are presented separately for each of the three drugs. In figure 4 an 
increase in median viral load is clearly visible between scenarios with variable treatment in-
terruptions. However, significant differences in the effect on poor adherence can be observed 
for the different drugs. Median viral load values above the threshold of clinical forgiveness are 
reached for efavirenz after repeated treatment interruptions of one week (7x3) or two weeks 
(14x2). On the other hand less frequent treatment interruptions (7x2) for lamivudine and boost-
ed lopinavir/ritonavir are sufficient to raise median values of viral load.  Moreover, our analysis 
shows that repeated treatment interruptions of three days do not seem to alter treatment re-
sponse for efavirenz, while similar interruptions may lead to treatment failure for lamivudine 
and lopinavir/ritonavir.
doses randomly missed
Different patterns of response were observed for each of the drugs when doses are missed 
randomly, as shown in figure 5. Missing a dose twice a day for 20% of the days of treatment 
and missing one dose a day for 40% of the days of treatment (the amount of total doses missed 
is the same) leads to different median viral load values but overlapping confidence interval. In 
the case of efavirenz, viral failure may be caused by 40% of the doses randomly missed during 
the trial, whilst for lamivudine and boosted lopinavir/ritonavir 20% of the daily dose or 40% of 
half-daily  dose missed may cause viral failure. In addition, we have found that the median viral 
load increases as the amount of missed doses increases. The difference between missing a dose 
once or twice a day appears to be important. For lopinavir/ritonavir when a dose is missed once 
a day for 20% of the days of treatment the median viral load does not reach the threshold of 
pharmacodynamic forgiveness while missing a dose twice a day for 20% of the days causes an 
increase in median viral load above the threshold for clinical forgiveness.
Delays	in	drug	intake
Based on the box plots in figure 6, no variations were observed in median viral load for the three 
drugs for delays in drug intake up to six hours. Although the 10th and 90th percentiles show small 
changes, the median values of viral load for efavirenz, lamivudine and boosted lopinavir/ritona-
vir remain very similar to the value observed in the case of perfect adherence for each scenario 
of delay in drug intake. Given that median viral load values for lopinavir/ritonavir stay below the 
limit of quantification for all the scenarios, in figure 6 c the values of viral load below the quanti-
fication limit are also shown. Such values can be predicted by the model but are not quantifiable 
in clinical practice.
8.4. discussions And conclusions
Using a model-based approach, we have shown that integration of pharmacokinetic and pharma-
codynamic models to a disease model for viral replication and infection can provide the basis for a 
framework for the evaluation of patient behaviour during a clinical trial. Our analysis clearly shows 
a relationship between the duration of treatment interruption and increase in viral load for the 
three classes of antiretroviral drugs evaluated.  For NNRTIs the risk for viral failure is statistically 
significant starting at interruptions between 7 and 14 days, whilst for PI-based regimens, the risk 
of viral failure is statistically significant at 2–7 days. This findings are in agreement with a previous 
investigation which shows the impact of treatment interruptions on treatment outcome (13).
Despite its long half-life (40-55 hours), efavirenz seems to be completely forgiving only to 
very short interruptions. Longer or repeated interruptions may lead either to change in treat-
ment outcome or to viral failure, depending on the duration and frequency of such interrup-
tions. These findings are in agreement with previous publications which show that, despite its 
pharmacokinetic and pharmacodynamic properties, high levels of adherence to NNRTIs are 
needed to control viral replication (5, 29). 
Published data also confirm our findings with boosted PIs. According to these studies, an ad-
herence rate of at least 80% is required to achieve viral suppression (30–34). In addition, longer 
half-life and increased PI concentrations produced by the boosting effect of ritonavir can in-
crease the forgiveness of PIs. However,  higher levels of adherence are needed to the boosted 
PIs compared with the NNRTIs in order to obtain the same virologic suppression. 
Very little information was available in literature about the impact of non-adherence to NR-
TIs. Based on our findings, lamivudine seems to be less forgiving than efavirenz due to its short-
er half-life.  Yet, despite its pharmacokinetic profiles, delays in drug intake do not seem to affect 
treatment outcome (as depicted in figure 6 b).
  
clinical relevance
From a clinical perspective, knowledge of the level of adherence necessary to achieve virologic 
suppression can be extremely valuable  as it may help to determine when adherence counselling 
is most necessary as well as whether alternative antiretroviral drugs need  to be administered 
given a patient’s adherence pattern (30). Furthermore, quantitative measures of forgiveness of 
non-adherence and class-specific thresholds may represent a powerful tool for patients and cli-
nicians. In fact, we envisage that the availability of a methodology that allows correlation of the 
forgiveness to the pharmacokinetic and pharmacodynamic properties of a drug may be used 
during the development of novel antiretroviral drugs and in the evaluation of the robustness of 
existing drugs not yet approved in children. 
Furthermore, it may be used to explore the behaviour of new antiretroviral compounds in 
children for which little empiric data exists. 
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We reiterate that the importance of our analysis relies mainly on the fact that the use of a 
model-based approach allows one to evaluate critical scenarios which cannot be investigated 
in real-life or controlled in a randomised protocol. In fact, it appears to be the only way to gen-
erate drug-specific thresholds of forgiveness of non-adherence. In conjunction with simulation 
techniques, this approach can provide the basis for improved dose rationale and better dosing 
regimens in children.
From a drug development perspective, the integration of pharmacokinetic-pharmacody-
namic models with a viral dynamics model also offers an opportunity to predict the efficacy of 
antiretroviral combinations. Estimates of pharmacokinetic-pharmacodynamic relationships in 
vivo are often challenging because of the use of combination therapy, which prevents detailed 
evaluation of the contribution of each drug to the overall inhibitory effect on viral load. Yet, sce-
narios can be considered in which drug effects are explored under the assumption of additivity 
and taking into account differences in pharmacokinetics (35).
limitations in our approach
We are aware that the clinical setting depicted in our simulation exercise does not fully reflect 
clinical practice, in that each drug is not administered as monotherapy. Antiretroviral drugs have 
been always administered in combination. In fact, monotherapy has been avoided mainly because 
of the rapid development of drug resistance. However this setting was required to investigate 
which properties determine the forgiveness of non-adherence to an antiretroviral drug . On the 
other hand, we have considered the implications of  drug resistance, which has been observed for 
monotherapy with antiretroviral drugs. However, we have not been able to identify a clear rela-
tionship between poor adherence and increased probability to develop drug resistance, particu-
larly for NNRTIs. In fact, it has been shown that despite their long half-life, such drugs may remain 
for long time at sub-therapeutic levels, which may lead to a higher risk of resistance.  
Given that our primary aim was to explore which pharmacological properties determine for-
giveness, we do not anticipate any bias due to this limitation. We acknowledge however that the 
inclusion of a correlation between non-adherence and development of resistance may improve 
the assessment of the time to viral failure and consequently the impact of poor adherence. 
conclusions 
In summary, we have evaluated the impact of non-adherence for three drugs used in first line 
therapy in children. Undoubtedly, our methodology offers the opportunity to explore the liabil-
ity of novel compounds to variable patterns of drug intake, which are often unfeasible in exper-
imental protocols. Although generalisation of the findings cannot be warranted without further 
investigations, we envisage that other mechanisms and drug combinations can be evaluated in 
a similar manner. In fact, the use of a model-based approach may provide a framework for the 
optimisation of the dosing regimens in paediatric HIV.
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impAct of non-Adherence to  
AntiretrovirAl combinAtion 
therApy in hiv-infected  
children
Chiara Piana, Donato Teutonico, Meindert Danhof, Oscar Della Pasqua
summAry
Sub-optimal adherence to therapy is among the main causes of failure in the treatment of HIV. In chil-
dren such issue is particularly serious given that they rely on caregivers to receive their medications. 
The aim of this study is to evaluate the impact of different patterns of non-adherence for a widely used 
NNRTI-based regimen in children.
Clinical trial simulations (CTS) were performed in R 2.14. A hypothetical population of HIV-infected 
children between 3 and 12 years old was simulated (n=100). Published pharmacokinetic and pharma-
codynamic models were integrated with an established model for viral replication to predict treatment 
outcome based on various degrees and different patterns of non-adherence to therapy. A logistic re-
gression was used to incorporate the relation between sub-therapeutic drug levels and the probability 
of developing resistance. The duration of the hypothetical trial was 48 weeks and the primary efficacy 
endpoint was the proportion of patients with HIV-1 RNA <50 copies/mL at week 48.
Treatment interruptions of two weeks to NNRTI-based regimens may extensively increase the pro-
portion of children experiencing viral failure compared to perfect adherence (76% vs. 90% of the chil-
dren achieving a viral load <50 copies/mL at week 48), as well as 10% of doses randomly missed during 
the 48-weeks trial (78% vs. 90% of the children achieving viral load <50 copies/mL at week 48). Delays 
in drug intake up to 4 hours do not impact the outcome of the treatment.
Based on our findings, treatment interruptions to a NNRTI-based regimen may pose more risk for 
virologic rebound than the same number of randomly missed doses. Clinical trial simulations can be ap-
plied as a tool to explore the impact of different patterns of non-adherence to combination treatment in 
children, which could not be evaluated in clinical practice due to obvious ethical reasons. 
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9.1. introduction  
  
In the last decades considerable progress has been made in the delivery of antiretroviral ther-
apy. Among other things, the use of fixed-dose combinations has been proven to be a powerful 
approach to improve patient adherence. However, these improvements are not always equal-
ly applicable to children, who will be subjected to lifelong treatment and who most likely will 
face the burden of disease in resource limited areas, where the access to the medication may be 
inadequate. Such challenges are further compounded by the fact that paediatric patients also 
have to rely on the availability of  caregiver for the administration of the drugs. 
As shown in previous studies, adherence is the strongest predictor of HIV-RNA suppression 
among individuals infected with HIV (1). In fact, many studies have been performed to investi-
gate the role of adherence in HIV therapy, however in most cases adherence has been  measured 
as the percentage of prescribed doses taken. Such a definition of adherence is outdated and has 
been shown to have important limitations (2). Today, it is acknowledged that differences in in-
dividual patterns of non-adherence can have different implications for the treatment outcome.
Thus far no quantitative assessment has been made of the patterns of non-adherence in chil-
dren, in which the role of extrinsic factors and intrinsic properties of the drugs used in combi-
nation therapy are distinguished. Such data may allow further understanding of the forgiveness 
of poor adherence to treatment and consequently provide guidance for the evaluation of al-
ternative dosing regimens as well as improved recommendations for prescribers and patients. 
In the previous chapter we have proposed a model-based approach to evaluate forgiveness of 
drug to treatment interruptions and deviations from the prescribed regimen using an integrat-
ed approach in which the pharmacokinetic characteristics and the potency of the drug were in-
tegrated with the properties of the viral system in order to predict treatment outcome. Herein, 
the same concept is applied to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
regimen and the pharmacokinetic-pharmacodynamic relationships of antiretroviral (ART) 
drugs are used to evaluate the effect of partial adherence to combination therapy. NNRTI- 
based regimens are widely administered as combination therapy in children, as recommended 
by the revised WHO guidelines (3). According to the guidelines, first-line antiretroviral therapy 
for HIV-infected children older than 3 years of age should include two nucleoside reverse tran-
scriptase inhibitors (NRTI) and a non-nucleoside reverse transcriptase inhibitor. At the moment, 
the combination between abacavir, lamivudine and efavirenz (ABC-3TC-EFV) is one of the most 
commonly prescribed to the paediatric population (4). In addition, it has been established that 
high levels of adherence to NNRTI-based regimens are required in order to achieve and main-
tain viral suppression (1). However, further investigation is needed to establish in a quantitative 
and systematic manner what is the clinical relevance of different levels of adherence.
The objective of this study was therefore to evaluate different scenarios of poor adherence 
in a hypothetical population of 100 HIV-infected children between 3 and 12 years old receiving 
abacavir, lamivudine and efavirenz according to the currently recommended doses. Using clini-
cal trial simulations we evaluate relevant scenarios of poor adherence, whilst discriminating the 
contribution of pharmacokinetic and pharmacodynamic factors from patient behaviour as de-
terminants of variability in treatment response. Moreover, our approach allows scrutiny of the 
aforementioned factors without subjecting children to the burden of an actual clinical protocol, 
which in many cases might not be feasible due to ethical reasons. In contrast to the empiricism 
that has prevailed in the development of antiretroviral therapies, we envisage that our work will 
shed light on how adherence concepts can be used in conjunction with  pharmacokinetic-phar-




Clinical trial simulations were performed in R (v 2.14.0) using a general template for clinical trial 
simulation previously developed by our group (5). In figure 1 an overview of the different simu-
lation steps required to implement a clinical trial simulation able to assess the impact of differ-
ent patterns of non-adherence for a combination of three drugs is presented. 
Figure 1 Flow diagram showing the simulation steps required for the implementation of the clinical trial  
simulations.
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Population	demographics	and	treatment	
A hypothetical population consisting of 100 HIV-infected between 3 and 12 years old was se-
lected with individuals evenly spread across the body weight range relevant to this group.  Body 
weight has been simulated from an empirical distribution represented by two clinical trials in 
which  HIV-infected children were enrolled, namely  PENTA 13 (6) and ARROW part 1 (7)). Sim-
ulations of body weight using a multivariate distribution were performed in R (v 2.14.0) accord-
ing to the method described by Tannenbaum et al (8). 
Patients in this population were given a combination of three drugs: abacavir (NRTI), lamivu-
dine (NRTI) and efavirenz (NNRTI), which is the currently recommended first-line therapy for 
HIV-infected children (9). The doses used for each compound were based on the latest Summa-
ry of Product Characteristics (table 1). The duration of the hypothetical trial was 48 weeks, with 
viral load at week 48 as the primary endpoint for evaluation of efficacy. A measure of viral load < 
50 copies/mL (detection limit) at week 48 was assumed to be treatment success. 
Table 1 Doses of antiretroviral drugs currently recommended for the treatment of HIV-infected children, which 
were used in the simulation scenarios
Antiretroviral	drug Dosing	regimen
Efavirenz 250 mg once daily (14-20 kg)   
300 mg once daily (20-25 kg)  
350 mg once daily (25-32 kg)   
400 mg once daily (32-39 kg)   
600 mg once daily (>39 kg)
Lamivudine 150 mg twice daily (14-21 kg)
225 mg twice daily (21-30 kg)
300 mg twice daily (>30 kg)
abacavir 300 mg twice daily (14-21 kg)
450 mg twice daily (21-30 kg)
600 mg twice daily (>30 kg)
Models	for	drug	pharmacokinetics,	drug	sensitivity	and	drug	efficacy
Three mathematical models were subsequently used to predict the effect of sub-optimal adher-
ence on treatment outcome. First a pharmacokinetic model was used to predict the time course 
of  plasma concentrations for each drug. Subsequently a pharmacodynamic model was applied 
to predict the time varying inhibitory effect of the drugs and ultimately a disease model for viral 
replication and infection was employed to predict the time varying clinical endpoint (viral load).
The pharmacokinetic profiles over time for each drug were simulated based on validated 
models available in literature (10–12). The median inhibitory concentration (IC50) was used 
to quantify agent-specific drug susceptibility. To model within-host changes over time in IC50 
attributable to the emergence of new-drug resistant mutations the function described in equa-
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are available in literature (14, 15), however in clinical 
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which is based on phenotypic resistance tests for each drug (17–19). 
Drug efficacy was considered to be constant over time in several viral dynamic studies (20–
22). However, drug efficacy may vary because of the differences in drug concentration and oth-
er factors (i.e. development of resistance), which may vary during treatment. A pharmacody-
namic sigmoidal additive I
max
 model was used to describe the concentration-effect relationship 
of three drugs and subsequently predict time-varying efficacy during the course of therapy with 
the drug combination:
 where ConcEFV(t) is time-varying efavirenz concentration, Conc3TC(t) is time-varying lamivu-
dine concentration,  ConcABC(t) is time-varying abacavir concentration, IC
50









ABC(t) is abacavir IC
50
; Φ is a factor which defines the 
in vitro-in vivo correlation and it was fixed to 1. 
(1)
(2)
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Time varying efficacy γ (t) of the treatment ranges from 0 to 1 and is referred to as the treat-
ment efficacy index (the inhibition rate of viral replication) in the viral dynamic model (Equation 
3-5). If γ (t) = 1, the treatment is 100% effective, whereas if γ (t) = 0, the treatment has no effect.
mathematical models for hiv dynamics
A widely used model for viral infection and replication was used to simulate the time course of 
viral load (16). The model is basic and consists of 3 compartments: uninfected target cells (T), 
free virions (V) and infected target cells (T*). Although more complex models for viral replication 
were available in literature, this simple model showed characteristics of stability and robust-
ness which were suitable for the purpose of our analysis. 
The model for viral replication is defined by three differential equations (equation 3, 4 and 5). 
Several parameters are used to describe the viral and immunological processes: λ (day-1 mm-3) is 
the birth rate of new T cells created in the body, dt (day-1) is the death rate of the T-cells, N is the 
amount of virions produced by each of the infected target cells, c (day-1) is the clearance of the 
free virions, k (day-1 mm3) is the infection rate, δ (day-1) is the death rate of infected target cells; γ 
(t) is the time varying inhibitory effect of the combination, predicted using the pharmacodynam-
ic model depicted in equation (2). 
dT / dt = λ – dT – [1-γ (t)] kTV          (3)
dT* / dt = [1-γ (t)] kTV –δT*            (4)
dV / dt = NδT* – cV                          (5)
Adherence-resistance relationship
A correlation between adherence and resistance in antiretroviral drugs has been previously es-
tablished by Bangsberg et al  (23). Despite their initial findings, different correlations appear 
to exist for different classes of  antiretroviral drugs (24). For example, most of the NNRTI and 
lamivudine mutations occurred in patients showing low adherence, suggesting that these two 
drugs have different adherence–resistance relationships compared to PIs and NRTIs. In our in-
vestigation a relationship between adherence and resistance was considered for efavirenz and 
lamivudine, given that these drugs are known to be more susceptible to resistance than abaca-
vir (25, 26). Such a relationship was described in terms of a logistic regression (figure 2), in which 
the probability of resistance is linked to the number of days during which the levels of efavirenz 
remain below the target therapeutic level or lamivudine remains below the quantification limit. 
The final model describing the correlation and the corresponding parameter estimates used in 
the simulations  were derived from published data  (27, 28).  
Figure 2 Logistic regression used to include the adherence-resistance relationship for efavirenz and lamivudine. 
PT50 values were set, respectively, at  8 and 10 days for efavirenz and lamivudine.
Simulation scenarios of variable adherence to treatment
The diagram in figure 3 depicts all the scenarios which were simulated for different patterns 
of non-adherence to treatment (treatment interruption, delay in drug intake or single doses 
randomly missed throughout the clinical trial). Based on average adherence in clinical trials de-
rived from objective measures  (29–31), a predefined fraction of patients (40%) was randomly 
selected to be non-adherent to the prescribed dosing regimen. For each scenario the period of 
non-adherence was randomly assigned to each subject across the duration of the trial. Dropout 
rates were considered to be zero for the purpose of this analysis. 100 replicates were simu-
lated for each scenario. Simulations were performed with NONMEM v7 and R (v 2.14.0) was 
used to produce the datasets for each simulation scenario and to numerically and graphically 
summarise the results.  A comparison between treatment outcome for the full population and 
for the subject non-compliant in case of perfect and imperfect adherence was made for each 
scenario of non-adherence in order to evaluate the forgiveness of non-adherence of a NNR-
TI-based regimen in HIV-infected children . 
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Figure 3 Diagram depicting the simulation scenarios of non-adherence to treatment investigated during the 
analysis.
9.3. results 
Under assumption of constant resistance rate, our simulations show that viral success is 10% 
for patients who show perfect adherence.  Our simulations reveal that delays in drug intake 
do not affect treatment outcome of ABC/3TC-EFV combination in HIV-infected children be-
tween 3 and 12 years old. As can be seen in figure 4,  the proportion of children who achieve 
viral success at week 48 in case of a delay in drug intake up to 4 hours in 20% or 40% of the days 
of treatment is not significantly different from the group showing perfect adherence. A closer 
evaluation of the viral load profiles also shows that delays in drug intake do not affect treatment 
outcome considering either the full population of 100 HIV-infected children or only the children 
who were not compliant to the prescribed dosing regimen.  On the other hand,  interruptions 
to the NNRTI-based regimen (i.e., simultaneous interruption of the three drugs) seem to have 
important implications for the outcome of antiretroviral therapy in this population of children. 
The treatment appears to be forgiving to interruptions of three days, whilst interruptions of 
one week may decrease the proportion of children experiencing treatment success at the end of 
the treatment from 90% to 87%, as compared to perfect adherence. A higher effect is observed 
for treatment interruptions of two weeks, which lead to a decrease the proportion of patients 
experiencing viral success from 90% to 78% (figure 5). In addition, treatment interruptions of 
30 days caused a decrease in the proportion of children achieving viral failure from 90% to 58%. 
By contrast, randomly missing 30 doses (i.e., 10% of the prescribed doses during the trial) 
resulted in a reduction in viral success from 90 to 80% (figure 6).
Figure 4  Proportion of subjects achieving viral success (HIV RNA<50 copies/mL) at week 48 based on different 
delays in drug intake. On the x-axis the number of hours of delay in drug intake is depicted. In parenthesis the 
percentage of days of treatment in which the delay happens is displayed.
Figure 5 Proportion of subjects achieving viral success at week 48 based on different duration of treatment inter-
ruption. On the x-axis the duration (days) of the treatment interruption is depicted.
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Figure 6 Proportion of subjects achieving viral success at week 48 based on different percentages of doses ran-
domly missed. On the x-axis the percentage of doses missed is displayed.
9.4. discussions And conclusions
This is the first attempt to describe in a quantitative manner the impact of poor adherence to a 
NNRTI-based regimen when evaluating efficacy in a paediatric population. Given that high lev-
els of adherence in paediatric antiretroviral therapy are very difficult to reach, efforts to iden-
tify which conditions represent a higher risk for viral failure is essential for ensuring positive 
treatment outcome. Using a model-based approach, we have shown that integration of phar-
macokinetic and pharmacodynamic models to a disease model for viral replication and infection 
can provide the basis for a framework for the evaluation of patient behaviour during a clinical 
trial. In fact, our results are in agreement with a previous investigation (32) which showed that 
in patients with incomplete adherence, missing doses over a continuous and sustained interval 
may pose more risk for virologic failure than interspersed missed doses. 
The possibility to identify the duration of treatment interruptions that pose more risk for vi-
rologic rebound in a specific population and for a specific drug combination represents a pow-
erful tool for mitigation strategies during drug development and risk management after drug 
approval. In addition, our analysis show the relevance of clinical trial simulations for the evalua-
tion of experimental design factors that cannot be controlled in a formal manner in real clinical 
trials. The availability of such an in silico methodology offers an alternative to the evaluation of 
clinically relevant questions in paediatric research, which may not be addressed in real proto-
cols due to ethical and practical issues. Moreover, it enables the characterisation of  patterns of 
non-adherence related to virologic failure before patients are exposed to the treatment. From a 
clinical safety perspective, this type of information can be transcribed into the label and commu-
nicated to prescribers and patients, with potential changes to the benefit-risk balance. It should 
be noted that the methodology developed here may be easily adapted to different treatment 
combinations. Furthermore, we can envisage different applications aimed at the evaluation of 
the robustness of different drug combinations, allowing different treatment options to be com-
pared. It is also conceivable that a different treatment may be prescribed to a patient based on 
his life-style or adherence records.  These opportunities are discussed in the next paragraphs.
optimisation of antiretroviral therapy 
The possibility to simplify antiretroviral therapy is crucial to improve patient adherence and 
consequently the proportion of patients achieving viral success. In fact, the use of fixed-dose 
combinations has been a huge success in antiretroviral treatment in adults. However, new opti-
mised dosing regimens are still required given that poor adherence to therapy remains a deter-
minant of resistance. The methodology developed here may be used to test the forgiveness of 
poor adherence for new simplified dosing regimens, which may not necessary be higher. In other 
words, a simplified regimen may improve compliance to treatment, but may not always lead to 
improved forgiveness in those patients who remain non-adherent. Thus far, this issue has not 
been evaluated in a systematic manner before enrolling the patients into a clinical trial with a 
fixed-dose combination.
Pharmacokinetic-pharmacodynamic	relationship	as	a	“proxy”	for	efficacy
Fixed-combination medicinal products have been increasingly used either to improve compli-
ance or to benefit from the added effects of the two or more medicinal products given together. 
According to the current EMA guideline on fixed-dose combinations (33), the proposed com-
bination should always be based on valid therapeutic principles. In addition, it is necessary to 
assess the potential advantages (e.g. product rapidly effective, higher efficacy or equal efficacy 
and better safety) in the clinical situation against possible disadvantages (e.g. cumulative tox-
icity), for each fixed-combination product and for each dose of the fixed-combination product. 
In fact,  the effectiveness of a simplified dosing regimen has been assessed through the use of 
pharmacokinetic, efficacy and safety trials (34–36).  Given that switching to a simplified dosing 
regimen may be considered as a particular scenario of forgiveness of non-adherence, we antici-
pate that the use of this type of in silico evaluation  will offer the advantage of using pharmacoki-
netic-pharmacodynamic relationships as a proxy for efficacy, preventing the need for costly and 
often complex efficacy trials in which it is not the efficacy (and safety) of the drugs or dose levels 
that are scrutinised, but rather the implications of the alternative dosing regimen.  Analogously, 
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a similar situation exists when pharmacokinetics is used as “proxy” for efficacy in bioequiva-
lence studies.
potential limitations 
The main limitation in our analysis is that toxicity was not taken into account in the simulation 
scenarios. It is well known that adverse events may influence the level of adherence of the pa-
tient. Taking into account the safety profile of abacavir and lamivudine and the mild adverse 
events that they seem to cause, efavirenz is the only drug for which toxicity should have been a 
concern. However, no association was found between efavirenz plasma concentrations and the 
risk of treatment discontinuations because of adverse events or toxicity (37). 
Another potential limitation is the fact that we have deliberately chosen to use a basic mod-
el of viral dynamics. More complicated models are available that describe viral infection and 
replication, including different steps and physiological compartments associated with immune 
response and viral resistance. We do not expect that these models would lead to significantly 
different results. On the other hand, it is important to point out that in our methodology the 
inhibitory effect of each single drug could not be evaluated separately. Rather, it was expressed 
through an additive equation. Although in vitro studies may be used to evaluate the inhibitory 
effect of a single drug, assessment of the contribution of each drug to the total inhibitory effect 
of a combination are usually not performed. Here we show that despite the lack of such infor-
mation, the use of a model-based approach enables the evaluation of the inhibitory effects in 
vivo of three drugs administered in combination.  
conclusions
In summary, we have shown that for similar levels of compliance treatment interruptions may 
pose a higher risk for viral rebound, as compared to randomly missed doses when using NNR-
TI-based regimens. Our analysis also illustrates how mathematical and statistical models can be 
used to investigate adherence scenarios which cannot be evaluated in clinical practice in paedi-
atric HIV due to obvious ethical and practical reasons. This methodology offers the opportunity 
for the development of patient-tailored treatments taking into account differences in compli-
ance pattern. Further investigation of the impact of non-adherence to different antiretroviral 
combination treatments (e.g. boosted protease inhibitor-based regimens) is required to confirm 
the generalisability of the approach used here.
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forGiveness of non-Adherence 
to once vs. tWice dAily  
lAmivudine/AbAcAvir  
in combinAtion With efAvirenz 
in hiv-infected children
Chiara Piana, Donato Teutonico, Meindert Danhof, Oscar Della Pasqua
summAry 
Optimisation of therapeutic management of infectious diseases is a priority in the European Union. 
Harmonisation of dosing regimens in order to encourage the development of fixed-dose combinations 
is therefore encouraged. Fixed-dose combinations are important as they can improve how well a pa-
tient is able to follow medical advice in terms of taking medicine at the right time and taking the correct 
number and combination of tablets. However, one of the main concerns of once daily dosing regimens 
based on fixed-dose combinations is the potentially lower robustness compared to twice daily dosing. 
This study was aimed at evaluating the forgiveness of non-adherence to once vs. twice daily lamivu-
dine/abacavir. 
Clinical trial simulations (CTS) were performed in R 2.14. Once and twice daily lamivudine/abacavir 
were administered with efavirenz to a hypothetical population of HIV-infected children between 3 and 
12 years old (n=30).  Different degrees of adherence to therapy were simulated for the two regimens. 
The primary efficacy endpoint was the measure of viral load at week 48. 
Our results show comparable forgiveness of non-adherence to the two dosing regimens in case of 
treatment interruptions, doses randomly missed and delays in drug intake.
Based on these findings, it appears that once daily lamivudine/abacavir could be administered in 
combination with efavirenz to children between 3 and 12 years old without any risk of decreased effi-
cacy, as compared to the currently recommended twice daily regimen. 
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10.1. introduction    
    
Several attempts have been made to improve patient adherence to antiretroviral therapy. 
Among other things, the development of fixed-dose combinations and the administration of 
once daily dosing options have determined a significant reduction in pill burden (1). Current-
ly once daily dosing regimens seem to be the preferred treatment options to improve patient 
adherence (2). In this context, a once daily single-tablet fixed-dose combination represents an 
important simplification of HIV treatment. Fixed-dose combinations include drugs with favour-
able pharmacokinetics that do not need dose adjustments, have no additional toxicities, and do 
not require dissimilar intake conditions (3). In fact, it has been shown that in newly diagnosed 
antiretroviral-naïve patients, once daily dosing of antiretroviral drugs resulted in higher adher-
ence than twice daily dosing (4).
Regardless of such advantages, one of the main regulatory concerns with modifications in a 
dosing regimen is that treatment response may change or be less robust as compared to the ref-
erence dosing regimens. In other words, despite the endorsement of current guidelines as to the 
importance of characterising  the relationships between dose, drug concentrations and clinical 
response for the safe and effective use of drugs in individual patients, including  the possibility 
to define dosage and administration instructions in the product label (5), confirmatory clinical 
trials are still deemed necessary to prove efficacy of new regimens for fixed-drug combinations, 
preferably by parallel group comparisons in which the new regimen is compared to the reference 
treatment (6). In most cases, these requirements appear to contradict each other, in that knowl-
edge of pharmacokinetic-pharmacodynamic relationships should enable accurate inferences of 
efficacy and safety. One should therefore dispute the need for confirmatory trials. Scientifically, 
what should be evaluated is whether the underlying pharmacokinetic-pharmacodynamic rela-
tionships are not affected by changes in dosing regimen. 
In reality, this concern pertains to the realm of quantitative clinical pharmacology and is closely 
related to the concept of compliance, treatment adherence and forgiveness. In conjunction with 
models of disease dynamics, pharmacokinetic-pharmacodynamic relationships can be used to 
explore whether simplified dosing regimens yield different response to therapy as compared to 
more frequent dosing regimens. 
In chapter 9 we have shown that a model-based approach may be used to assess the effect of 
partial adherence to a fixed-drug combination of abacavir, lamivudine and efavirenz. Our results 
suggest that pharmacokinetic-pharmacodynamic relationships of antiretroviral drugs could be 
used as “proxy” of efficacy. Moreover, it shows that the evaluation of forgiveness of non-adher-
ence for simplified dosing regimens is crucial to assess the feasibility of alternative treatment 
options.
In contrast to current guidelines, which impose pharmacokinetic, efficacy and safety trials to 
assess the suitability of a simplified dosing regimen, this study aims at showing how pharmaco-
kinetic-pharmacodynamic relationships may be used as predictors of response to changes in 
dosing regimen, thereby avoiding the need to unnecessarily enroll children into an efficacy trial. 
Here we use abacavir and lamivudine as a paradigm combination to explore the forgiveness of 
treatment to changes in dosing regimen. The use of dual nucleoside reverse transcriptase inhib-
itors (NRTI) is recommended as a part of combination antiretroviral therapy (7). Abacavir (ABC) 
and lamivudine (3TC) constitute the NRTI backbone in HIV-therapy and are usually administered 
in adults and children in combination with one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) or one boosted protease inhibitor (PI). At present abacavir and lamivudine are adminis-
tered as twice daily in children and once daily in adults. Among the various trials in which abaca-
vir and lamivudine have been investigated in children, the PENTA 13 trial demonstrated similar 
pharmacokinetics between once and twice daily doses, after administration of either a liquid or 
tablet formulation (8). In the same study, acceptability data demonstrated that caregivers pre-
ferred once daily dosing only if all drugs in the regimen were once daily. The PENTA 15 trial also 
demonstrated similar pharmacokinetics between once and twice daily dosing with abacavir and 
lamivudine in children aged 3 months- 3 years old (9). In addition, a sub-study of the ARROW 
trial (a randomised trial monitoring practice and induction maintenance of antiretroviral therapy 
regimens) (10) has shown that once daily regimens resulted in equivalent AUC0-24 to twice daily 
regimens in 3 to 12 year-old African children receiving World Health Organization (WHO) rec-
ommended doses of scored tablets.  It should also be noted that two previous population phar-
macokinetic analyses have been performed by our group, which showed comparable exposure 
of once and twice daily lamivudine and abacavir in a large simulation of a paediatric population 
including children between 3 months and 12 years old. 
Based on the points discussed above, it is clear that the evaluation of once daily dosing of lami-
vudine and abacavir in children will be crucial for treatment optimisation and further  alignment 
with  its current use in the adult indication (11). Despite similar pharmacokinetic exposure for the 
two dosing regimens, the impact of non-adherence on treatment outcome should be investigat-
ed to ensure the robustness of once daily lamivudine/abacavir.
10.2. methods
clinical trial simulation
The simulation scenarios described in the next paragraphs were performed in R (v 2.14.0) us-
ing a clinical trial simulations template, which was developed by our group (12). In figure 1 an 
overview is presented of the different simulation steps required to implement a clinical trial 
simulation aimed at the assessment of the impact of non-adherence for a combination of three 
drugs after once and twice daily dosing regimens. 
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Figure 1 Diagram depicts the simulation steps required to implement the clinical trial simulation.
Population	demographics	and	treatment	
A hypothetical population consisting of 200 HIV-infected between 3 and 12 years old was se-
lected with individuals evenly spread across the body weight range relevant to this group.  Body 
weight has been simulated from an empirical distribution represented by two clinical trials in 
which  HIV-infected children were enrolled, namely  PENTA 13 (8) and ARROW part 1 (10)). 
Simulations of body weight using a multivariate distribution were performed in R (v 2.14.0) ac-
cording to the method described by Tannenbaum et al (13). The outcome of the treatment was 
split into two cases, namely perfect and imperfect adherence. Given the high number of scenar-
ios evaluated and the computational time required, a smaller population was simulated (n=30) 
during the evaluation of the scenarios of poor adherence. However, more subjects (n=200) were 
evaluated when the sample size was deemed important for the interpretation of the results.
Three drugs (abacavir, lamivudine and efavirenz), currently used as first-line therapy in 
HIV-infected children (14), were administered according to body weight as established in the 
latest summary of product characteristics. The duration of the hypothetical trial was 48 weeks. 
The children received the drugs either as twice daily or once daily dosing regimens. The end-
point for efficacy was the probability of viral failure (HIV RNA higher than detection limit) at 
week 48. Viral failure was defined as a value of viral load higher than the detection limit. The 
thresholds used as detection limit were 50 and 400 copies/mL in case of perfect adherence. 
In the subsequent evaluation of the scenarios of poor adherence the strictest threshold of 50 
copies/mL was used. 
Models	for	drug	pharmacokinetics,	drug	resistance	and	drug	efficacy
Three mathematical models were subsequently used to predict the effect of sub-optimal adher-
ence on treatment outcome after the use of once or twice daily doses of a fixed-dose combina-
tion. First a pharmacokinetic model was used to predict the time course of plasma concentra-
tions for each drug. Subsequently a pharmacodynamic model was applied to predict the time 
varying inhibitory effect of the drugs and ultimately a disease model for viral replication and 
infection was employed to predict the time varying clinical endpoint (viral load).
The pharmacokinetic profiles over time for each drug were simulated based on validated 
models available in literature (15–17). The median inhibitory concentration (IC
50
) was used to 
quantify agent-specific drug susceptibility. To model within-host changes over time in IC
50
 at-
tributable to the emergence of new-drug resistant mutations the function described in equa-
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, no new drug resistant mutation is developed during treat-
ment. More complicated models for IC
50
 are available in literature (19, 20), however in clinical 
practice it is common to collect IC
50
 values only at baseline and failure time (21). The values of 
ic
50 
for the drugs included in our analysis were obtained from literature, such as the values of I
r
, 
which is based on phenotypic resistance tests for each drug (22–24). 
Drug efficacy was considered to be constant over time in several viral dynamic studies (25–
27). However, drug efficacy may vary because of the differences in drug concentration and oth-
er factors (i.e. development of resistance), which may vary during treatment. A pharmacody-
namic additive sigmoid I
max
 model was used to describe the concentration-effect relationship of 
three drugs and subsequently predict time-varying efficacy during the course of therapy with 
the drug combination:
where ConcEFV(t) is time-varying efavirenz concentration, Conc3TC(t) is time-varying lamivu-
dine concentration,  ConcABC(t) is time-varying abacavir concentration, IC
50









ABC(t) is abacavir IC
50
; Φ is a factor which defines the 
in vitro-in vivo correlation. In our simulations, Φ was fixed to 1. 
(1)
(2)
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Time varying efficacy γ (t) of the treatment ranges from 0 to 1 and is referred to as the treat-
ment efficacy index (the inhibition rate of viral replication) in the viral dynamic model (Equation 
3-5). If γ (t) = 1, the treatment is 100% effective, whereas if γ (t) = 0, the treatment has no effect.
mathematical models for hiv dynamics
A widely used model for viral infection and replication was used to simulate the time course of 
the clinical endpoint (viral load) (21). The model consists of 3 compartments: uninfected target 
cells (T), free virions (V) and infected target cells (T*). Although more complex models for viral 
replication were available in literature, this simple model showed characteristics of stability and 
robustness which were suitable for the purpose of our analysis. 
The model for viral replication is defined by three differential equations (equation 3, 4 and 5). 
Several parameters are used to describe the viral and immunological processes: λ (day-1 mm-3) is 
the birth rate of new T cells created in the body, dt (day-1) is the death rate of the T-cells, N is the 
amount of virions produced by each of the infected target cells, c (day-1) is the clearance of the 
free virions, k (day-1 mm3) is the infection rate, δ (day-1) is the death rate of infected target cells; 
γ (t) is the time varying inhibitory effect of the combination, predicted using the pharmacody-
namic model depicted in equation (2). 
dT / dt = λ – dT – [1-γ (t)] kTV (3)
dT* / dt = [1-γ (t)] kTV –δT*            (4)
dV / dt = NδT* – cV                          (5)
correlation between adherence and resistance
A correlation between adherence and resistance in antiretroviral drugs has been previously 
established by Bangsberg et al (28). Despite their initial findings, different correlations appear 
to exist for different classes of  antiretroviral drugs (29). For example, most of the NNRTI and 
lamivudine mutations occurred in patients showing low adherence, suggesting that these two 
drugs have different adherence–resistance relationships compared to PIs and NRTIs. In our in-
vestigation a relationship between adherence and resistance was considered for efavirenz and 
lamivudine, given that these drugs are known to be more susceptible to resistance than aba-
cavir (30, 31). Such a relationship was described in terms of a logistic regression, in which the 
probability of resistance is linked to the number of days during which the levels of efavirenz 
remain below the target therapeutic level or lamivudine remains below the quantification limit. 
The final model describing the correlation and the corresponding parameter estimates used in 
the simulations  were derived from published data  (32, 33).
simulation scenarios of variable adherence to treatment
Scenarios representing perfect adherence and different patterns of non-adherence to treat-
ment (treatment interruption, delay in drug intake or single doses randomly missed throughout 
the clinical trial) were simulated.  In each scenario of non-adherence all the patients participat-
ing in the trial were assumed to be non-adherent to treatment. For each scenario the period 
of non-adherence was randomly assigned to each subject across the duration of the trial. 100 
replicates were simulated for each scenario. Simulations were performed with NONMEM v7 
and R v 2.14.0 was used to produce the datasets for each simulation scenario and to numerically 
and graphically summarise the results. The impact of changes in dosing regimen was assessed 
by comparing the results obtained in each scenario of non-adherence with that of perfect ad-
herence. A measure of viral load above the threshold of 50 copies/mL was selected to indicate 
viral failure at week 48.
The results were compared for twice daily and once daily dosing regimens. In order to obtain 
a quantitative relationship between the probability of viral failure and the percentages of doses 
randomly missed or the duration of treatment interruptions for each dosing regimen, the data 
were fitted using the -nls (nonlinear least squares) function in R.
10.3. results 
During our analysis the forgiveness of non-adherence of once daily lamivudine/abacavir has 
been evaluated and compared to the forgiveness of the currently licensed twice daily dosing 
in children, both administered in combination with efavirenz as a fixed-dose combination. Ini-
tially, the two combination treatments were compared in terms of efficacy assuming perfect 
adherence to therapy. As shown in figure 2, the probability to experience viral failure at week 
48 is not significantly different after once or twice daily doses. In addition, our results show that 
time-varying viral load remains indistinguishable during the whole trial period, i.e., 48 week. 
Moreover, the therapeutic equivalence of the treatment is observed at week 48 considering 
both the detection limits of 50 and 400 copies/mL. 
Under the assumption of imperfect adherence, similar findings were observed. As shown in 
figures 3, 4 and 5, the probability of viral failure at week 48 for the two treatment combinations 
in a group of 30 HIV infected children does not reveal any significant differences between dos-
ing regimens. The similarities were observed irrespective of whether non-compliance was due 
to delays in drug intake (figure 3), treatment interruptions (figure 4) or randomly missed doses 
(figure 5). As expected, delays in drug intake up to 4 hours were shown not to affect the outcome 
of the treatment (figure 3), whilst changes in the probability of viral failure could be observed 
for the scenarios depicting treatment interruptions or doses randomly missed. These differenc-
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es were independent of the dosing regimen. 
To ensure  accuracy of the estimated effects, additional simulations were performed for a 
larger population (n=200), including the most significant scenarios of non-adherence, namely, 
4 hours delay in drug intake, two weeks interruptions and 10% of the doses randomly missed. 
No differences were observed in the results compared to the same scenarios evaluated with 30 
patients.
In figure 4 and 5 the quantitative relationships between the probability of viral failure and the 
duration of treatment interruptions and the percentages of doses randomly missed are shown, 
respectively. The fitting of the data, illustrated in figure 6, allowed us to derive the mathematical 
function that links the number of days of treatment interruption with the probability to experi-
ence viral failure. Practically, the same parameter estimates were obtained for both once daily 
and twice daily dosing regimens. As shown in figure 6, a function linking the percentage of doses 
randomly missed with the probability of viral failure was also obtained for the two regimens.
Figure 2  Probability of viral failure in case of perfect adherence for once and twice daily dosing regimen at the end 
of the treatment (left panel) and across the whole duration of the treatment (right panel).
Figure 3 Probability of viral failure associated with variable delay in drug intake for twice daily (left) and once daily 
(right) dosing regimen. On the x-axis the hours of delay in drug intake are displayed. In parenthesis the percentage 
of days in which the delay takes place is represented. 
Figure 4 Probability of viral failure associated with variable duration of treatment interruption for twice daily (left) 
and once daily (right) dosing regimen. On the x-axis the duration of the treatment interruption is displayed.
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Figure 5 Probability of viral failure associated with variable percentage of randomly missed doses for twice daily 
(left) and once daily (right) dosing regimen. On the x-axis the percentage of doses missed is displayed.
10.4. discussions And conclusions
Efficacy	of	once	vs.	twice	daily	lamivudine/abacavir	in	children
This investigation shows the robustness of a simplified treatment combination (efavirenz + 
lamivudine/abacavir once daily) in terms of its impact on treatment outcome as compared to 
the currently licensed regimen (efavirenz + lamivudine/abacavir twice daily), taking different 
patterns of non-adherence into account.
Conceptually, our analysis also demonstrates the relevance of pharmacokinetic-pharmacody-
namic relationships as a proxy for the assessment of efficacy when changes are made to dosing 
regimens. Initially, a comparison of the two treatments was made assuming perfect adherence 
in order to test whether the dosing regimens would show the same efficacy in ideal conditions. 
The results summarised in figure 2 clearly shows comparable efficacy for both regimens and 
corroborate our previous evaluation of the pharmacokinetics of abacavir and lamivudine after 
oral administration performed in chapters 3 and 4. Besides being used as baseline to evaluate 
the forgiveness of non-adherence of once daily treatment, these findings reveal for  the first 
time that the delivery of the same drug amount over 24 hours, as assessed in terms of systemic 
exposure (AUC), correlates with efficacy in children. In fact, such results are in agreement with 
sosa et al., who have already shown non-inferiority of once daily fixed-dose combination abaca-
vir/lamivudine compared to twice daily in adults (34). 
optimisation of antiretroviral therapy
In addition to the conceptual aspects of the methodology and the evidence of therapeutic 
equivalence of the two regimens, it is interesting to highlight that our approach allowed the 
identification of the level of adherence that is required or desirable to prevent the risk of viral 
rebound for each of the dosing regimens investigated here.  The fitting of the data using a logis-
tic model enabled us to obtain mathematical functions linking the number of days of treatment 
interruption and the percentage of doses randomly missed with the probability of viral failure 
for the two dosing regimens. Regarding treatment interruptions, our results show that an in-
terruption of two weeks may have consequences for the clinical outcome and may increase the 
probability of viral failure from 0.1 to above 0.4, whilst a continuous interruption of 30 days 
yields a probability of viral failure of 0.9. On the other hand, randomly missing as little as 10% 
of the doses during a treatment of 48 weeks may increase the probability of viral failure from 
0.1 up to 0.4. In practical terms, this means that continuous treatment interruptions with a NN-
RTI-based regimen are more likely to result in viral failure than when the same number of doses 
is randomly missed.  These figures are in agreement with the investigation of Parienti et al. (35), 
who found that sustained treatment interruptions more closely predicted viral rebound than 
interspersed missed doses in 72 patients who were administered a NNRTI-based regimen. In 
their investigation a logistic regression model was used to estimate the relationship between 
treatment interruptions and probability of viral failure, with treatment interruptions of 15 days 
associated with a 50% probability of viral rebound.  Our results also appear to be in agreement 
with Cohen et al. (36) and Dybul et al (37), who showed that virologic rebound is uncommon 
among NNRTI treated patients with repeated short cycles on and off treatment. 
Figure 6 Fitting of the data of probability of viral failure associated with treatment interruption (figure 6a) and 
doses randomly missed (figure 6b). The fitting was obtained using the nls (Nonlinear least squares) function in R.
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use of clinical trial simulation
In addition to the findings which are specific to the fixed combination of abacavir, lamivudine and 
efavirenz, our results unravel an important aspect of model-based drug development. The use 
of models of disease dynamics in conjunction with models describing pharmacokinetic-pharma-
codynamic relationships and differences in patterns of drug intake enables the assessment of 
the predictive value of pharmacokinetic-pharmacodynamic relationships. The ability to make 
inferences about treatment outcome using such data may avoid the need to expose children to 
the burden of clinical trial protocols. Based on our investigation, pharmacokinetic-pharmaco-
dynamic studies, combined with pharmacokinetic and safety trials, may suffice for generating 
evidence of the suitability of a simplified dosing regimen. Furthermore, we show that clinical 
trial simulations may be applied to generate information which cannot be obtained in clinical 
practice. Despite improvement in clinical research, it is still impossible to control or explore all 
the scenarios of non-adherence investigated here. Clinical trial simulations provide a solid basis 
for study design optimisation before subjecting patients to a clinical protocol. 
We are aware that our investigation relies on a hypothetical population of children, which 
cannot be replicated with real data, as the scenarios evaluated here cannot be easily generated 
in a clinical protocol.  Nevertheless, we are confident in the results given the concordance with 
the findings observed by Parienti et al., which were based on real data. Formal validation would 




In summary, we have shown that pharmacokinetic-pharmacodynamic relationships can be used 
as a proxy for efficacy and that a simplified once daily lamivudine/abacavir regimen adminis-
tered in combination with efavirenz yields comparable efficacy as the currently licensed twice 
daily dosing in HIV-infected children between 3 and 12 years old. Moreover, our results show 
that both regimens show similar forgiveness of poor adherence, which implies exchangeability 
of the treatment options. These findings represent another step towards the availability of once 
daily regimens for fixed-dose combinations in children, which are crucial for increased patient 
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And perspectives
The development of antiretroviral therapy has been one of the greatest accomplishments of ba-
sic and translational research. In the 30 years since the discovery of the HIV virus, 31 medicines 
have been approved to treat HIV infection and evidence-based guidelines have been developed 
for their optimal use (1). Initially, in the early 1990s, drugs were administered to HIV-infected 
patients as monotherapy. Nucleoside monotherapy in previously untreated patients reduced 
plasma HIV RNA levels by 0.5 to 0.7 log10 copies/mL of plasma. These effects slowly dissipated 
over months even in the absence of drug resistance, thereby resulting in progressive immuno-
logic decline (2). In the following years it was found that the combination of two antiretrovi-
ral nucleosides with relatively modest activities was beneficial in terms of the magnitude and 
durability of viral suppression. Several nucleoside combinations have resulted in reductions of 
1 to 1.5 log10 copies/mL HIV RNA levels in plasma. Even more beneficial were the protease 
inhibitors (ritonavir, indinavir, and nelfinavir) that produce reductions of HIV RNA levels in the 
plasma of some patients by as much as 3 log10 copies/mL, with corresponding increases in CD4 
levels of 300 to 500 cells/mm3. These findings have contributed to further efforts in establish-
ing the value of therapeutic combinations, with the use of boosted protease inhibitors in the 
last years, which clearly increased the probability to achieve viral suppression. At the moment, 
combination antiretroviral therapy with at least three drugs has resulted in substantial reduc-
tions in morbidity and mortality in both rich and poor countries. Antiretroviral therapy has been 
simplified to the point where treatment with a single, multidrug pill once a day is feasible  with 
generally manageable adverse effects (3).  
Despite such important improvements, a high number of patients fails to achieve viral sup-
pression. In a marked proportion of HIV-infected individuals on treatment, the virus develops 
resistance to the currently available drugs. In fact, patients with circulating virus showing re-
sistance to all three classes of conventional antiretroviral drugs is not uncommon. Children are 
among the group of patients who are most at risk of resistance.                                 
The research performed in this thesis is therefore focused on the treatment of HIV-infected 
children, a population which presents major challenges compared to adults. Based on the cur-
rent guidelines for the use of antiretroviral agents in paediatric HIV (4), the most appropriate 
regimen for an individual child depends on multiple factors, including  1) the age and availabil-
ity of appropriate drug formulations, 2) the potency, complexity and toxicity of the regimen, 3) 
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the child and caregiver’s ability to adhere to the regimen, 4) the child’s personal situation at 
home and  5) the child’s antiretroviral treatment history. Consequently, the use of combination 
therapy with at least three drugs is recommended for initial treatment of HIV-infected children, 
including either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor and a 
dual nucleoside analogue reverse transcriptase inhibitor backbone. Because antiretroviral ther-
apy will be administered lifelong, the choice of initial antiretroviral regimen should be based 
on considerations regarding the barriers to adherence, the complexity of schedules and food 
requirements for different regimens, differences in formulations, palatability problems and po-
tential limitations in subsequent treatment options should resistance develop. 
as presented in Chapter 1, another important point to consider is the dose rationale for an-
tiretroviral therapy in children. Currently recommended doses have been derived from empir-
ical evidence of clinical response rather than on the pharmacological (virological) properties of 
the combinations. In addition, the dose of antiretroviral drugs given to children is often based 
either on weight or body surface area without taking into account in a strictly quantitative man-
ner the underlying physiological changes due to growth, which are known to affect drug phar-
macokinetics. Inappropriate exposure, i.e., lower than optimal (sterilising) levels may promote 
viral mutations which mostly lead to drug resistance. With respect to the disease, an overview of 
viral characteristics and of the available antiretroviral drug classes currently combined to avoid 
development of resistance was provided. Taking into account pharmacokinetic and pharmaco-
dynamic properties, we have shown the advantages and limitations of existing methodologies 
for dosing recommendation. Finally, the role of the patient was scrutinised: a detailed definition 
of adherence to therapy has been considered together with the main strategies used to enhance 
treatment compliance in children. Here we highlight the importance of adherence for the de-
velopment of resistance, which has been shown to differ for each class of antiretroviral drugs.
In this thesis we have explored opportunities to support evidence generation and extrapola-
tion across populations, with special focus on the selection of the dose, the optimisation of dos-
ing regimens and the impact of patient behaviour towards the treatment, namely adherence to 
therapy. After having identified some of the challenges which need to be overcome to decrease 
viral failure in children, in Chapter 2 we propose the use of a model-based approach for the eval-
uation of covariate effects and forgiveness of non-adherence, which may allow simplification of 
current dosing regimens taking into consideration inadequate compliance and its implication 
for efficacy and drug resistance. In conjunction with clinical trial simulations, we aim to demon-
strate that it is possible to evaluate relevant clinical scenarios and predict treatment outcome 
of simplified dosing regimens, taking into account the differences in the patterns of drug intake 
and the pharmacokinetic-pharmacodynamic properties of antiretroviral drugs. Such factors 
may all be involved in the development of resistance and thus may ultimately cause viral failure. 
Our work clearly shows that, even in the event of adequate dosing regimen and dosing frequen-
cy, adherence to antiretroviral therapy is crucial to achieve viral suppression.
Although the approval of medicines is primarily determined by empirical evidence genera-
tion, situations exist in paediatric diseases in which evidence cannot be generated and infer-
ences from, e.g., underpowered trials, single arm studies, surrogate endpoints or from other 
populations have to be made to assess the efficacy and safety of a compound. Inferences may 
also be required to ensure access to treatment and availability of suitable therapeutic regimens 
to patients. In these circumstances, it has been demonstrated that the assessment of pharmaco-
kinetic–pharmacodynamic relationships in conjunction with modelling and simulation concepts 
can support dose rationale as well as dose adjustment in specific subgroups of a population. 
Here we also emphasise that modelling and simulation tools are very useful when ethical issues 
preclude the possibility to obtain new data  and  historical data is used as basis for evidence syn-
thesis (5). In fact, throughout this thesis we have used historical data and modelling and simula-
tion to make inferences about the dose and dosing regimens for a range of antiretroviral drugs. 
From a conceptual perspective, our approach expands beyond the current paradigm for the 
evaluation of dosage forms based primarily on pharmacokinetics; it shows how pharmacokinet-
ic-pharmacodynamic relationships can be used as a proxy for efficacy and safety. Our approach 
also relies on the principles of bridging and extrapolation.  As defined in the draft EMA concept 
paper (6), extrapolation may be generally defined as “extending information and conclusions 
available from studies in one or more subgroups of the patient population (source population), 
or in related conditions or with related medicinal products, to make inferences for another sub-
group of the population (target population), or condition or product, thus reducing the need 
to generate additional information (types of studies, design modifications, number of patients 
required) to reach conclusions for the target population, or condition or medicinal product”. On 
the other hand, from a regulatory perspective the term bridging has been introduced to refer 
to the generation of data across populations when extrapolation is unsuccessful or not appro-
priate. Bridging studies are defined by guidelines as supplemental studies performed to provide 
pharmacokinetic, pharmacodynamic or clinical data on efficacy, safety, dosage, and dose regi-
men in a new population, region or condition. Obviously, an implicit assumption for such studies 
is that of pharmacokinetic non-inferiority and therapeutic equivalence when comparable phar-
macodynamic effects are observed.
The scientific and clinical questions raised in the various chapters of this thesis illustrate the 
implementation of the concepts mentioned above. Among other things we have shown that 
pharmacokinetic-pharmacodynamic relationships can be used as basis for the evaluation of 
therapeutic equivalence. However, as illustrated for lamivudine and abacavir, a basic require-
ment must be satisfied, i.e., one needs to ensure the predictive performance of pharmacokinetic 
models. Of particular interest for paediatric drug research is the role of demographic covari-
ates on drug disposition. In section 2 we have demonstrated that when defining dosing recom-
mendations in children one should pay attention to the relationships between pharmacokinetic 
parameters and demographic covariates. The identification of the correct parameter-covariate 
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relationship has been shown to be particularly challenging in children, especially when the avail-
able datasets have limited sample size (i.e., number of patients) or present unbalanced covariate 
distribution. The role of covariates was then investigated when the model is used for simulation 
purposes. In particular, we have demonstrated that extrapolations beyond the covariate range 
used during model building are not feasible in children. Practical recommendations for the use 
of models for simulation purposes have been provided. In brief, it is concluded that simulations 
should only be performed after the predictive power of a model has been evaluated.
Based on the evidence of predictive performance, in section 3 we have presented  how mod-
elling and simulation tools can be applied for the evaluation of alternative dosing regimens in a 
virtual population of HIV-infected children. Such an application is particularly relevant in pae-
diatric HIV, given that simplified dosing regimens with reduced dosing frequency have been 
shown to improve adherence to therapy. In this section we show that abacavir and lamivudine, 
two nucleoside-reverse transcriptase inhibitors, can be administered as a once or twice daily 
dosing regimen without the risk of under or over-exposure in children from 3 months to 12 
years old. The possibility to use modelling and simulation to predict the pharmacokinetic prop-
erties of a drug in children was then extended to the evaluation of the impact of variable pat-
terns of drug intake and adherence to therapy. In section 4, we have explored the implications 
of partial adherence to antiretroviral treatment outcome. In contrast to the previous section, 
where pharmacokinetic equivalence underpinned the use of models for bridging and extrap-
olation purposes, here we have highlighted the importance of pharmacokinetic-pharmacody-
namic relationships as the basis for the assessment of efficacy and safety. Extrapolations were 
performed under the assumption that pharmacokinetic-pharmacodynamic relationships serve 
as proxy for therapeutic equivalence. This assumption has allowed us to evaluate  forgiveness 
of non-adherence,  an important property which reflects the ability of a drug or a regimen to 
achieve viral suppression despite sub-optimal adherence (7). This concept is illustrated in fig-
ures 1-4, which show indistinguishable differences in the pharmacokinetics of lamivudine and 
abacavir after three-day and two-week interruptions in therapy, irrespective of the dosing reg-
imen.  
Figure 1 Lamivudine pharmacokinetic profile for twice daily dosing regimen in a hypothetical group of children 
(n=30) aged between 3 and 12 years. Perfect adherence (a), treatment interruption of three days (b) and two 
weeks (c) have been simulated.
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Figure 2 Lamivudine pharmacokinetic profile for once daily dosing regimen in a hypothetical group of children 
(n=30) aged between 3 and 12 years. Perfect adherence (a), treatment interruption of three days (b) and two 
weeks (c) have been simulated. 
Figure 3 Abacavir pharmacokinetic profile for twice daily dosing regimen in a hypothetical group of children 
(n=30) aged between 3 and 12 years. Perfect adherence (a), treatment interruption for three days (b) and two 
weeks (c) have been simulated. 
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Figure 4 Abacavir pharmacokinetic profile for once daily dosing regimen in a hypothetical group of children (n=30) 
aged between 3 and 12 years. Perfect adherence (a), treatment interruption for three days (b) and two weeks (c) 
have been simulated. 
Our investigations were performed using a clinical trial simulation template, which allowed for 
detailed evaluation of relevant scenarios of non-adherence in children, providing important in-
sight into the patterns of non-adherence which should be avoided by the patients. In fact, the 
opportunity to derive data which would not be attainable in real-life due to obvious ethical and 
practical reasons constitutes one of the main achievements of this thesis. Furthermore, we have 
shown that clinical trial simulations also allow assessment of the robustness of alternative dos-
ing regimens in the event of partial adherence. We have found that when both drugs are admin-
istered once daily in combination with efavirenz, not only the exposures are comparable but 
also the forgiveness of non-adherence of the drug combination. This is illustrated in Figure 5, 
which depicts a clinical trial simulation scenario in which the treatment is interrupted for three 
consecutive days and for two consecutive weeks.
Figure 5 Change in viral load after administration of lamivudine and abacavir in combination with efavirenz as a 
twice (b.i.d.) (left panel) and once (q.d.) daily dosing regimen (right panel) in a hypothetical group of children (n=30) 
between 3 and 12 years of age. For comparative purposes, perfect adherence, a three-day treatment interruption 
and a two-week treatment interruption have been simulated for each regimen.
From a clinical perspective these findings dismiss the concerns regarding the use of a simplified 
dosing regimen in children, given that the forgiveness of non-adherence is comparable to the 
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11.1. impAct of dAtAset size And covAriAte 
distribution on the predictive performAnce 
of phArmAcokinetic models in children
One of the primary issues in paediatric clinical pharmacology research is the management of 
exposure differences attributed to variation in size, age and other developmental factors (8). 
A model-based approach may be used to systematically evaluate and quantify these differenc-
es. However, one has to keep in mind that models misspecifications may lead to serious conse-
quences when conclusions based on these models are used for clinical decision making, such as 
erroneous dose recommendations. In chapter 3 we performed a thorough assessment of the 
pharmacokinetics of lamivudine in children, with focus on the correlation between pharmaco-
kinetic parameters and demographic covariates.  A meta-analysis was performed, in which data 
from three clinical trials in children between 3 months and 12 years old were combined. We 
found that lamivudine was best described by a one compartment model with body weight ex-
ponentially correlated to clearance and volume of distribution. Interestingly, we show that such 
relationships can be identified only when the three datasets were analysed together. This find-
ing emphasises a very important concept in paediatric pharmacokinetic modelling: sample size 
is critical when assessing parameter-covariate relationships in children. These results clearly 
suggest that, although a model built using a small population may be suitable for descriptive 
purposes its use for predictive purposes in a new population should be avoided. In addition, our 
findings reveal the implications of unbalanced covariate distributions. Unbalanced covariate 
distributions may introduce model misspecification which may easily compromise model-based 
predictions in a new population. Such findings were confirmed in chapter 4, in which a popula-
tion pharmacokinetic analysis was performed in children receiving abacavir, an antiretroviral 
drug often given in combination with lamivudine.  Again, in this chapter we showed the impor-
tance of a meta-analytical approach to investigate the pharmacokinetics of a drug in children. 
Furthermore, our work highlights the clinical application of model-based data analysis. Using 
simulation tools, we showed that drug exposure can be predicted even in case of very sparse 
sampling, which has always been a concern for drug therapeutic monitoring.
The importance of the correlation between pharmacokinetic parameters and covariates in 
children and its impact on the predictive performance of a model has been further evaluated 
in chapter 5. In this chapter we use simulations to explore whether drug exposure can be pre-
dicted for a population belonging to a different age range than the ones used for model build-
ing. Clearly, this attempt failed, indicating that pharmacokinetic models should not be used to 
perform extrapolations beyond the covariate range available during model building. Predictions 
from pharmacokinetic models are reliable only in case of interpolations involving a subgroup of 
the initial population. In addition, we showed that the covariate point estimates (e.g. median) 
used to describe the mathematical relationship between covariate and pharmacokinetic param-
eters should be fixed even when interpolations are referred to a subset of the initial population.
In summary, this section shows the importance of demographic factors on the pharmacoki-
netics of two drugs currently administered as first-line therapy in HIV-infected children. In ad-
dition, our findings highlight some critical issues for covariate selection. We recommend there-
fore the use of somewhat larger sample sizes than what is currently done in clinical practice. 
Ultimately we have shown the importance of balanced covariate distribution and its implica-
tions for the predictive performance of a pharmacokinetic model: a model in children should 
not be used for extrapolation beyond the covariate range explored during model building. This 
finding raises further questions about the widespread use of allometric scaling concepts in pae-
diatric research.
11.2. evAluAtion of simplified AntiretrovirAl 
dosinG reGimens in children
The possibility to administer an antiretroviral drug according to a once daily dosing regimen in 
children is certainly very appealing. However, one needs to be entirely confident that drug ex-
posure achieved after once daily dosing is comparable to historical values achieved after twice 
daily dosing. In the third section of this thesis we show the use of a model-based approach to 
evaluate the feasibility of an alternative dosing regimen for lamivudine, which is currently ad-
ministered as once daily in adults and twice daily in children. In chapter 6 we apply simulations 
to assess whether lamivudine could be administered as once daily dosing in a virtual group of 
children between 3 months and 12 years old. The pharmacokinetic model developed and vali-
dated previously in chapter 3 was used for this purpose. Evidently, once daily doses of lamivu-
dine leads to AUC
0-24
 and peak concentrations comparable to historical values in children who 
received a twice daily dosing regimen. The same simulation exercise was performed for abacavir, 
which is also administered as once daily in adults and twice daily in children. In chapter 7 we used 
a population pharmacokinetic model developed in chapter 4 to evaluate whether the exposure 
of abacavir following a once daily dosing regimen was comparable to the current regimen. Again 
it was demonstrated that once daily doses of abacavir in children leads to AUC
0-24
 and  peak con-
centration values comparable to those observed in historical data in children and adults. 
Such results are crucial for the improvement of antiretroviral therapy in children, given that 
once daily doses may improve acceptability and adherence to therapy. In addition, our approach 
illustrates how to explore hypothetical scenarios in virtual patients. This concept is particularly 
useful in paediatric clinical pharmacology research. One of the main advantages is the possibil-
ity to evaluate treatment response in a large number of children, without exposing them to the 
actual treatment. Further details on the implementation of virtual clinical trials are discussed 
and expanded in the next section of this thesis. 
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11.3. Adherence to hiv therApy: “druGs do not Work  
in pAtients Who do not tAke them”
It is well known that the continuity of drug action derives from the continuity of execution of 
a prescribed dosing regimen, which is aimed at yielding pharmacologically suitable exposure 
to the active moiety between successive doses. Treatment interruptions can alter drug action, 
but the consequences of interruptions in dosing may vary according to the drug, the length of 
interruption and the disease being treated (9). In this context, the sentence attributed to former 
US Surgeon General C. Everett Koop, “Drugs don’t work in patients who don’t take them”, sum-
marises perfectly the importance of patient adherence to therapy.
However, to fully understand the implications of the factors determining drug response and 
variability, one needs a comprehensive approach that takes into account the effects of develop-
mental growth as well as other patient-specific characteristics which could modify drug phar-
macokinetics. In addition, it is important to recognise how these factors interrelate with the 
proposed dosing regimen or interval. Current mainstream views on the use of fixed-dose com-
binations suggest that reduced dosing frequency improves antiretroviral therapy. Yet, evidence 
of therapeutic equivalence cannot be derived from bioequivalence studies or simply by compar-
ison of pharmacokinetic data alone. In HIV therapy, the benefit of drug combinations results pri-
marily from pharmacodynamic interactions.  Accurate evaluation of changes in dosing regimen 
requires therefore an assessment of the impact of patient adherence on pharmacodynamics. 
Differences in the patterns of drug intake  are a major cause of unintended variability in drug 
exposure, which have been associated with the failure of treatment (10).  Here we have shown 
how to quantitatively evaluate the role of partial adherence to therapy. In other words, we have 
provided the framework for addressing an important clinical question: “How many doses can a 
patient miss without affecting treatment outcome?” 
Modelling as well as other statistical approaches have been previously used to investigate 
the impact of adherence on therapeutics, which are worth mentioning. In fact, the consequence 
of partial adherence to antiretroviral therapy  is one of the focus areas in this research field. 
For instance, Pfister et al. integrated adherence information as model covariate to determine 
its effect on drug exposure (11). Subsequently longitudinal models have been proposed to esti-
mate the effect of patient adherence on the rate at which the patients progress through the HIV 
infection. Other investigators have considered the use of Markov models and other stochastic 
methods (12–17). Among other advantages, the approach allows the response at any time point 
to be conditional on that observed in the previous time period.  The novelty of our work lies 
in the fact that for the first time the effect of imperfect adherence has been evaluated using a 
framework in which all the elements of a clinical trial simulation were combined. Compared to 
the abovementioned studies, important elements were introduced which were missing previ-
ously, including the use of combination therapy, more realistic patterns of non-adherence (ran-
dom drug holidays, imperfect timing of successive doses) and a correlation between adherence 
and drug resistance.  To illustrate the usefulness of such an integrated approach, three scenarios 
were selected for evaluation in this thesis: a single drug used as monotherapy, a cocktail con-
sisting of three drugs and a fixed dose combination of three drugs administered according to a 
simplified dosing regimen.  Our analysis also included a relationship between adherence and the 
probability to develop drug resistance. This clinical trial simulation framework represents an 
important improvement in that it encompasses a combination of various mathematical models, 
allowing for the prediction of treatment outcome for scenarios that cannot be assessed empiri-
cally in a controlled, randomised manner. 
in chapter 8, the forgiveness of non-adherence of the three different classes of antiretroviral 
drugs currently used as first-line therapy in children (NNRTI, NRTI and boosted PI) has been 
evaluated. This study represents the first attempt to predict treatment outcome using a com-
bined approach in which pharmacokinetic, pharmacodynamic and disease models are applied 
concurrently. In addition, the use of a logistic regression to describe the relationship between 
the number of days in which the drug exposure remains below the expected therapeutic levels 
and the probability to develop drug resistance provided the basis for linking partial adherence 
and viral failure. For practical purposes and ease of interpretation, we have parameterised ad-
herence in terms of the patterns of doses not taken rather than as percentage of doses taken. 
It is essential to mention that for predictive purposes, all the models used here have been pre-
viously evaluated and validated. Our findings provide a preliminary indication about the level 
of adherence required by each antiretroviral drug to prevent viral failure when used as mono-
therapy. In reality, these scenarios represented a starting point to characterise the implications 
of non-adherence or partial adherence when a combination of two or more drugs is used. Sub-
sequently, in chapter 9, a clinical trial simulation was performed in which a cocktail of three 
drugs is administered to a population of HIV-infected children. Our results reveal that for a NN-
RTI-based regimen long periods of treatment interruption may represent a higher risk of viral 
failure than when the same number of doses is missed randomly. 
The aforementioned findings indicate that the pharmacokinetic-pharmacodynamic relation-
ships of antiretroviral drugs may be used to predict treatment efficacy in the investigation of 
forgiveness of non-adherence and, consequently, of simplified dosing regimens. In fact, phar-
macokinetic-pharmacodynamic relationships may be considered a “proxy” of therapeutic 
equivalence in the assessment of forgiveness of non-adherence, in an analogous manner as 
pharmacokinetics in bioequivalence studies. Conceptually, this offers the possibility to replace 
efficacy trials by pharmacokinetic-pharmacodynamic studies. As shown in chapter 10, the ef-
fect of partial adherence to a simplified dosing regimen was evaluated using the underlying 
pharmacokinetic-pharmacodynamic relationships of lamivudine and abacavir in combination 
with efavirenz. Our results reveal that a once daily regimen yields comparable forgiveness of 
non-adherence as the currently approved twice daily in all the scenarios of non-adherence. In 
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practical terms, this means that a reduction in dosing frequency can ultimately reduce pill-bur-
den in children without increasing the risk of resistance.
In summary, the clinical trial simulation framework used in chapters 8, 9 and 10, provide the 
opportunity to evaluate clinically relevant information about the level of adherence required 
to prevent viral failure and, if extended to other treatment options, may enable physicians to 
consider the best drug regimen based on historical adherence patterns of the patient.  It is also 
worth mentioning that dropout information was not included in the simulations to ensure ap-
propriate characterisation of the impact of poor adherence without the confounding effects of 
dropout. However, our findings suggest that poor adherence may have equal, if not more influ-
ential, effects on treatment outcome as dropout.
11.4. conclusions, recommendAtions And perspectives
The results presented in this thesis highlight the value of a model-based approach to address 
important issues in paediatric HIV research, which have remained unaddressed despite the on-
going scientific and clinical progress in the field. The first point regards the dose recommenda-
tion for children based on bridging concepts, rather than on body size. This implies the char-
acterisation of developmental factors influencing drug exposure in the target population, so 
that exposure attained in children is comparable to adults. In addition, our work has shown the 
potential limitations of modelling and simulation methodologies for the prediction of pharma-
cokinetics in children.  We have therefore delineated the following recommendations for the 
implementation of a model-based approach in paediatric research: 
1)  Population pharmacokinetic studies must consider suitable inclusion or stratification criteria 
to ensure balanced covariate distribution; 
2)  The use of meta-analysis including different population subgroups is strongly encouraged 
to prevent model misspecification due to the confounding effects of unbalanced covariates; 
3)  The predictive performance of a model is limited to interpolations. The accuracy of extrapo-
lations beyond the range of the population used for model building cannot be warranted even 
when diagnostic and model validation procedures show evidence of goodness-of-fit.
4)  Extrapolation across populations beyond the conditions or population under investigation 
requires the use of models for simulation, which are not the same as models for estimation, as 
in the case of models developed using the maximum likelihood.
5)  Models for simulation are essential for hypothesis generation and inferences. They provide 
insight into conditions and scenarios which may not be observed or controlled in real life. 
As such, they can be parameterised in term of drug, patient and system-specific parameters, 
irrespective of precision or identifiability, which are data driven.
Based on the aforementioned recommendations, the use of a model-based approach can be ex-
tended beyond the issues regarding the dose rationale. It can be applied systematically for the eval-
uation of simplified treatment options, which is very appealing in paediatric research. Undoubtedly, 
in conjunction with clinical trial simulations, models become an experimental design tool.
Despite our efforts to incorporate non-adherence into the analysis, several issues were en-
countered, which need to be highlighted as they impose additional assumptions for model pa-
rameterisation. One of these assumptions refers to the relationship between adherence and the 
probability to develop resistance. We have noticed that the data on adherence available in liter-
ature are expressed as percentage of doses taken, which did not meet our objectives. Instead, we 
have used a logistic regression to describe that relationship.  This adaptation brings to light the 
need for more precise and continuous data on patient adherence. In fact, this situation calls for 
the systematic use of medication event monitoring systems (MEMs), currently the most reliable 
measure of patient adherence. Moreover genotyping should be carried out more frequently to 
gain insight in the correlation between adherence and probability to develop drug resistance.
We are also aware about the impossibility to validate the results from our clinical trial simula-
tion with a prospective trial. In this respect, we can conclude that forgiveness of non-adherence 
is better defined by means of a not-in-trial simulation (NITS), a concept which has been recently 
applied  for the assessment of  pro-arrhythmic risk (18). In contrast to typical clinical trial sim-
ulations, this methodology makes use of simulations to characterise the role of design factors 
which have been omitted from a randomised trial; in our case we have characterised patient 
adherence to therapy, which cannot be explored in a controlled manner for ethical reasons. 
Not-in-trial-simulations constitute therefore a promising starting point for the evaluation 
of design factors or patient characteristics which cannot be reproduced in real life. Most im-
portantly, this feature opens new opportunities for the evaluation of effectiveness of the treat-
ment. In HIV research, we envisage the prospect for exploring the thresholds of non-adherence 
which should be avoided to prevent viral failure. In addition, other therapeutic areas, such as 
e.g., tuberculosis, oral contraceptives or hormonal replacement, would greatly benefit from the 
concepts presented here (19). In tuberculosis, an in vitro model was used to evaluate, for the 
first time, the forgiveness of a standard tuberculosis drug regimen with the objective to deter-
mine whether poor adherence, in the form of simulated drug holidays, would lead to incomplete 
sterilisation and/or emergence of drug resistance. 
Interestingly, several attempts have been made to quantify forgiveness of non-adherence 
to oral contraceptive drugs. Despite the use of empirical protocols, quantitative evaluation of 
non-adherence in this area has been based on study designs that include controlled, blinded 
substitution of placebo for active drug, with frequent measurements of drug action to deter-
mine how long it takes, after the last-taken dose of active drug, for the drug’s actions to wash-
out. Such a study design, known as the placebo substitution-for-active (PSA), has guided the 
first efforts to write evidence-based instructions for patients on what to do if they miss one or 
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more pills (9). PSA designs have also been applied in the evaluation of non-adherence in depres-
sion by Rosenbaum et al., who carried out a 5- to 8-day placebo substitution study in patients 
treated with fluoxetine, sertraline, or paroxetine (20).
Obviously, such a trial design could not be applied in antiretroviral therapy and other serious, 
fatal diseases. The use of NITS methodology, as developed in this thesis, represents a novel and 
alternative approach to evidence synthesis. Eventually, this will allow information on forgive-
ness of non-adherence to be systematically included in the summary of product characteristics, 
providing guidance for prescribers and patients on how to minimise the consequences of missed 
doses and define the course of action to correct any deviation from the prescribed dosing regi-
men. Another important aspect that pertains to risk management is the possibility to evaluate 
prospectively the forgiveness of non-adherence. In other words, NITS can be used to under-
stand what happens in real life irrespective of the evidence derived during a clinical trial, which 
often shows higher degree of adherence as compared to day-to-day treatment. 
The assumption that evidence generation is a sine qua non condition for regulatory approval 
and optimisation of the therapeutic use of medicines needs to be revisited. The hurdles for pro-
tocol implementation and feasibility issues in paediatric research and other serious infectious 
diseases raise questions about the relevance of evidence generated under strict controlled con-
ditions, as they do not reproduce or reflect real life use of medicines. It should be noted that 
the reliance on empirical evidence is kindled by regulatory agencies, which continue to issue 
guidelines that outline the requirements for the approval of medicines based on evidence gen-
eration. By contrast, formal acknowledgement of the role of evidence synthesis as the basis for 
the evaluation of efficacy and safety has not been fully embraced in clinical therapeutic practice 
or by the regulatory approval process, despite its widespread application in the evaluation of 
effectiveness and cost–benefit analyses. 
A shift in paradigm is required in which evidence synthesis is favoured, making evidence gener-
ation a confirmatory step in the continuum between assumptions and empirical evidence. Among 
the lessons learned from the work presented throughout this thesis, it is worth emphasising that 
evidence generation without data integration, including systematic incorporation of prior knowl-
edge leads to less than optimal experimental protocols and potentially inappropriate decision cri-
teria. This aspect is often ignored in the rationale for mainstream paediatric clinical trials. Another 
important point arising from our examples is that evidence synthesis can be far more powerful than 
evidence generation, as it gives insight into conditions that cannot be evaluated experimentally.
We finish this thesis by evoking the very initial question in its title, i.e., does half a day make a 
difference to treatment outcome? Based on evidence synthesis by modelling and simulation it 
can be concluded that it does not.  Moreover, it is our expectation that this work will contribute 
to consolidating the use of  pharmacokinetic-pharmacodynamic relationships as the basis for in-
ferences about therapeutic equivalence, thereby overcoming the need to perform unnecessary 
efficacy trials in children.  
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nederlAndse sAmenvAttinG
(synopsis in dutch)
Het chronische karakter van de behandeling impliceert toediening van verschillende genee-
smiddelen gedurende de volledige kinderleeftijd. Daarnaast zijn aanpassingen van de dosering 
vaak nodig om te verzekeren dat de juiste blootstelling wordt bereikt en behouden gedurende 
de behandelperiode. Fysiologische groei en ontwikkeling in pediatrische patiënten kunnen sig-
nificante invloed hebben op ADME processen, in het bijzonder de opname en de uitscheiding 
van het geneesmiddel. Onrijpe nierfunctie, afwijkende hepatische enzymactiviteit en verschil-
len in opname van het medicijn leiden tot variaties in de systemische blootstelling van antiret-
rovirale geneesmiddelen bij kinderen.Het chronische karakter van de behandeling impliceert 
toediening van verschillende geneesmiddelen gedurende de volledige kinderleeftijd. Daarbij 
zijn aanpassingen van de dosering vaak nodig om te verzekeren dat de juiste blootstelling wordt 
bereikt en behouden gedurende de gehele behandelperiode. Fysiologische groei en orgaan 
ontwikkeling in pediatrische patiënten kunnen significante invloed hebben op de absorptie, de 
distributie, de metabole afbraak en de excretie van een geeensmiddel (de zgn. ADME proces-
sen). Dat betreft in het bijzonder de opname en de uitscheiding. Onrijpe nierfunctie, afwijkende 
hepatische enzymactiviteit en verschillen in opname van het medicijn leiden tot variaties in de 
systemische blootstelling van antiretrovirale geneesmiddelen bij kinderen.
Vanuit het therapeutische invalshoek ziet men een groeiende hoeveelheid bewijs van de com-
plexiteit van therapietrouw in HIV geïnfecteerde kinderen, waarbij huidige niveaus vaak subop-
timaal zijn. Lage therapietrouw kan het resultaat van de behandeling negatief beïnvloeden, zelfs 
wanneer men met de toegediende dosis rekening houdt en deze aanpast op basis van demograf-
ische eigenschappen en leeftijds-gerelateerde veranderingen. Dit kan leiden tot ontwikkeling 
van resistentie tegen het merendeel van de geneesmiddelen, wat uiteindelijk leidt tot falen van 
de antivirale behandeling. Therapietrouw wordt beïnvloed door veel factoren, die verdeeld 
kunnen worden in eigenschappen van het kind, de hulpverlener(s) en het gezin, de formuler-
ing en het doseringsschema. Doordat kinderen overwegend afhankelijk zijn van hun ouders of 
verzorger bij het toedienen van medicatie, kan een frequente doseringsschema een uitdaging 
zijn.  In deze gevallen kan het verlagen van de het aantal doseringen cruciaal zijn bij het ver-
beteren van de therapietrouw.  Echter, men moet bedacht zijn op het feit dat een vereenvoudigd 
doseringsschema het risico op een te lage of te hoge blootstelling kan verhogen. De beoordeling 
hiervan is nog gecompliceerder doordat de werkzaamheid en veiligheid in patiënten ingeschat 
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moet worden voor combinatietherapieën, waarbij de bijdrage in het effect van elk individueel 
medicijn vaak moeilijk te bepalen is. 
Bovengenoemde in ogenschouw nemende is het moeilijk te begrijpen waarom de keus voor 
dosering en doseringsschema’s voor de behandeling van pediatrische HIV patiënten  gestuurd 
blijft worden vanuit empirische beslissingen. Een integrale benadering is vereist, waarin de 
evaluatie van werkzaamheid en veiligheid niet alleen bepaald wordt door bewijs uit klinische 
studies in kinderen, maar ook met gevolgtrekkingen vanuit historische data en kwantitatieve 
farmacologische concepten. 
Het doel van het onderzoek in dit proefschrift is de ontwikkeling van nieuwe benaderingen 
voor de vergelijking van de werking van geneesmiddelen tussen populaties, met  speciale aan-
dacht voor de selectie van de juiste dosis en het juiste doseringsschema in met HIV geïnfect-
eerde kinderen. We stellen het gebruik van een modelmatige benadering voor, die het mogelijk 
maakt de oorzaken van variatie in de blootstelling van geneesmiddelen in kinderen vast te stel-
len, rekening houdend met de interactie tussen therapietrouw en de eigenschappen van antiret-
rovirale geneesmiddelen. Hiernaast laten we het nut van simulaties van klinische studies en de 
rol van gesimuleerde scenario’s zien, waardoor bekende problemen bij pediatrisch onderzoek 
voorkomen kunnen worden. Hierin worden de gevolgen van veranderingen in farmacokinetiek 
en farmacodynamiek beoordeeld die samenhangen met verschillen in dosering, doseringssche-
ma en verschillende patronen van therapietrouw. Deze factoren kunnen niet op een ethisch 
aanvaardbare wijze in de klinische praktijk worden geëvalueerd. 
Drie kernvragen zullen de basis vormen voor het werk dat gepresenteerd wordt in de volgen-
de hoofdstukken van dit proefschrift:
1.  Hoe kan de juiste dosering geselecteerd worden, rekening houdend met het feit dat veran 
deringen in blootstelling als gevolg van groei tijdens ontwikkeling vaak niet-lineair gecor-
releerd zijn met de lichaamsgrootte en dat bewijs vanuit klinische studies gebaseerd is op 
waarnemingen in kleine, niet gebalanceerde cohorten?
2.  Kan het doseringsschema bij kinderen aangepast worden op basis van farmacokinetischfa 
macodynamische en farmacokinetische-farmacodynamische modellen en  overbruggingscon-
cepten?
3.  Kunnen farmacokinetische-farmacodynamische relaties gebruikt worden om de invloed van 
verschillende patronen van therapietrouw op de behandeluitkomst op een kwantitatieve wi-
jze te evalueren, omdat dit niet formeel getest kan worden in de klinische praktijk vanwege 
ethische bezwaren? 
Het is ons streven om aan te tonen hoe het gebruik van een modelmatige benadering de mo-
gelijkheid geeft om de invloed van verschillen in farmacokinetiek op de farmacodynamiek te 
beoordelen, om vervolgens de behandeluitkomst (bijvoorbeeld virologisch falen) in kinderen te 
voorspellen, alvorens ze bloot te stellen aan een klinisch protocol. Uiteindelijk zullen we aan-
tonen dat de aanname van een vergelijkbare relatie tussen blootstelling en respons in volwass-
enen en kinderen het niet alleen mogelijk maakt om tijdens de selectie van de dosering rekening 
te houden met verschillen in fysiologische processen veroorzaakt door groei en ontwikkeling 
die tot veranderingen in farmacokinetiek leiden, maar dat deze aanname ook de basis geeft voor 
evaluatie van de invloed van veranderingen in het doseringsschema. 
12.1. AlGemene inleidinG
Zoals is aangetoond in hoofdstuk 1 is de motivering achter de dosering van antiretrovirale 
therapie in kinderen een cruciaal punt ter overweging. De huidige doseringsadviezen zijn ee-
rder afgeleid uit empirisch bewijs van klinische respons dan gebaseerd op de farmacologische 
of virologische eigenschappen van de geneesmiddelcombinaties. Daarbij is de bij kinderen 
toegediende dosering van antiretrovirale geneesmiddelen vaak gebaseerd op gewicht of li-
chaamsoppervlakte zonder dat op een strikt kwantitatieve manier rekening wordt gehouden 
met de onderliggende fysiologische veranderingen, waarvan bekend is dat deze de farmacoki-
netiek beïnvloeden. Hierbij is belangrijk dat een te lage blootstelling mutaties in de hand kan 
werken, mogelijk leidend tot resistentie. Voor ons onderzoek hadden wij een overzicht van hui-
dige combinatietherapieën tezamen met eigenschappen van verschillende virale subklassen tot 
onze beschikking. De farmacokinetische en farmacodynamische eigenschappen in acht nemend 
hebben we de voordelen en beperkingen van bestaande methodologieën voor de selectie van 
de dosering laten zien. Ten slotte is de rol van de patiënt bij het vastellen van de behandeluit-
komst onderzocht: we bekeken in het licht van een gedetailleerde definitie van therapietrouw 
de meest gebruikte strategieën om therapietrouw bij kinderen te verhogen. Hiermee onder-
strepen we het belang van therapietrouw ter bestrijding van resistentieontwikkeling die, zoals 
is aangetoond, verschillend is voor elke klasse van antiretrovirale geneesmiddelen.
Daarnaast hebben we in dit proefschrift de mogelijkheden onderzocht om bewijsvorming en 
extrapolaties tussen populaties te versterken, met speciale aandacht voor de selectie van de 
dosering, de optimalisatie van het doseringsschema en invloed van patiëntgedrag aangaan-
de de behandeling, namelijk therapietrouw. Na de uitdagingen geïdentificeerd te hebben die 
overwonnen zullen moeten worden om virologisch falen in kinderen te verlagen, wordt in 
hoofdstuk 2 het gebruik van een modelmatige benadering voor de evaluatie van effecten van 
covariaten en de vergevingsgezindheid van therapieontrouw beschreven. Met deze benadering 
kunnen de huidige doseringsschema’s worden vereenvoudigd, rekening houdend met mogelijk 
onvoldoende therapietrouw en de gevolgen hiervan voor zowel effectiviteit van de behandel-
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ing en de ontwikkeling van resistentie. Door middel van simulaties van klinische studies zullen 
we laten zien dat de uitkomst van aangepaste doseringsschema’s in relevante scenario’s kan 
worden voorspeld, waarbij de invloed van de therapietrouw en de farmacokinetische-farmaco-
dynamische eigenschappen in ogenschouw worden genomen. Deze factoren zouden betrokken 
kunnen zijn bij de ontwikkeling van resistentie en kunnen de oorzaak zijn van  virologisch falen. 
Dit werk laat helder zien dat, zelfs in het geval van een adequaat doseringsschema en doserings-
frequentie, de compliantie cruciaal is om onderdrukking van HIV te bereiken.
12.2. invloed vAn de Grootte vAn de populAtie  
(steekproef) en de verdelinG vAn covAriAten op het 
voorspellend vermoGen vAn fArmAcokinetische  
modellen in kinderen
Een van de primaire problemen in klinisch farmacologisch onderzoek in kinderen is hoe om te 
gaan met verschillen in blootstelling die het gevolg zijn van variaties in grootte, leeftijd en an-
dere factoren die tijdens ontwikkeling een rol spelen. Een modelmatige benadering kan gebrui-
kt worden om deze verschillen systematisch te evalueren en kwantificeren. Echter, men moet 
zich realiseren dat misspecificaties in het model kunnen leiden tot ernstige gevolgen wanneer de 
op deze modellen gebaseerde conclusies gebruikt worden voor klinische besluitvormingen als 
doseringsadviezen. in hoofdstuk 3 hebben we de farmacokinetiek van lamivudine in kinderen 
grondig beoordeeld, met een focus op het vaststellen van de correlatie tussen farmacokinetische 
parameters en demografische covariaten. Wij hebben een meta-analyse verricht waarbij data 
van drie klinische studies werden gecombineerd. De leeftijd van de in deze studie geïncludeerde 
kinderen varieerde van 3 maanden tot 12 jaar. De farmacokinetiek van lamivudine werd het 
best beschreven door een  één-compartimentsmodel met lichaamsgewicht exponentieel gecor-
releerd aan klaring en het verdelingsvolume. Hierbij viel op dat deze relaties alleen geïdentifi-
ceerd konden worden wanneer de drie studies gezamenlijk geanalyseerd werden. Dit benadrukt 
een concept dat erg belangrijk is bij het modelleren van farmacokinetiek in kinderen: de grootte 
van de studiegroep is beslissend wanneer de relatie tussen  parameter en covariaat bij kinderen 
beoordeeld moet worden. Verder laat dit onderzoek duidelijk zien dat, hoewel een op een kleine 
populatie gebaseerd model een goede beschrijving kan geven van deze specifieke groep, men 
terughoudend moet zijn met voorspellingen in een nieuwe populatie. Hiernaast tonen onze re-
sultaten aan hoe belangrijk de verdeling van covariaten kan zijn. Een ongebalanceerde verdel-
ing kan een misspecificatie in het model introduceren, die leidt tot een beperkte voorspellende 
waarde in nieuwe populaties. Dit werd bevestigd in hoofdstuk 4, waarin een populatie farmaco-
kinetische analyse werd verricht bij kinderen die abacavir toegediend kregen; een antiretroviraal 
geneesmiddel dat vaak in combinatie met lamivudine gegeven wordt. Ook hier wordt het belang 
van een meta-analytische benadering onderstreept bij onderzoek naar de farmacokinetiek van 
een geneesmiddel in kinderen. Verder illustreert ons werk de klinische toepasbaarheid van een 
modelmatige data-analyse. Door middel van simulaties laten we zien dat de blootstelling aan een 
geneesmiddel zich goed laat voorspellen, zelfs wanneer zeer weinig bloedmonsters beschikbaar 
zijn, wat traditioneel een punt van aandacht is in de kliniek.
Het belang van de correlatie tussen farmacokinetische parameters en covariaten bij kinderen 
en de invloed hiervan op het voorspellend vermogen van een model is verder geëvalueerd in 
hoofdstuk 5.  Hier simuleren we de blootstelling van geneesmiddelen wanneer deze aan kin-
deren in een andere leeftijdscategorie worden voorgeschreven dan waarmee het model ontwik-
keld is. Dit  bleek niet succesvol, wat impliceert dat extrapolaties buiten het bereik van de co-
variaten dat beschikbaar was bij de ontwikkeling van het model, af te raden zijn.  Voorspellingen 
van farmacokinetische modellen zijn slechts betrouwbaar in geval van interpolaties binnen een 
subgroep van de originele populatie. Daarnaast lieten we zien dat de puntschattingen van de 
covariaat (bijvoorbeeld mediaan), welke gebruikt worden voor de mathematische beschrijving 
van de relatie tussen covariaat en farmacokinetische parameters, gefixeerd moeten worden, 
zelfs wanneer interpolaties zijn gedaan in een subgroep van de originele populatie. 
Samenvattend laat dit onderdeel het belang zien van demografische factoren in de farmaco-
kinetiek  voor twee geneesmiddelen die momenteel toegediend worden als eerstelijns therapie 
bij HIV-geïnfecteerde kinderen. Hiernaast illustreren onze resultaten enkele essentiële rand-
voorwaarden voor de selectie van covariaten. We raden aan om grotere studiegroepen te geb-
ruiken dan in de huidige klinische praktijk gebruikelijk is. Bovendien hebben we de invloed van 
een evenwichtige  verdeling van covariaten en de implicaties hiervan op het voorspellend ver-
mogen van een farmacokinetisch model laten zien. Op grond daarvan is er geconcludeerd dat 
het is af te raden een model te gebruiken buiten het bereik van de covariaten die zijn onderzocht 
gedurende de ontwikkeling daarvan.  Deze ontdekking roept verdere vragen op aangaande het 
wijdverbreid gebruik van allometrische schaling in pediatrisch onderzoek.
12.3. de evAluAtie vAn vereenvoudiGde Anti-retrovirAle 
doserinGsschemA’s in kinderen
De mogelijkheid om een geneesmiddel eenmaal daags toe te dienen is vaak een aantrekkelijke 
optie. Echter, men moet er zeker van zijn dat de blootstelling aan het geneesmiddel die bereikt 
wordt met een dosering van eenmaal per dag vergelijkbaar is met historische waardes die 
bereikt werden met een ander doseringsschema. In het tweede deel van dit proefschrift laten 
we zien hoe een modelmatige benadering kan worden gebruikt om de toepasbaarheid van een 
alternatief doseringsschema voor lamivudine te evalueren. Lamivudine wordt momenteel een-
maal daags toegediend bij volwassenen terwijl kinderen tweemaal per dag gedoseerd krijgen. In 
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hoofdstuk 6 gebruiken we simulaties om te beoordelen of lamivudine eenmaal daags toegediend 
kan worden in een virtuele groep van kinderen  tussen 3 maanden en 12 jaar oud. Hiervoor werd 
het farmacokinetische model gebruikt dat was ontwikkeld en gevalideerd in hoofdstuk 3. Wij 
hebben aangetoond dat dit doseerregime  tot AUC
0-24 h
 en piekconcentratie waardes leidt, welke 
vergelijkbaar zijn met historische data in kinderen bij een tweemaal daagse dosering. Eenzelfde 
simulatie werd uitgevoerd voor abacavir, dat ook eenmaal per dag toegediend wordt bij volwas-
senen en tweemaal per dag in kinderen. In hoofdstuk 7 hebben we het in hoofdstuk 4 ontwik-
kelde farmacokinetische model gebruikt om te beoordelen of de blootstelling van abacavir bij 
eenmaal daags doseren vergelijkbaar was met een tweemaal daagse dosering. Wederom werd 
aangetoond dat eenmaal daagse abacavir doseringen in kinderen leiden tot AUC0-24 h en piek-
concentratie waardes die vergelijkbaar zijn met historische data van kinderen en volwassenen. 
Deze resultaten zijn belangrijk voor de verbetering van antiretrovirale therapie in kinderen, 
omdat eenmaal daags doseren kan de therapietrouw en acceptatie aanzienlijk verbeteren. 
Daarnaast laat onze benadering zien hoe hypothetische scenario’s in virtuele patiënten onder-
zocht moeten worden. Dit concept is in het bijzonder bruikbaar in pediatrisch klinisch farma-
cologisch onderzoek. Een van de belangrijkste voordelen is de mogelijkheid om de respons op 
behandeling te evalueren in een groot aantal kinderen, zonder hen bloot te stellen aan de daad-
werkelijke behandeling. Verdere details aangaande de implementatie van virtuele klinische 
studies worden besproken in het volgende deel van dit proefschrift.
12.4. trouW AAn hiv therApie: “mediciJnen Werken niet 
in de pAtienten die ze niet innemen”
Het is algemeen bekend dat de continuïteit van de werking van een geneesmiddel afhangt van 
de correcte uitvoering van een voorgeschreven regime, wat gericht is op een adequate bloot-
stelling aan de werkzame stof tussen de verschillende doses. Onderbrekingen tijdens de thera-
pie kunnen de werking van het medicijn negatief beïnvloeden. De gevolgen van onderbrekingen 
van de behandeling zijn afhankelijk van het medicijn, de lengte van de onderbreking en de te 
behandelende ziekte. De uitspraak, toegeschreven aan voormalig Amerikaanse Chirurg Gen-
eraal C. Everett Koop, “Medicijnen werken niet in de patienten die ze niet innemen”, vat in deze 
context het belang van therapietrouw mooi samen.
Om de implicaties van de factoren die de variabiliteit in de werking van een geneesmiddel 
bepalen goed te kunnen begrijpen is een aanpak nodig die rekening houdt met zowel het effect 
van ontwikkelingsgroei als van het effect  van andere patiënt-specifieke karakteristieken die 
de farmacokinetiek kunnen beïnvloeden. Bovendien is het belangrijk om te bepalen hoe deze 
factoren in verband staan met het voorgestelde doseringsschema. De huidige algemene op-
vattingen over het gebruik van combinatiepreparaten suggereren dat een verminderde doser-
ingsfrequentie de werking van antiretrovirale therapie zou doen verbeteren. Echter, bewijs 
van therapeutische equivalentie kan niet worden afgeleid uit bio-equivalentie studies  of het 
vergelijken van farmacokinetische data; de werkzaamheid van combinatietherapie berust op 
een synergistische werking op farmacodynamisch niveau. Een nauwkeurige evaluatie van ve-
randeringen in het doseringsschema maakt een beoordeling van het effect van therapietrouw 
van patiënten op de farmacodynamiek noodzakelijk. Verschillen in de patronen van therapi-
etrouw zijn een belangrijke oorzaak van onvoorziene variabiliteit in de blootstelling aan het 
geneesmiddel, geassocieerd met het falen van de therapie. We hebben laten zien hoe de rol van 
onvolledige therapietrouw kwantitatief geëvalueerd kan worden. Hiermee hebben we een kad-
er gecreëerd waarin de vraag beantwoord kan worden hoeveel doses een patiënt kan missen 
zonder dat dit de uitkomst van behandeling beïnvloedt. 
In het verleden zijn naast modelleren andere statistische methoden gebruikt om de gevolgen 
van therapietrouw aan geneesmiddelen te onderzoeken. De consequenties van partiële therapi-
etrouw aan de antiretrovirale therapie is één van de aandachtspunten in dit onderzoeksgebied. 
De groep van Pfister et al. integreerde bijvoorbeeld informatie over therapietrouw als covariaat 
in een farmacokinetisch-farmacodynamisch (PKPDP) model om het effect hiervan op de bloot-
stelling van het geneesmiddel te bepalen. Hiernaast zijn er longitudinale modellen opgesteld om 
het effect van therapietrouw op de progressie van de HIV-infectie te schatten. Andere onder-
zoekers maakten gebruik van Markovmodellen en weer andere van stochastische methoden. 
Naast andere voordelen maakt deze laatste aanpak het mogelijk de respons op elk tijdspunt  af-
hankelijk te maken van die op het vorige tijdspunt. Het vernieuwende in ons werk is het beoor-
delen van het effect van imperfecte therapietrouw in een kader waarin alle elementen van een 
clinical trial simulation gecombineerd zijn. In vergelijking met eerder werk zijn belangrijke ele-
menten geïntroduceerd die voorheen ontbraken, waaronder het gebruik van combinatiethera-
pie, meer realistische patronen van ontrouw aan de therapie (willekeurige onderbrekingen van 
doses, imperfecte timing van opvolgende doses) en een correlatie tussen therapietrouw en resis-
tentie tegen het geneesmiddel. Om het effect van deze geïntegreerde aanpak te illustreren zijn 
er drie scenario’s geselecteerd voor evaluatie: een enkel geneesmiddel gebruikt als monothera-
pie, combinatietherapie bestaand uit drie geneesmiddelen en een combinatiepreparaat van drie 
geneesmiddellen toegediend aan de hand van een versimpeld dosisregime. Deze analyse bevat 
hiernaast een relatie tussen therapietrouw een kans op geneesmiddel resistentie. Dit kader voor 
simulaties van klinische studies, waarin verscheidene mathematische modellen zijn geïncludeerd, 
maakt het mogelijk een precieze voorspelling van de uitkomst van behandeling te doen. Hierbij 
kunnen ook voorspellingen gedaan worden voor scenario’s waarbij een empirische, gerandomi-
seerde benadering op praktische en ethische bezwaren stuit.
in hoofdstuk 8 is de invloed van ontrouw aan de therapie geëvalueerd van drie verschillende 
klassen van antiretrovirale geneesmiddelen die op dit moment gebruikt worden als eerste keus 
behandeling bij kinderen (NNRTI, NRTI en gestimuleerde PI). Deze studie is de eerste poging tot 
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het voorspellen van de uitkomst van therapie door een gecombineerde aanpak waarbij farma-
cokinetiek, farmacodynamiek en ziektemodellen gelijktijdig worden toegepast. Hiernaast werd 
een logistische regressie gebruikt om de relatie tussen het aantal dagen waarop de blootstelling 
op een subtherapeutisch niveau was en de kans op resistentie te beschrijven, wat de schakel 
tussen onvolledige compliantie en het virologisch falen was. Hierbij hebben we om praktische 
redenen, in combinatie met een gemakkelijkere interpretatie, de therapietrouw beschreven 
als patronen van inname van doses in plaats van het percentage genomen doses. Hierbij is het 
belangrijk te vermelden dat alle gebruikte modellen zijn geëvalueerd en gevalideerd. Onze re-
sultaten geven een voorlopige indicatie van het niveau van therapietrouw dat noodzakelijk om 
virologisch falen van diverse geneesmiddelen te voorkomen in geval van monotherapie. Deze 
scenario’s vormen een beginpunt voor de evaluatie van de implicaties van slechte of matige 
therapietrouw in geval van combinatietherapie. Vervolgens werd in hoofdstuk 9 een virtuele 
klinische studie uitgevoerd waarbij een combinatie van drie geneesmiddelen werd voorges-
chreven in een populatie van HIV-geïnfecteerde kinderen. Hier lieten wij zien dat, bij een op 
NNRTI gebaseerd regime, een langere periode van onderbreking in de behandeling een hogere 
kans op virologisch falen kan geven in vergelijking tot wanneer ditzelfde aantal doses willekeurig 
gemist zouden worden. 
De genoemde resultaten laten zien dat de PKPD-relaties van antiretrovirale geneesmiddelen 
gebruikt zouden kunnen worden om het effect van verminderde therapietrouw, en daarmee 
ook van versimpelde doseringsregimes, te voorspellen. PKPD-relaties kunnen gezien worden 
als een surrogaat of proxy van therapeutische equivalentie in de beoordeling van de vergev-
ingsgezindheid van therapieontrouw, vergelijkbaar met de farmacokinetiek in bioequivalentie 
studies. Dit concept biedt de mogelijkheid om onderzoek naar de effectiviteit van geneesmid-
delen te vervangen door PKPD-studies. Zoals weergegeven in hoofdstuk 10, werd het effect 
van partiële compliantie op een versimpeld doseringsregime geëvalueerd met gebruik van de 
onderliggende PKPD-relaties van lamivudine en abacavir in combinatie met efavirenz. Onze re-
sultaten laten zien dat non-compliantie bij een eenmaal daags regime vergelijkbaar is met het 
op dit moment goedgekeurde tweemaal daagse regime wat betreft de implicatie van gemiste 
doses in de onderzochte scenario’s van therapieontrouw. Praktisch betekent dit dat een ver-
mindering in doseringsfrequentie kan zorgen voor een vermindering van de medicatielast bij 
kinderen zonder een toename van het risico op resistentie.
Samengevat verschaft het kader van klinische simulaties, beschreven in hoofdstukken 8, 9 en 
10, de mogelijkheid om klinisch relevante informatie te evalueren over het niveau van de thera-
pietrouw dat nodig is om virologisch falen te voorkomen. Bovendien zou dit, in bredere zin, art-
sen kunnen helpen met het overwegen van het beste dosisregime gebaseerd op het patroon van 
therapietrouw van de patiënt. Het is vermeldingswaardig dat ter voorkoming van het mogelijk 
misleidend effect van uitval van patiënten op de uitkomst van therapie dit in de huidige analy-
ses niet is meegenomen. Onze bevindingen suggereren echter dat een slechte therapietrouw 
gelijke, of zelfs grotere effecten kan hebben op de resultaten van de behandeling dan uitval van 
patiënten tijdens een klinische studie.
12.5. conclusies, AAnbevelinGen  en perspectieven
in hoofdstuk 11 zijn de resultaten van de opeenvolgende hoofdstukken van deze thesis 
samengevat. Onze bevindingen benadrukken de waarde van een modelmatige benadering in 
pediatrisch onderzoek naar HIV bij vraagstukken die, ondanks de wetenschappelijke en klin-
ische vooruitgang in dit onderzoeksveld, onbeantwoord bleven. Het eerste punt betreft de 
aanbevolen dosering van antiretrovirale middelen voor kinderen welke, wanneer gebaseerd op 
overbruggingsconcepten, een vergelijkbare blootstelling geeft op verschillende leeftijden, in 
tegenstelling tot een dosis gebaseerd op lichaamsgewicht. Hiervoor dienen de groei en ontwik-
keling, welke de geneesmiddelblootstelling in de doelgroep beïnvloeden, te worden gekarakter-
iseerd en gekwantificeerd, om zodoende een blootstelling te bereiken in kinderen die vergelijk-
baar is met volwassenen. Hiernaast laat ons werk potentiele beperkingen zien van het gebruik 
van modellen en simulaties voor het voorspellen van farmacokinetiek in kinderen. We willen om 
die reden  de volgende aanbevelingen voor de implementatie van een modelmatige benadering 
in pediatrisch onderzoek benadrukken:
1)  Populatie farmacokinetische studies moeten geschikte inclusie- of stratificatiecriteria over-
wegen om verzekerd te zijn van een  evenwichtige verdeling van covariaten;
2)  Het gebruik van een meta-analyse, waar verschillende subgroepen van de populatie zijn inbe-
grepen, verdient een sterke aanbeveling om misspecificatie van het model door misleidende 
effecten als gevolg van een onevenwichtige verdeling van covariaten te voorkomen;
3)   Het voorspellend vermogen van een model is beperkt tot interpolaties. De nauwkeurigheid 
van extrapolaties buiten de populatie die gebruikt is in het bouwen van het model kan niet 
gewaarborgd worden, zelfs wanneer diagnostische en validatie procedures een bevredigend 
resultaat geven.
4)  Extrapolatie tussen populaties buiten de onderzochte condities of populatie vereist het geb-
ruik van simulatiemodellen, welke niet hetzelfde zijn als de modellen die gebruikt worden 
voor het schatten, zoals in het geval van modellen die ontwikkeld zijn met de maximum waar-
schijnlijkheid methode.
5)  Simulatiemodellen zijn essentieel voor het genereren van hypotheses en gevolgtrekking, 
welke inzicht kunnen geven ook  in relevante condities en scenario’s die in de praktijk niet 
waargenomen  of gecontroleerd zouden kunnen worden. Zodoende kunnen deze geparame-
triseerd worden in  termen van geneesmiddel-, patiënt- en systeem-specifieke eigenschap-
pen, ongeacht de precisie of identificeerbaarheid, welke gedreven worden door de data.
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Gebaseerd op de eerdergenoemde aanbevelingen kan het gebruik van een modelmatige bena-
dering uitgebreid worden naar vraagstellingen  die betrekking hebben op het doseringsadvies. 
Het kan systematisch toegepast worden voor de evaluatie van versimpelde behandelingsopties, 
hetgeen erg aantrekkelijk is in de pediatrische praktijk. Ongetwijfeld zullen modellen, gecombi-
neerd met simulaties van klinische studies, een hulpmiddel worden voor het opzetten van ex-
perimenten.
De aanname dat het genereren van bewijs een sine qua non conditie is voor  goedkeuring door 
de registratie autoriteiten en voor de optimalisatie van het therapeutisch gebruik van genee-
smiddelen, zou herzien moeten worden. De belemmeringen voor het opzetten van een protocol 
en problemen rond de haalbaarheid bij zowel pediatrisch onderzoek als ernstige infectieziekten 
roept vragen op over de relevantie van het bewijs gegenereerd onder strikte gecontroleerde 
condities, gezien deze niet het gebruik van geneesmiddelen in de praktijk reproduceren of re-
flecteren.  Het is noemenswaardig dat het leunen op empirische bewijsvoering wordt aange-
wakkerd door registratie autoriteiten, die richtlijnen blijven uitbrengen waarin deze nieuw 
gegenereerde bewijsvoering wordt vereist voor de goedkeuring van nieuwe geneesmiddelen. 
Dit terwijl de synthese van bewijs (evidence synthesis) op basis van nieuwe en bestaande data 
in combinatie met een modelmatige benadering, ondanks zijn brede toepassing in de evaluatie 
van effectiviteit en de analyse van de kosten en baten, niet volledig geaccepteerd wordt in zow-
el de kliniek als door regulatoire instanties.
Een verschuiving in het paradigma is nodig waarbij synthese van bewijs de voorkeur heeft, 
waardoor het generen van bewijs een bevestigende stap is in het continuüm tussen aannames 
en empirisch bewijs. Een van de lessen geleerd van het werk dat in dit proefschrift is gepre-
senteerd is dat het genereren van bewijs zonder integratie van data, inclusief de systematische 
incorporatie van voorafgaande kennis, kan leiden tot suboptimale experimentele protocollen 
en mogelijk verkeerde beslissingscriteria. Dit aspect wordt vaak genegeerd in de rationale voor 
de reguliere pediatrische klinische studies. Een ander belangrijk punt dat voortkomt uit onze 
voorbeelden is dat de synthese van bewijs veel krachtiger kan zijn dan het generen van bewijs, 
doordat het inzicht geeft in condities die niet experimenteel geëvalueerd kunnen worden.
We sluiten deze thesis af door het eerste vraagstuk in de titel te herhalen; maakt een halve 
dag een verschil op het resultaat van de behandeling? Gebaseerd op de synthese van bewijs 
door modelleren en simuleren kan worden geconcludeerd dat dit niet het geval is. Sterker nog, 
het is het onze verwachting dat dit werk zal bijdragen aan het consolideren van het gebruik van 
PKPD-relaties als de basis voor conclusies betreffende therapeutische equivalentie, waardoor 
het gebruik van onnodige effectiviteitsstudies in kinderen overbodig wordt.
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